SUPPLEMENTAL INFORMATION:

GWAS defines pathogenic signaling pathways and prioritizes drug targets for IgA nephropathy

Kiryluk K et al.

SUPPLEMENTAL INFORMATION:

SUPPLEMENTARY FIGURES:

Extended Data Fig. 1. 3
Extended Data Fig. 2. 4
Extended Data Fig. 3. 5
Extended Data Fig. 4. 6
Extended Data Fig. 5. 7
Extended Data Fig. 6. 8
Extended Data Fig. 7. 9
Extended Data Fig. 8. 10

SUPPLEMENTARY TABLES:

Supplementary Table S1. 11
Supplementary Table S2. 12
Supplementary Table S3. 13
Supplementary Table S4. 14
Supplementary Table S5. 15
Supplementary Table S6. 16
Supplementary Table S7. 17
Supplementary Table S8. 18
Supplementary Table S9. 19
Supplementary Table S10. 20
Supplementary Table S11. 21
Supplementary Table S12. 22
Supplementary Table S13. 23
Supplementary Table S14. 24
Supplementary Table S15. 25
Supplementary Table S16. 26
Supplementary Table S17. 27
Supplementary Table S18. 28
Supplementary Table S19. 29
Supplementary Table S20. 30
Supplementary Table S21. 31
Supplementary Table S22. 32
Supplementary Table S23. 33
Supplementary Table S24. 34
Supplementary Table S25. 35
Supplementary Table S26. 36
Supplementary Table S27. 37
Supplementary Table S28. 38
Supplementary Table S29. 39
Supplementary Table S30. 40

SUPPLEMENTARY NOTES:

Discovery Cohorts 41
Supplementary References 44



Extended Data Fig. 1. Quantile-quantile (QQ) plot of the combined meta-analysis across 38,897 individuals. Blue dots represent the QQ plot based on all SNPs in the meta-analysis and red dots represent the QQ plot after exclusion of SNPs within the MHC region. The overall genomic inflation factor (λ) was 1.048 with MHC, and 1.042 without MHC region.



Extended Data Fig. 2. Regional plots for non-HLA genome-wide significant loci: (a) the *FCRL* locus, **(b)** the *TNFSF4* locus, **(c)** the *CFH* locus, **(d)** the *REL* locus, **(e)** the *CD28* locus, **(f)** the *PF4V1/CXCL8* locus, **(g)** the *IRF4* locus, **(h)** the *RREB1* locus, **(i)** the *DEFA* locus, **(j)** the *LYN* locus, **(k)** the *ANXA3* locus, **(l)** the *TNFSF8* locus, **(m)** the *CARD9* locus, **(n)** the *REEP3* locus, **(o)** the *ZMIZ1* locus, **(p)** the *RELA* locus, **(q)** the *ETS1* locus, **(r)** the *IGH* locus, **(s)** the *ITGAM* locus, **(t)** the *IRF8* locus, **(u)** the *TNFSF13* locus, **(v)** the *TNFRSF13B* locus, **(w)** the *FCAR* locus, **(x)** the *HORMAD2/LIF* locus. The x-axis shows the physical position in megabases (Mb, hg19 coordinates) and known genes; the left y-axis presents -log10 p-values for association statistics and the right y-axis shows the recombination rate across the region; the dotted horizontal line indicates a genome-wide significant threshold of 5.0E-08.



Extended Data Fig. 3. Manhattan plots for East Asian GWAS subgroup analyses. (a) East Asian meta-analysis under an additive genetic model (λ=1.040) revealed a new genome-wide significant locus on chr.6 (*CCR6,* green); **(b)** East Asian meta-analysis under a recessive model (λ=0.940) revealed a new genome-wide significant locus on chr.1 (encoding *PADI3* and *PADI4*, green); y-axis: -log10 of the p-value and is truncated to accommodate the HLA peak; x-axis: genomic position along each chromosome (1-22 and X); the dotted horizontal line indicates a genome-wide significant threshold of 5.0E-08.



Extended Data Fig. 4. Stepwise Conditional Analyses of the *CFH* and *HLA* loci. (a) *CFH* locus: initial meta-analysis results without conditioning (top left); after conditioning for the top SNP rs6677604 (top middle); and after controlling for the two significant SNPs rs6677604 and rs12029571 (top right). **(b) *HLA* locus:** initial meta-analysis results without conditioning (middle left); after conditioning for the top SNP rs9268557 (middle), after controlling for rs9268557 and rs9275355 (middle right), after controlling for rs9268557, rs9275355 and rs9272105 (bottom left), after controlling for rs9268557, rs9275355 rs9272105 and rs9275596 (bottom middle), and after controlling for rs9268557, rs9275355 rs9272105, rs9275596 and rs3128927 (bottom right) with no additional significant signals. The x-axis shows genomic position in Mb (hg19 coordinates) and known genes; the left y-axis presents -log10 p-values for association statistics; the right y-axis (light-blue line) shows the averaged recombination rate across the region; the dotted horizontal line indicates a genome-wide significant threshold of 5.0E-08; the top SNP in each panel is marked by a red diamond.



Extended Data Fig. 5. Stepwise conditional analysis of imputed polymorphic amino-acid positions in DRβ1, DQβ1, and DQα1 peptides in (a) East Asian and (b) European cohorts. Each symbol represents a polymorphic site tested for association with IgAN along the peptide sequence. Y-axis: genomic position of the sequence encoding each amino acid. X-axis: global statistical significance for each polymorphic site (multiallelic test with adjustment for cohort and principal components of ancestry).





Extended Data Fig. 6. Enrichment tests for the GWAS candidate gene set against human ortholog gene sets that when knocked out in mice result in (a) "Abnormal Antibody Levels" and **(b)** "Abnormal Immunoglobulin A Levels"



Extended Data Fig. 7. Pathway, cell type and tissue enrichment analyses: MAGMA pathway enrichment analysis based on GWAS summary statistics with **(a)** and without **(b)** the HLA region; -log10 P-value for the enrichment test are depicted along the x-axis, significant pathways are listed along the y-axis, red vertical lines indicate significance threshold corrected for multiple testing; **(c)** cell type-specific heritability enrichment for functional annotations in ImmGen dataset of mouse regulatory elements and expression data demonstrating the strongest enrichment in small intestine-derived macrophages profiled three days after Salmonella infection, and (**d)** Cell type-specific heritability enrichment for individual functional annotations generated by Roadmap Epigenomics demonstrates significant enrichment in immune cells, especially of B-cell lineage. All enrichments at nominal p-value<0.05 are displayed and grouped according to cell and tissue class. A solid red line represents a stringent Bonferroni-corrected -log10 of the p-value threshold of significance for the Roadmap dataset (P=1.3x10^{-4}). A dotted black line represents the -log10 of the nominal p-value of 0.05. GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; MF: macrophages; P/I: post-injection.



Extended Data Fig. 8. Cis-regulatory effects at the *CARD9* locus: **(a)** the *CARD9* gene model depicting 13 exons of *CARD9* and the splicing events from GTEx blood RNA-seq; the top IgAN risk allele (rs4077515-T) encodes S12N substitution in the second exon of *CARD9*; this SNP also exhibits a strong and statistically significant blood sQTL effect, wherein the risk allele is associated with higher rates of the chr9:136372094:136373532:clu_47895 splicing event, leading to the retention of exon 2 (red) in the coding sequence of CARD9 (isoform A), while the protective (rs4077515-C) allele is associated with the alternative splicing event that truncates exon 2 (isoform B); the functional CARD domain (green) maps to a portion of exon 2 that is intact in isoform A, but truncated in isoform B; **(b)** blood splice eQTL plots of normalized intron excision ratios (corresponding to the ratio of isoform A to isoform B) by the genotype of rs10870077 (top blood sQTL in GTEx) and rs4077515 (top SNP in GWAS for IgAN); these two SNPs are in near perfect linkage disequilibrium (r^2>0.98); **(c)** both rs10870077 and rs4077515 are also associated with a significant cis-eQTL effect on *CARD9* mRNA levels in GTEx blood; **(d)** the blood eQTL signal for CARD9 significantly co-localizes with the GWAS signal (PP4 of 0.86): top panel represents a regional plot for the GWAS signal (Immunochip data excluded); the bottom panel represents a blood cis-eQTL signal for CARD9 from the QTLGen Consortium meta-analysis (Y-axis truncated at P<1e-310); rs10870077 and rs4077515 are indicated in red.

Table S1. Summary of study cohorts and genotyping platforms.

Cohort	Ethnicity	N Total	N Cases	N Controls	Genotyping Platform
French	European	364	205	159	Illumina 370-duo
Italian	European	2385	1045	1340	Illumina 1M-omni/1M-duo
North American	European	1854	303	1551	Illumina 550/660-quad
UK	European	5243	464	4779	Illumina HumanHap300/1M-duo
Turkish	European	439	115	324	Illumina Multi-Ethnic Global Array-8
European I	European	2456	920	1536	Illumina Multi-Ethnic Global Array-8
European II	European	754	397	357	Illumina Multi-Ethnic Global Array-8
Argentinian	European	194	100	94	Illumina Multi-Ethnic Global Array-8
Beijing I	East Asian	2096	1194	902	Illumina 610-quad
Shanghai	East Asian	1345	656	689	Illumina Multi-Ethnic Global Array-8
Japanese	East Asian	776	414	362	Illumina Multi-Ethnic Global Array-8
South Korean	East Asian	1443	735	708	Illumina Multi-Ethnic Global Array-8
Beijing II	East Asian	4151	479	3672	Illumina Infinium OmniZhongHua-8 v1.3
Beijing III	East Asian	2352	1112	1240	Illumina Infinium Global Screening Array-24 (GSA)
North Europe	European	7624	527	7097	Illumina HumanImmuno BeadChip (Immunochip)
Central-West Europe	European	2202	966	1236	Illumina HumanImmuno BeadChip (Immunochip)
South Europe	European	3219	514	2705	Illumina HumanImmuno BeadChip (Immunochip)
	Total	38,897	10,146	28,751	

Table S2. Novel and known genome wide significant loci (p<5.0E-08)

				EUROPEAN				EAST ASIAN				COMBINED				
Chr	BP	SNP	Risk Allele	RAF Cases	RAF Controls	OR	P	RAF Cases	RAF Controls	OR	P	Meta OR	Meta P	Q test (P)	I2 (%)	Chip
1	196686918	rs6677604	G	0.828	0.798	1.19	4.43E-12	0.956	0.934	1.28	1.77E-07	1.21	1.50E-17	0.966	0	GWAS + IC
1	157542162	rs849815	A	0.690	0.663	1.13	3.36E-06	0.496	0.504	1.16	2.63E-04	1.14	3.91E-09	0.574	0	GWAS + IC
1	173146357	rs4916312	A	0.371	0.355	1.15	5.14E-07	0.077	0.075	1.13	3.21E-02	1.14	5.00E-08	0.678	0	GWAS + IC
2	204584759	rs3769684	T	0.951	0.946	1.26	2.69E-05	0.503	0.491	1.17	1.97E-07	1.19	5.14E-11	0.927	0	GWAS + IC
2	61092678	rs842638	T	0.416	0.441	1.13	4.78E-05	0.120	0.149	1.23	1.44E-06	1.17	9.58E-10	0.002	63.8	GWAS
4	74725320	rs6828610	G	0.169	0.156	1.26	3.62E-05	0.303	0.275	1.12	1.29E-04	1.14	3.54E-08	0.974	0	GWAS
6	249571	rs12201499	C	0.116	0.119	1.12	2.11E-02	0.235	0.283	1.20	1.87E-10	1.18	3.07E-11	0.394	5.05	GWAS
6	7214676	rs12530084	C	0.797	0.772	1.13	1.40E-04	0.535	0.513	1.13	2.29E-06	1.13	1.28E-09	0.488	0	GWAS
6	32389305	rs9268557	C	0.6136	0.509	1.32	4.25E-38	0.626	0.566	1.21	2.72E-12	1.24	4.52E-47	<0.0001	73.4	GWAS + IC
6	167445139	rs2282859*	C	0.017	0.014	1.02	8.33E-01	0.188	0.157	1.14	6.07E-07	1.17	2.68E-07	0.059	43.8	GWAS+IC
8	6808722	rs2075836	T	0.284	0.311	1.17	4.04E-03	0.254	0.292	1.22	3.11E-09	1.21	5.85E-11	0.898	0	GWAS
8	56852496	rs75413466	A	0.025	0.019	1.52	1.52E-06	0.069	0.059	1.34	1.06E-05	1.40	1.37E-10	0.797	0	GWAS + IC
8	124765474	rs34354351	T	0.159	0.173	1.20	2.44E-05	0.301	0.319	1.13	1.90E-04	1.15	3.51E-08	0.838	0	GWAS
9	139266496	rs4077515	T	0.437	0.413	1.17	2.46E-10	0.311	0.290	1.09	7.05E-03	1.14	2.65E-11	0.415	1.83	GWAS + IC
9	117643362	rs13300483	T	0.262	0.245	1.14	9.74E-06	0.331	0.307	1.13	3.34E-04	1.13	1.27E-08	0.877	0	GWAS + IC
10	81043743	rs1108618	A	0.643	0.599	1.13	7.22E-06	0.488	0.495	1.15	5.67E-06	1.14	1.93E-10	0.435	0.32	GWAS + IC
10	65363048	rs57917667	G	0.018	0.020	1.18	2.83E-01	0.161	0.191	1.23	1.88E-08	1.22	1.09E-08	0.910	0	GWAS
11	65555524	rs10896045	A	0.322	0.299	1.12	1.52E-03	0.473	0.485	1.23	1.16E-11	1.18	4.77E-13	0.033	50.6	GWAS
11	128487069	rs7121743	C	0.172	0.156	1.11	1.27E-02	0.491	0.474	1.14	7.03E-07	1.13	3.40E-08	0.790	0	GWAS
14	107222014	rs751081288	A	0.463	0.433	1.13	2.52E-03	0.601	0.565	1.20	1.31E-06	1.17	1.94E-08	0.743	0	GWAS
16	31357760	rs11150612	A	0.599	0.645	1.15	4.00E-08	0.233	0.270	1.20	2.32E-07	1.16	8.37E-14	0.105	36.8	GWAS+IC
16	86017715	rs1879210	T	0.668	0.637	1.12	2.51E-05	0.876	0.856	1.19	5.06E-05	1.14	9.92E-09	0.963	0	GWAS + IC
17	7462969	rs3803800	A	0.221	0.210	1.09	4.94E-03	0.364	0.324	1.22	1.43E-10	1.15	1.21E-10	0.186	27.1	GWAS + IC
17	16851450	rs57382045	A	0.146	0.113	1.24	1.93E-06	0.355	0.326	1.13	9.52E-05	1.16	3.45E-09	0.842	0	GWAS
19	55397217	rs1865097	A	0.335	0.301	1.10	3.21E-04	0.412	0.380	1.15	2.65E-06	1.12	7.74E-09	0.493	0	GWAS + IC
22	30512478	rs48230748	G	0.549	0.538	1.10	4.29E-04	0.709	0.669	1.22	3.18E-14	1.16	7.76E-15	0.506	0	GWAS

*** East Asian-specific locus**

Table S3. Suggestive loci in the combined trans-ethnic meta-analysis (p<5.0E-05)

				EUROPEAN				EAST ASIAN				COMBINED				
CHR	BP	SNP	Risk Allele	RAF Cases	RAF Controls	OR	P	RAF Cases	RAF Controls	OR	P	Meta OR	Meta P	Q test (P)	I2 (%)	Chip
1	15613946	rs531901	A	0.492	0.459	1.16	1.14E-04	0.666	0.650	1.14	1.07E-02	1.153	3.76E-06	0.733	0	GWAS
1	161197244	rs4233368	A	0.251	0.254	1.07	1.45E-02	0.446	0.412	1.15	7.21E-06	1.106	1.28E-06	0.147	31.54	GWAS+IC
1	161470505	rs12139150	G	0.593	0.532	1.09	2.12E-04	0.789	0.773	1.10	1.75E-03	1.093	1.37E-06	0.818	0	GWAS+IC
1	17630193	rs2501784	A	0.449	0.420	1.10	1.28E-04	0.650	0.628	1.12	2.36E-04	1.107	1.22E-07	0.019	53.11	GWAS+IC
1	38379770	rs4653337	G	0.707	0.678	1.13	5.79E-04	0.722	0.686	1.11	3.67E-03	1.117	7.39E-06	0.856	0	GWAS
1	68720758	rs10493441	A	0.095	0.090	1.13	2.22E-02	0.266	0.250	1.16	8.62E-06	1.154	6.29E-07	0.317	13.31	GWAS
1	85743741	rs2735592	G	0.324	0.294	1.12	1.55E-05	0.289	0.291	1.09	2.22E-02	1.111	1.35E-06	0.863	0	GWAS+IC
2	167244822	rs16852104	A	0.142	0.119	1.17	5.30E-03	0.269	0.245	1.15	2.25E-04	1.155	3.95E-06	0.326	13.64	GWAS
2	201739327	rs4035021	A	0.389	0.360	1.13	5.40E-05	0.577	0.549	1.08	2.07E-02	1.110	5.68E-06	0.387	5.94	GWAS
2	218991005	rs4674259	G	0.456	0.459	1.07	1.66E-03	0.653	0.634	1.10	4.79E-04	1.085	3.73E-06	0.036	48.25	GWAS+IC
2	234115739	rs14243	G	0.245	0.210	1.16	6.53E-06	0.365	0.353	1.10	3.07E-03	1.127	1.70E-07	0.139	34.83	GWAS
2	43352888	rs737013	T	0.402	0.373	1.13	3.26E-05	0.249	0.233	1.07	3.96E-02	1.100	8.86E-06	0.408	3.6	GWAS
2	62551472	rs10865331	A	0.433	0.393	1.12	7.09E-06	0.382	0.368	1.07	3.19E-02	1.097	1.29E-06	0.458	0	GWAS+IC
3	101663386	rs7625614	T	0.355	0.359	1.11	1.44E-03	0.667	0.653	1.11	1.22E-03	1.108	5.64E-06	0.913	0	GWAS
3	29361792	rs55711830	A	0.375	0.347	1.16	4.65E-05	0.108	0.101	1.11	5.23E-02	1.143	7.77E-06	0.106	37.87	GWAS
3	39249753	rs12497322	G	0.681	0.655	1.12	1.53E-02	0.524	0.489	1.11	1.82E-04	1.109	8.58E-06	0.008	79.18	GWAS
3	77447376	rs28378063	G	0.355	0.336	1.11	2.36E-04	0.475	0.453	1.08	4.94E-03	1.096	5.20E-06	0.828	0	GWAS
4	2841240	rs4690002	T	0.389	0.367	1.16	3.13E-03	0.484	0.448	1.16	1.99E-05	1.163	2.12E-07	0.834	0	GWAS
5	133455961	rs151822	G	0.258	0.229	1.08	3.09E-02	0.512	0.473	1.14	2.61E-05	1.110	7.14E-06	0.417	2.06	GWAS
5	158748679	rs3213097	T	0.249	0.228	1.10	1.24E-03	0.472	0.448	1.09	1.73E-03	1.092	6.88E-06	0.279	17.84	GWAS+IC
5	35857850	rs10213865	A	0.767	0.741	1.11	2.60E-04	0.806	0.786	1.10	8.14E-03	1.108	6.57E-06	0.393	5.29	GWAS+IC
5	38867732	rs395157	T	0.490	0.471	1.14	1.32E-06	0.253	0.247	1.06	9.95E-02	1.108	1.55E-06	0.527	0	GWAS+IC
5	40463739	rs4957300	C	0.644	0.658	1.11	1.80E-05	0.306	0.298	1.07	2.89E-02	1.091	2.52E-06	0.629	0	GWAS+IC
5	55438851	rs10065637	C	0.812	0.778	1.16	7.78E-08	0.967	0.978	0.53	2.26E-01	1.155	1.77E-07	0.198	30.14	GWAS+IC
5	79564517	rs62364037	A	0.171	0.153	1.22	1.85E-06	0.000	0.000	NA	NA	1.219	1.85E-06	0.797	0	GWAS
6	138132123	rs58905141	G	0.036	0.031	1.31	6.43E-07	0.048	0.039	1.20	1.44E-01	1.293	3.26E-07	0.954	0	GWAS
6	159499748	rs2485360	T	0.297	0.286	1.11	5.20E-04	0.063	0.047	1.25	1.09E-03	1.126	7.77E-06	0.588	0	GWAS+IC
6	167445139	rs2282859	C	0.017	0.014	1.02	8.33E-01	0.179	0.151	1.20	3.88E-08	1.172	2.68E-07	0.059	43.76	GWAS+IC
6	168048619	rs111387965	G	0.050	0.040	1.21	5.46E-02	0.087	0.061	1.33	2.72E-05	1.286	7.67E-06	0.665	0	GWAS
6	5675845	rs2142738	T	0.485	0.464	1.13	6.28E-05	0.710	0.686	1.10	1.38E-02	1.118	3.34E-06	0.039	47.55	GWAS
7	11625652	rs17574506	C	0.391	0.439	1.13	4.60E-04	0.564	0.513	1.14	7.22E-05	1.139	1.24E-07	0.706	0	GWAS
7	158600277	rs710423	T	0.175	0.163	1.09	4.43E-02	0.327	0.296	1.17	9.12E-07	1.137	3.07E-07	0.419	2.45	GWAS
7	50476778	rs79441475	A	0.089	0.078	1.23	1.66E-06	<0.001	<0.001	NA	NA	1.228	1.66E-06	0.548	0	GWAS+IC
8	128226195	rs6989575	T	0.320	0.287	1.12	8.63E-04	0.473	0.459	1.10	8.03E-04	1.111	2.40E-06	0.483	0	GWAS
8	18848034	rs2410596	C	0.866	0.852	1.09	3.47E-02	0.328	0.349	1.11	8.76E-05	1.107	9.65E-06	0.148	31.44	GWAS
8	61022672	rs2611364	T	0.628	0.610	1.14	2.21E-04	0.487	0.466	1.12	1.32E-04	1.131	1.17E-07	0.489	0	GWAS
8	81128822	rs9774752	C	0.385	0.354	1.13	9.47E-03	0.437	0.474	1.10	3.03E-04	1.110	9.57E-06	0.008	79.21	GWAS
9	92078518	rs4877094	C	0.194	0.174	1.08	4.69E-02	0.364	0.338	1.14	1.48E-05	1.121	3.51E-06	0.570	0	GWAS
10	3918174	rs10904115	T	0.507	0.493	1.08	1.15E-02	0.471	0.438	1.14	8.97E-06	1.111	7.37E-07	0.441	0	GWAS
10	67783437	rs10509258	G	0.331	0.307	1.10	1.24E-03	0.261	0.244	1.10	1.65E-03	1.102	6.52E-06	0.117	37.74	GWAS
11	64275670	rs34429336	C	0.446	0.436	1.09	1.49E-03	0.348	0.323	1.10	1.16E-03	1.095	5.54E-06	0.081	40.13	GWAS
12	110666136	rs56838584	A	0.913	0.900	1.27	9.24E-06	0.990	0.982	0.00	1.29E-01	1.274	4.68E-06	0.494	0	GWAS
16	72163694	rs10492815	A	0.949	0.956	1.05	6.42E-01	0.756	0.712	1.20	6.41E-07	1.177	3.91E-06	0.814	0	GWAS
17	40565916	rs72823055	T	0.106	0.091	1.19	4.26E-05	0.226	0.217	1.09	1.43E-02	1.133	6.79E-06	0.528	0	GWAS+IC
17	8038789	rs9913189	A	0.625	0.588	1.16	4.12E-05	0.882	0.879	1.12	7.63E-02	1.147	8.82E-06	0.634	0	GWAS
19	38687076	rs62123462	A	0.420	0.398	1.11	5.62E-03	0.476	0.401	1.17	1.63E-04	1.134	4.85E-06	0.057	48.89	GWAS
19	45487178	rs204474	C	0.387	0.367	1.10	5.03E-03	0.579	0.557	1.11	1.21E-04	1.105	2.10E-06	0.668	0	GWAS
22	29957911	rs469295	T	0.258	0.235	1.09	2.27E-03	0.603	0.577	1.13	4.55E-04	1.104	4.59E-06	0.736	0	GWAS+IC

Table S4. Ancestry-specific suggestive loci (p<5.0E-05): (a) East Asians, (b) Europeans.

(a)				EUROPEAN				EAST ASIAN				COMBINED				
CHR	BP	SNP	Risk Allele	RAF Cases	RAF Controls	OR	P	RAF Cases	RAF Controls	OR	P	OR	P	Q test (P)	I2 (%)	Chip
1	11937404	rs7554327	C	0.513	0.528	1.03	2.05E-01	0.546	0.516	1.14	5.46E-07	1.04	2.60E-02	0.125	34.15	GWAS+IC
8	103543524	rs10088534	C	0.627	0.631	1.02	5.97E-01	0.509	0.474	1.14	3.25E-07	1.08	4.18E-05	0.038	47.98	GWAS
9	37023483	rs77134091	C	0.000	0.000	NA	NA	0.923	0.903	1.21	8.15E-06	1.21	8.15E-06	0.226	32.72	GWAS EAS
13	70019147	rs79246816	T	0.897	0.902	1.06	2.60E-01	0.837	0.813	1.17	2.97E-06	1.13	1.25E-05	0.477	0	GWAS
14	21087181	rs1652035	A	0.493	0.496	1.00	9.21E-01	0.677	0.645	1.18	5.37E-06	1.10	4.63E-04	0.009	65.17	GWAS
15	60913415	rs339993	A	NA	NA	NA	NA	0.494	0.497	1.16	3.65E-06	1.16	3.65E-06	0.888	0	GWAS EAS
15	74869438	rs8041357	C	0.953	0.961	1.04	5.73E-01	0.232	0.207	1.14	8.80E-06	1.13	1.92E-05	0.074	41.27	GWAS
18	72833866	rs28694297	T	0.877	0.885	1.05	3.08E-01	0.793	0.444	1.14	9.33E-06	1.08	2.08E-03	0.077	40.75	GWAS
18	74760875	rs7227084	T	0.753	0.739	1.03	3.88E-01	0.846	0.825	1.17	9.79E-06	1.10	2.21E-04	0.049	47.1	GWAS
19	52151778	rs2902877	A	0.439	0.438	1.00	9.47E-01	0.686	0.663	1.16	3.59E-06	1.09	4.77E-04	0.163	30.78	GWAS
22	48968790	rs910580	C	0.234	0.240	1.01	7.59E-01	0.448	0.401	1.18	1.61E-06	1.11	1.11E-04	0.032	52.37	GWAS

(b)				EUROPEAN				EAST ASIAN				COMBINED				
CHR	BP	SNP	Risk Allele	RAF Cases	RAF Controls	OR	P	RAF Cases	RAF Controls	OR	P	OR	P	Q test (P)	I2 (%)	Chip
1	106622787	rs61814213	A	0.958	0.938	1.70	6.14E-06	0.723	0.718	1.03	4.56E-01	1.06	5.11E-02	0.840	0	GWAS
1	206656292	rs10863389	C	0.650	0.620	1.11	2.43E-06	0.371	0.368	1.04	2.49E-01	1.05	4.42E-03	0.527	0	GWAS+IC
2	100801198	rs11677053	C	0.423	0.403	1.11	7.29E-06	0.462	0.459	1.01	8.35E-01	1.07	2.98E-04	0.238	21.53	GWAS+IC
2	2516093	rs79067042	G	0.188	0.176	1.21	5.54E-06	<0.001	<0.001	NA	NA	1.21	5.54E-06	0.238	26.16	GWAS
2	34183606	rs12611527	A	0.678	0.639	1.22	4.34E-07	0.368	0.341	1.07	2.62E-02	1.04	1.08E-01	0.000	81.92	GWAS
2	595891	rs35662997	G	0.124	0.094	1.33	1.10E-06	0.040	0.040	1.05	5.71E-01	1.21	7.27E-05	0.078	45.21	GWAS
4	103475444	rs4648011	T	0.655	0.604	1.14	6.27E-07	0.489	0.501	1.01	7.89E-01	1.08	7.14E-05	0.002	63.71	GWAS+IC
5	71843755	rs381734	G	0.788	0.757	1.16	1.06E-06	0.760	0.758	1.02	5.47E-01	1.09	1.00E-04	0.504	0	GWAS+IC
5	96370879	rs248215	G	0.490	0.477	1.14	1.63E-06	0.536	0.535	1.01	7.09E-01	1.07	2.99E-04	0.057	44.15	GWAS
7	120550667	rs2040762	T	0.268	0.239	1.27	5.37E-07	0.381	0.384	0.99	6.76E-01	1.06	2.02E-02	0.016	57.31	GWAS
7	36707837	rs73094969	G	0.176	0.168	1.17	8.42E-06	0.106	0.109	1.00	9.79E-01	1.10	8.36E-04	0.097	37.81	GWAS
8	131361477	rs7018225	T	0.570	0.550	1.17	1.50E-06	0.336	0.337	0.97	4.00E-01	1.10	6.46E-05	0.410	3.37	GWAS
11	64097233	rs694739	A	0.655	0.626	1.13	1.61E-06	0.830	0.840	1.05	2.15E-01	1.07	8.43E-04	0.617	0	GWAS+IC
12	28850736	rs10843237	T	0.694	0.640	1.17	2.52E-06	0.692	0.679	1.03	4.18E-01	1.09	1.34E-04	0.070	41.85	GWAS
16	9677083	rs6498785	A	0.584	0.541	1.15	9.94E-06	0.501	0.505	1.04	1.76E-01	1.04	4.23E-02	0.226	22.82	GWAS
18	11971994	rs9303756	G	0.166	0.157	1.18	2.90E-06	0.171	0.165	1.00	9.52E-01	1.09	1.08E-03	0.001	67.65	GWAS
18	12737037	rs2847247	A	0.408	0.369	1.18	2.42E-06	0.264	0.267	1.01	7.56E-01	1.10	5.40E-04	0.747	0	GWAS
18	74983830	rs75152619	C	0.041	0.027	1.39	9.88E-07	<0.001	<0.001	NA	NA	1.39	9.88E-07	0.344	11.25	GWAS
19	3263999	rs66654893	T	0.481	0.432	1.25	9.14E-06	0.262	0.271	1.05	2.53E-01	1.08	2.94E-02	0.151	43.45	GWAS

Table S5. Stepwise conditional analysis to define independent SNPs within each genome-wide significant locus (p<5.0E-08)

				Unconditional Analysis		Conditional Analysis	
CHR:BP	SNP	GENE	Risk Allele	OR	P-value	OR	P-value
1:196686918	rs6677604	*CFH*	G	1.21	1.50E-17		
1:196603302	rs12029571		A	1.12	2.54E-06	1.15	3.60E-09
1:196674330	rs567086291		A	1.26	3.19E-10	1.22	5.70E-08
1:157542162	rs849815	*FCRL3, FCRL4*	A	1.14	3.91E-09		
1:157502863	rs73011558		T	1.21	9.37E-05	1.21	1.02E-04
1:173146357	rs4916312	*TNFSF4*	A	1.14	5.00E-08		
1:172903845	rs12565596		A	1.07	3.71E-03	1.10	9.58E-05
2:204584759	rs3769684	*CD28*	T	1.19	5.14E-11		
2:204722752	rs926169		G	1.09	4.74E-06	1.09	6.28E−5
2:61092678	rs842638	*REL*	T	1.17	9.58E-10		
2:61151983	rs78037521		TCA	1.23	3.04E-07	1.18	1.06E-04
4:74725320	rs6828610	*PF4V1*	G	1.14	3.54E-08		
4:75044689	rs60069701		G	1.11	1.96E-03	1.12	6.65E-04
6:249571	rs12201499	*IRF4*	C	1.18	3.07E-11		
6:428486	rs12526822		A	1.12	1.52E-04	1.11	2.50E-04
6:7214676	rs12530084	*LY86*	C	1.13	1.28E-09		
6:7328454	rs79358471		T	1.86	5.38E-04	1.81	9.45E-04
8:6808722	rs2075836	*DEFA1*	T	1.21	5.85E-11		
8:6766505	rs34087549		A	1.11	6.13E-05	1.11	3.72E-05
8:56852496	rs75413466	*LYN*	A	1.40	1.37E-10		
8:56802069	rs333619		T	1.06	3.02E-03	1.07	1.65E-04
8:124765474	rs34354351	*ANXA13*	T	1.15	3.51E-08		
8:124713994	rs76705386		C	1.22	2.35E-03	1.21	3.50E-03
9:139266496	rs4077515	*CARD9*	T	1.14	2.65E-11		
9:139393067	rs7852557		C	1.09	2.51E-04	1.07	7.09E-03
9:117643362	rs13300483	*TNFSF8, TNFSF15*	T	1.13	1.27E-08		
9:117604858	rs540928691		CA	1.10	2.91E-04	1.08	2.70E-03
10:81043743	rs1108618	*ZMIZ1, PPIF*	A	1.14	1.93E-10		
10:81006391	rs117464630		T	1.20	5.34E-04	1.20	3.50E-04
10:65363048	rs57917667	*REEP3*	G	1.22	1.09E-08		
10:65752896	rs77436363		C	2.03	3.12E-04	2.08	1.97E-04
11:65555524	rs10896045	*RELA*	A	1.18	4.77E-13		
11:65562257	rs2276133		G	1.04	5.03E-02	1.09	5.30E-05
11:128487069	rs7121743	*ETS1*	C	1.13	3.40E-08		
11:127683477	rs7945213		C	1.08	1.05E-03	1.11	2.01E-05
14:107106655	rs746398	*IGH*	A	1.17	1.94E-08		
14:107031982	rs2731189		G	1.04	3.91E-01	1.06	4.21E-03
16:31357760	rs11150612	*ITGAM, ITGAX*	A	1.16	8.37E-14		
16:31362711	rs67898294		C	1.19	2.88E-10	1.13	3.23E-05
16:86017715	rs1879210	*IRF8*	T	1.14	9.92E-09		
16:86485321	rs6540296		G	1.10	3.13E-05	1.00	4.87E-06
17:7462969	rs3803800	*TNFSF13*	A	1.15	1.21E-10		
17:7521764	rs72829406		T	1.08	2.63E-03	1.10	2.83E-04
17:16851450	rs57382045	*TNFRSF13B*	A	1.16	3.45E-09		
17:16883047	rs201993221		AT	1.14	3.62E-03	1.16	8.29E-04
19:55397217	rs1865097	*FCAR*	A	1.12	7.74E-09		
19:55177929	rs760186		A	1.18	5.89E-05	1.17	9.47E-05
22:30512478	rs4823074	*LIF*	G	1.16	7.76E-15		
22:30037168	rs564157878		T	1.15	2.89E-08	1.13	2.04E-06

Table S6. Summary of independent SNPs defined by stepwise conditioning of the HLA locus. RAF: Risk Allele Frequency, OR: Odds Ratio.

					European RAF		East Asian RAF		Independent SNPs	
Cohorts	**SNP**	**BP**	**Closest Gene(s)**	**Risk Allele**	**Cases**	**Controls**	**Cases**	**Controls**	**OR**	**P-value**
Combined	rs9268557	32389305	*HLA-DRA/BTNL2*	C	0.614	0.509	0.6257	0.5656	1.24	4.52E-47
	rs9275355	32667829	*HLA-DQB1/HLA-DQA2*	C	0.267	0.226	0.3925	0.3249	1.26	1.71E-34
	rs9272105	32599999	*HLA-DQA1*	A	0.661	0.598	0.4778	0.4483	1.25	1.18E-28
	rs9275596	32681631	*HLA-DQB1/HLA-DQA2*	T	0.748	0.663	0.8726	0.8127	1.33	3.16E-36
	rs3128927	33074288	*HLA-DPA2/HLA-DPB2*	C	0.776	0.729	0.8606	0.8271	1.22	1.50E-25
European	rs9268557	32389305	*HLA-DRA/BTNL2*	C	0.614	0.509	0.6257	0.5656	1.27	4.25E-38
	rs3128927	33074288	*HLA-DPA2/HLA-DPB2*	C	0.776	0.729	0.8606	0.8271	1.22	1.73E-18
	rs9272105	32599999	*HLA-DQA1*	A	0.661	0.598	0.4778	0.4483	1.31	2.66E-22
	rs542418	31836442	*SLC44A4*	A	0.777	0.692	0.6701	0.6716	1.30	1.27E-12
	rs4496841	32389997	*HLA-DRA/BTNL2*	T	0.804	0.742	0.7608	0.7324	1.29	1.76E-11
East Asian	rs2760994	32574308	*HLA-DRB1/HLA-DQA1*	T	0.659	0.622	0.7943	0.7195	1.50	5.13E-34
	rs1612904	32669018	*HLA-DQB1/HLA-DQA2*	A	0.730	0.681	0.8725	0.8121	1.48	1.88E-22
	rs117552038	32583937	*HLA-DRB1/HLA-DQA1*	C	0.995	0.981	0.8723	0.8508	1.20	4.65E-05
	rs11459466	32853221	*TAP1*	G	0.799	0.785	0.7745	0.7476	1.20	6.99E-07

Table S7. Association analysis for *HLA-DRB1* amino-acid substitutions at positions 11 & 71. Odds Ratio (OR) and 95% confidence intervals (95%CI) are depicted for each amino-acid substitution in reference to all other substitutions; P-value corresponds to a biallelic test of association; only amino-acid substitutions with frequency in controls greater than 1% are included in the association testing; NA = Not Available (control allele frequency < 1%).

		East Asian				European			
Position	**Substitution**	**OR**	**L95**	**U95**	**P**	**OR**	**L95**	**U95**	**P**
DRB1_11	**P**	**0.618**	**0.554**	**0.689**	**3.24E-18**	**0.706**	**0.656**	**0.760**	**9.83E-21**
	V	**1.498**	**1.362**	**1.647**	**6.71E-17**	**1.146**	**1.075**	**1.221**	**2.93E-05**
	G	NA	NA	NA	NA	**0.731**	**0.678**	**0.789**	**6.11E-16**
	L	0.907	0.737	1.117	3.58E-01	**1.270**	**1.181**	**1.365**	**9.34E-11**
	S	1.120	1.040	1.207	2.81E-03	1.126	1.074	1.180	7.41E-07
	D	0.876	0.786	0.976	1.64E-02	NA	NA	NA	NA
DRB1_71	**A**	**0.617**	**0.550**	**0.692**	**1.54E-16**	**0.738**	**0.680**	**0.801**	**2.79E-13**
	R	**1.953**	**1.782**	**2.140**	**1.04E-23**	**1.194**	**1.138**	**1.253**	**5.18E-13**
	K	0.669	0.554	0.809	3.15E-05	0.871	0.819	0.927	1.43E-05
	E	0.806	0.688	0.945	7.98E-03	1.041	0.973	1.114	2.45E-01

Table S8. Association testing of the classical HLA alleles in the East Asian case-control cohorts. OR: Odds Ratio; L95 and U95: lower and upper bounds of the 95% confidence interval.

HLA Allele	Unconditional				Conditioned on DRB1*1501 and DRB1*0405			
	OR	L95	U95	P	OR	L95	U95	P
HLA_DRB1_0101	0.91	0.74	1.12	3.85E-01	0.91	0.74	1.13	3.91E-01
HLA_DRB1_0405	**1.67**	**1.46**	**1.90**	**1.73E-14**				
HLA_DRB1_0406	1.26	1.05	1.52	1.31E-02	1.28	1.06	1.55	9.12E-03
HLA_DRB1_0803	1.06	0.91	1.24	4.44E-01	1.07	0.92	1.25	3.76E-01
HLA_DRB1_0901	0.88	0.79	0.98	1.76E-02	0.88	0.79	0.99	2.90E-02
HLA_DRB1_1202	1.23	1.06	1.43	6.55E-03	1.21	1.04	1.40	1.42E-02
HLA_DRB1_1302	0.83	0.70	0.99	4.17E-02	0.82	0.69	0.98	3.09E-02
HLA_DRB1_1501	**0.58**	**0.50**	**0.66**	**2.17E-15**				
HLA_DRB1_1502	0.76	0.62	0.92	5.27E-03	0.77	0.63	0.94	9.57E-03
HLA_DQB1_0301	1.20	1.09	1.31	1.36E-04	1.21	1.10	1.33	5.50E-05
HLA_DQB1_0302	1.20	1.05	1.37	6.57E-03	1.22	1.07	1.40	2.94E-03
HLA_DQB1_0303	0.89	0.80	0.99	2.51E-02	0.89	0.80	0.99	4.00E-02
HLA_DQB1_0401	1.68	1.46	1.94	3.05E-13	1.19	0.91	1.57	2.08E-01
HLA_DQB1_0501	1.01	0.86	1.18	9.21E-01	1.01	0.86	1.18	9.36E-01
HLA_DQB1_0502	1.01	0.83	1.22	9.09E-01	1.04	0.86	1.26	6.82E-01
HLA_DQB1_0503	1.36	1.13	1.63	1.10E-03	1.39	1.16	1.67	4.39E-04
HLA_DQB1_0601	0.95	0.84	1.08	4.48E-01	0.99	0.88	1.13	9.35E-01
HLA_DQB1_0602	0.55	0.48	0.64	1.20E-14	0.79	0.57	1.08	1.41E-01
HLA_DQA1_0101	1.21	1.08	1.36	8.18E-04	1.22	1.09	1.37	8.21E-04
HLA_DQA1_0102	0.63	0.57	0.71	7.80E-17	0.78	0.67	0.90	8.15E-04
HLA_DQA1_0103	0.90	0.80	1.02	8.99E-02	0.92	0.81	1.04	1.74E-01
HLA_DQA1_0301	1.23	1.14	1.33	4.15E-07	1.02	0.94	1.12	6.05E-01
HLA_DQA1_0501	1.08	0.97	1.19	1.64E-01	1.09	0.98	1.21	1.16E-01
HLA_DQA1_0601	1.20	1.03	1.38	1.57E-02	1.18	1.02	1.36	3.03E-02
HLA_DPA1_0103	1.10	1.02	1.18	1.88E-02	1.10	1.02	1.19	1.29E-02
HLA_DPA1_0201	0.73	0.65	0.82	1.07E-07	0.73	0.65	0.82	2.87E-07
HLA_DPA1_0202	1.05	0.97	1.13	2.50E-01	1.04	0.96	1.12	3.56E-01
HLA_DPB1_0201	1.10	1.01	1.20	2.31E-02	1.17	1.08	1.28	2.92E-04
HLA_DPB1_0202	1.16	0.96	1.39	1.22E-01	1.16	0.96	1.39	1.26E-01
HLA_DPB1_0402	1.06	0.91	1.24	4.25E-01	1.01	0.87	1.18	8.76E-01
HLA_DPB1_0501	1.08	1.00	1.17	5.06E-02	1.05	0.97	1.14	2.07E-01
HLA_DPB1_1301	0.77	0.64	0.93	6.99E-03	0.77	0.63	0.93	6.07E-03
HLA_A_0206	0.97	0.85	1.10	6.13E-01	0.97	0.85	1.11	6.42E-01
HLA_A_1101	1.16	1.04	1.28	5.47E-03	1.16	1.04	1.28	6.52E-03
HLA_A_2402	1.06	0.96	1.16	2.33E-01	1.05	0.96	1.15	3.09E-01
HLA_A_2601	0.99	0.84	1.17	9.16E-01	1.02	0.86	1.20	8.31E-01
HLA_A_3101	1.05	0.88	1.25	5.82E-01	1.08	0.91	1.29	3.83E-01
HLA_A_3303	0.83	0.73	0.95	5.29E-03	0.82	0.72	0.94	3.59E-03
HLA_B_0702	0.75	0.59	0.95	1.85E-02	0.82	0.64	1.04	1.06E-01
HLA_B_1301	1.04	0.84	1.27	7.32E-01	1.07	0.87	1.31	5.43E-01
HLA_B_3501	1.14	0.97	1.35	1.20E-01	1.16	0.98	1.37	8.69E-02
HLA_B_4001	1.13	0.97	1.31	1.12E-01	1.14	0.98	1.33	8.33E-02
HLA_B_4403	0.86	0.72	1.02	7.99E-02	0.85	0.71	1.01	5.93E-02
HLA_B_5101	1.02	0.89	1.16	8.04E-01	1.03	0.90	1.17	6.77E-01
HLA_B_5201	0.67	0.55	0.82	8.80E-05	0.68	0.56	0.84	2.11E-04
HLA_B_5401	1.24	1.06	1.45	6.03E-03	1.04	0.89	1.23	6.08E-01
HLA_C_0102	1.10	0.99	1.21	7.38E-02	1.01	0.91	1.12	8.76E-01
HLA_C_0303	1.01	0.90	1.15	8.17E-01	1.06	0.93	1.21	3.60E-01
HLA_C_0304	1.06	0.94	1.19	3.43E-01	1.08	0.96	1.22	2.11E-01
HLA_C_0401	0.96	0.83	1.11	5.55E-01	0.96	0.83	1.11	5.61E-01
HLA_C_0602	0.89	0.77	1.02	9.44E-02	0.88	0.76	1.01	7.09E-02
HLA_C_0702	0.99	0.88	1.11	8.07E-01	1.01	0.90	1.14	8.70E-01
HLA_C_0801	1.14	1.02	1.28	2.66E-02	1.16	1.03	1.31	1.19E-02
HLA_C_1202	0.73	0.61	0.88	7.77E-04	0.75	0.62	0.90	2.37E-03
HLA_C_1402	1.08	0.92	1.27	3.60E-01	1.09	0.93	1.29	2.84E-01
HLA_C_1502	0.99	0.82	1.20	9.06E-01	1.03	0.85	1.25	7.58E-01

Table S9. Association testing of the classical HLA alleles in the European case-control cohorts. OR: Odds Ratio; L95 and U95: lower and upper bounds of the 95% confidence interval.

HLA Allele	Unconditional				Control for 4 significant DRB1 alleles				Control for DRB1 alleles & DQA1*0102				Control for DRB1 alleles, DQA1*0102 & DPA1*0103			
	OR	L95	U95	P	OR	L95	U95	P	OR	L95	U95	P	OR	L95	U95	P
HLA_DRB1_0101	**1.31**	**1.20**	**1.41**	**6.48E-11**												
HLA_DRB1_0301	**0.77**	**0.71**	**0.83**	**2.84E-10**												
HLA_DRB1_0701	**0.73**	**0.68**	**0.79**	**2.96E-16**												
HLA_DRB1_1201	1.14	0.96	1.35	1.39E-01	1.03	0.87	1.23	7.38E-01	0.99	0.83	1.18	8.90E-01	0.99	0.83	1.18	8.87E-01
HLA_DRB1_1301	0.98	0.88	1.08	6.66E-01	0.88	0.79	0.97	1.24E-02	0.84	0.76	0.93	1.12E-03	0.85	0.77	0.95	3.11E-03
HLA_DRB1_1302	0.99	0.88	1.11	8.50E-01	0.89	0.79	1.00	4.25E-02	1.39	1.17	1.65	2.20E-04	1.38	1.16	1.64	3.19E-04
HLA_DRB1_1501	**0.73**	**0.67**	**0.79**	**2.50E-13**												
HLA_DQB1_0201	0.79	0.73	0.86	1.30E-08	1.45	1.01	2.06	4.31E-02	1.38	0.96	1.98	8.01E-02	1.42	0.99	2.03	5.95E-02
HLA_DQB1_0202	0.75	0.69	0.82	1.18E-10	1.09	0.92	1.28	3.11E-01	1.09	0.92	1.28	3.15E-01	1.12	0.95	1.32	1.86E-01
HLA_DQB1_0301	1.25	1.18	1.32	5.83E-16	1.12	1.06	1.20	1.56E-04	1.06	1.00	1.13	6.30E-02	1.05	0.98	1.12	1.42E-01
HLA_DQB1_0302	1.10	1.01	1.19	2.61E-02	0.97	0.89	1.05	4.71E-01	0.93	0.86	1.01	9.47E-02	0.93	0.85	1.01	8.49E-02
HLA_DQB1_0303	0.74	0.65	0.84	5.71E-06	0.88	0.76	1.01	7.38E-02	0.87	0.76	1.00	5.84E-02	0.86	0.74	0.99	3.34E-02
HLA_DQB1_0402	1.05	0.90	1.22	5.22E-01	0.95	0.82	1.11	5.35E-01	0.92	0.79	1.07	2.56E-01	0.92	0.79	1.07	2.54E-01
HLA_DQB1_0501	1.34	1.25	1.43	1.85E-16	1.23	1.09	1.39	8.83E-04	1.18	1.05	1.34	7.09E-03	1.19	1.05	1.35	5.34E-03
HLA_DQB1_0503	1.39	1.24	1.56	1.69E-08	1.26	1.12	1.42	8.12E-05	1.22	1.08	1.37	1.07E-03	1.22	1.09	1.37	7.67E-04
HLA_DQB1_0602	0.73	0.67	0.80	6.71E-12	1.02	0.78	1.33	8.92E-01	1.07	0.82	1.40	6.05E-01	1.05	0.80	1.37	7.47E-01
HLA_DQB1_0603	0.96	0.87	1.06	3.88E-01	0.88	0.79	0.97	1.03E-02	0.84	0.76	0.93	1.01E-03	0.86	0.77	0.95	3.21E-03
HLA_DQB1_0604	1.09	0.96	1.23	2.02E-01	0.98	0.86	1.11	7.07E-01	1.54	1.29	1.83	1.15E-06	1.51	1.27	1.80	3.23E-06
HLA_DQA1_0101	1.38	1.30	1.47	1.42E-24	1.26	1.15	1.38	2.85E-07	1.21	1.11	1.32	3.19E-05	1.22	1.11	1.33	1.75E-05
HLA_DQA1_0102	**0.76**	**0.71**	**0.81**	**7.04E-17**	**0.75**	**0.68**	**0.82**	**6.35E-10**								
HLA_DQA1_0103	0.97	0.88	1.06	4.79E-01	0.86	0.78	0.95	3.15E-03	0.83	0.75	0.91	1.35E-04	0.84	0.76	0.93	6.22E-04
HLA_DQA1_0201	0.74	0.68	0.80	2.96E-15												
HLA_DQA1_0301	1.08	1.01	1.16	1.63E-02	0.94	0.88	1.01	9.49E-02	0.89	0.83	0.96	2.18E-03	0.89	0.83	0.96	1.43E-03
HLA_DQA1_0401	0.98	0.84	1.14	7.87E-01	0.89	0.76	1.04	1.39E-01	0.85	0.73	1.00	4.88E-02	0.85	0.73	1.00	4.73E-02
HLA_DQA1_0501	1.08	1.03	1.14	2.82E-03	1.17	1.10	1.25	1.46E-06	1.11	1.04	1.19	1.43E-03	1.11	1.03	1.18	3.35E-03
HLA_DPA1_0103	**0.77**	**0.72**	**0.82**	**4.96E-16**	**0.82**	**0.76**	**0.87**	**1.12E-09**	**0.82**	**0.77**	**0.88**	**1.06E-08**				
HLA_DPA1_0201	0.75	0.70	0.80	1.88E-15	0.80	0.75	0.86	2.80E-09	0.81	0.75	0.87	1.86E-08	0.90	0.78	1.04	1.65E-01
HLA_DPA1_0202	0.93	0.80	1.07	3.15E-01	0.96	0.83	1.12	6.26E-01	0.97	0.84	1.12	6.59E-01	1.17	1.00	1.37	5.43E-02
HLA_DPB1_0101	0.71	0.62	0.81	1.65E-07	0.81	0.71	0.93	2.79E-03	0.81	0.71	0.93	3.26E-03	0.95	0.82	1.11	5.28E-01
HLA_DPB1_0201	1.14	1.07	1.21	9.01E-05	1.11	1.04	1.18	1.60E-03	1.11	1.04	1.18	2.05E-03	1.07	1.00	1.14	4.49E-02
HLA_DPB1_0301	0.84	0.77	0.91	1.38E-05	0.82	0.76	0.89	1.95E-06	0.83	0.77	0.90	6.59E-06	0.80	0.73	0.86	4.39E-08
HLA_DPB1_0401	1.06	1.01	1.11	2.79E-02	1.07	1.02	1.12	1.03E-02	1.06	1.01	1.11	2.02E-02	1.01	0.96	1.06	7.07E-01
HLA_DPB1_0402	1.20	1.12	1.29	2.03E-07	1.13	1.05	1.21	5.50E-04	1.12	1.05	1.21	1.13E-03	1.09	1.02	1.17	1.70E-02
HLA_DPB1_0501	1.02	0.85	1.21	8.52E-01	1.02	0.85	1.22	8.32E-01	1.07	0.89	1.27	4.83E-01	1.28	1.06	1.55	9.39E-03
HLA_DPB1_1301	0.91	0.77	1.09	3.16E-01	0.94	0.79	1.12	5.07E-01	0.95	0.79	1.13	5.53E-01	1.09	0.91	1.31	3.65E-01
HLA_A_0101	0.82	0.77	0.88	1.56E-08	0.88	0.82	0.95	6.84E-04	0.88	0.82	0.95	9.44E-04	0.89	0.83	0.96	1.62E-03
HLA_A_0201	1.10	1.04	1.16	6.42E-04	1.06	1.00	1.12	3.50E-02	1.06	1.01	1.12	2.87E-02	1.06	1.01	1.12	2.99E-02
HLA_A_0301	1.01	0.94	1.08	8.68E-01	1.00	0.93	1.07	9.36E-01	0.99	0.93	1.07	8.70E-01	0.99	0.92	1.06	7.99E-01
HLA_A_1101	1.12	1.02	1.23	2.28E-02	1.06	0.96	1.17	2.80E-01	1.05	0.95	1.15	3.76E-01	1.05	0.95	1.16	3.34E-01
HLA_A_2301	0.90	0.76	1.06	1.92E-01	0.96	0.82	1.13	6.54E-01	0.96	0.81	1.13	6.27E-01	0.96	0.81	1.13	5.96E-01
HLA_A_2402	1.00	0.93	1.08	9.89E-01	0.97	0.90	1.05	5.17E-01	0.97	0.90	1.05	4.47E-01	0.97	0.89	1.05	3.95E-01
HLA_A_2601	1.04	0.92	1.18	5.04E-01	1.01	0.89	1.15	8.63E-01	1.01	0.89	1.15	8.79E-01	1.01	0.89	1.14	9.16E-01
HLA_A_3001	0.98	0.82	1.16	7.80E-01	1.10	0.92	1.31	2.99E-01	1.11	0.93	1.33	2.54E-01	1.12	0.94	1.34	2.02E-01
HLA_A_3101	1.04	0.90	1.21	6.03E-01	0.99	0.85	1.15	9.09E-01	0.99	0.85	1.15	8.98E-01	0.99	0.85	1.15	8.61E-01
HLA_A_3201	0.89	0.79	1.00	5.19E-02	0.87	0.77	0.98	2.76E-02	0.87	0.77	0.99	2.78E-02	0.87	0.77	0.99	2.81E-02
HLA_A_6801	1.25	1.10	1.43	6.44E-04	1.20	1.05	1.37	6.47E-03	1.21	1.06	1.38	4.11E-03	1.21	1.06	1.38	3.97E-03
HLA_B_0702	0.84	0.77	0.91	2.12E-05	0.93	0.84	1.01	9.94E-02	0.92	0.84	1.01	9.32E-02	0.92	0.84	1.01	9.20E-02
HLA_B_0801	0.74	0.68	0.81	5.67E-11	0.82	0.73	0.92	6.47E-04	0.82	0.73	0.92	5.43E-04	0.83	0.74	0.93	1.40E-03
HLA_B_1302	1.00	0.87	1.15	9.89E-01	1.25	1.07	1.45	3.78E-03	1.25	1.08	1.46	2.94E-03	1.26	1.09	1.47	2.15E-03
HLA_B_1402	0.86	0.74	1.01	5.87E-02	0.81	0.69	0.95	8.77E-03	0.82	0.70	0.95	1.13E-02	0.83	0.70	0.97	1.75E-02
HLA_B_1801	1.00	0.91	1.10	9.45E-01	1.02	0.92	1.12	7.56E-01	1.00	0.91	1.10	9.66E-01	0.99	0.90	1.09	8.56E-01
HLA_B_2705	1.21	1.07	1.36	3.06E-03	1.09	0.96	1.24	1.66E-01	1.08	0.95	1.22	2.31E-01	1.08	0.95	1.23	2.22E-01
HLA_B_4001	1.17	1.04	1.31	1.11E-02	1.06	0.94	1.20	3.06E-01	1.11	0.99	1.25	8.38E-02	1.11	0.98	1.25	1.03E-01
HLA_B_4402	1.15	1.06	1.26	1.24E-03	1.06	0.97	1.16	1.90E-01	1.05	0.96	1.14	3.15E-01	1.04	0.95	1.14	3.77E-01
HLA_B_4403	0.79	0.70	0.89	8.42E-05	0.93	0.81	1.05	2.50E-01	0.93	0.82	1.06	2.61E-01	0.94	0.83	1.07	3.83E-01
HLA_B_4901	1.26	1.08	1.47	2.81E-03	1.21	1.04	1.41	1.65E-02	1.24	1.06	1.45	6.60E-03	1.24	1.06	1.45	6.21E-03
HLA_B_5101	1.21	1.10	1.32	3.87E-05	1.14	1.04	1.25	4.45E-03	1.13	1.03	1.24	7.27E-03	1.14	1.04	1.24	6.31E-03
HLA_B_5701	0.73	0.63	0.85	3.40E-05	0.83	0.71	0.97	2.08E-02	0.83	0.71	0.98	2.28E-02	0.82	0.70	0.96	1.41E-02
HLA_C_0102	1.20	1.07	1.35	2.68E-03	1.08	0.96	1.22	1.86E-01	1.07	0.95	1.21	2.54E-01	1.07	0.95	1.21	2.64E-01
HLA_C_0202	1.21	1.09	1.34	3.29E-04	1.13	1.02	1.25	2.27E-02	1.14	1.03	1.27	1.25E-02	1.15	1.03	1.27	1.10E-02
HLA_C_0303	0.93	0.83	1.04	1.81E-01	0.87	0.77	0.97	1.26E-02	0.85	0.76	0.95	5.47E-03	0.86	0.77	0.96	7.26E-03
HLA_C_0304	1.11	1.01	1.23	3.86E-02	1.02	0.92	1.13	7.15E-01	1.04	0.94	1.16	4.02E-01	1.04	0.94	1.15	4.57E-01
HLA_C_0401	1.08	1.01	1.16	2.44E-02	1.00	0.93	1.07	9.95E-01	1.00	0.93	1.07	9.34E-01	0.99	0.93	1.07	8.46E-01
HLA_C_0501	1.20	1.10	1.31	3.22E-05	1.15	1.06	1.26	1.20E-03	1.13	1.04	1.24	4.45E-03	1.12	1.03	1.22	8.98E-03
HLA_C_0602	0.95	0.88	1.03	2.30E-01	1.09	1.00	1.19	4.45E-02	1.09	1.00	1.19	4.96E-02	1.08	0.99	1.18	7.25E-02
HLA_C_0701	0.85	0.80	0.91	1.83E-06	0.90	0.84	0.97	6.19E-03	0.91	0.85	0.98	1.50E-02	0.92	0.85	0.99	2.16E-02
HLA_C_0702	0.85	0.78	0.92	2.90E-05	0.92	0.85	1.00	5.97E-02	0.92	0.84	1.00	4.43E-02	0.92	0.84	1.00	4.20E-02
HLA_C_0704	1.08	0.91	1.29	3.83E-01	1.01	0.84	1.20	9.40E-01	1.03	0.86	1.23	7.44E-01	1.02	0.86	1.22	8.07E-01
HLA_C_0802	0.87	0.76	1.00	4.69E-02	0.86	0.75	0.98	2.97E-02	0.86	0.75	0.99	3.50E-02	0.87	0.75	1.00	4.29E-02
HLA_C_1203	1.08	0.98	1.18	1.04E-01	1.04	0.94	1.14	4.56E-01	1.04	0.94	1.14	4.48E-01	1.04	0.95	1.14	4.22E-01
HLA_C_1502	1.22	1.06	1.41	4.80E-03	1.17	1.01	1.34	3.15E-02	1.16	1.01	1.34	3.91E-02	1.17	1.01	1.34	3.33E-02

Table S10. Pleiotropy analysis of significant non-HLA GWAS loci: lead IgAN SNPs and their LD proxies (r2>0.5) were annotated against the NHGRI GWAS Catalogue to retrieve previously reported GWAS associations with other traits with $P<5x10^{-8}$.

Previously published GWAS associations									Associations with IgAN				Top SNP in the Locus	LD with the top SNP
Locus	DISEASE/TRAIT	PMID	Journal	Year	Index SNP	Risk Allele	OR or BETA	P value	Risk allele	OR	P value	Direction	SNP	R2
TNFSF4	Allergy	29083406	*Nat Genet*	2017	rs4090390	A	1.05	1.00E-15	A	1.08	1.57E-02	Concordant	rs4916312	0.750
CFH	Neovascular age-related macular degeneration	28703135	*J Hum Genet*	2017	rs800292	G	1.67	3.00E-08	G	1.12	4.68E-08	Concordant	rs6677604	0.910
CFH	Circulating myeloperoxidase levels (serum)	23620142	*Hum Mol Genet*	2013	rs800292	A	0.15	5.00E-41	G	1.12	4.68E-08	Opposed		0.910
CFH	Sub-foveal choroidal thickness	29844195	*Proc Natl Acad Sci USA*	2018	rs800292	A	10.27	2.00E-10	G	1.12	4.68E-08	Opposed		0.910
CFH	Matrix metalloproteinase-8 levels	29212897	*Circ Cardiovasc Genet*	2017	rs800292	A	0.24	2.00E-35	G	1.12	4.68E-08	Opposed		0.910
REL	Multiple sclerosis	24076602	*Nat Genet*	2013	rs842639	A	1.10	2.00E-14	G	1.11	3.95E-08	Opposed	rs842638	0.672
REL	Rheumatoid arthritis	23143596	*Nat Genet*	2012	rs13031237	A	1.12	5.00E-14	G	1.08	6.73E-04	Opposed		0.661
REL	Psoriasis	25574825	*Am J Hum Genet*	2015	rs35741374	T	1.20	4.00E-12	T	1.13	5.31E-09	Concordant		0.988
CD28	Primary biliary cirrhosis	28425483	*Nat Commun*	2017	rs4675369	G	1.30	1.00E-13	A	1.09	2.01E-04	Opposed	rs3769684	0.596
IRF4	Takayasu artheritis	30498034	*Proc Natl Acad Sci USA*	2018	rs17133698	C	1.50	3.00E-09	C	1.20	2.11E-10	Concordant	rs12201499	0.792
LY86	Neutrophil count	27863252	*Cell*	2016	rs1334577	A	0.02	3.00E-09	G	1.13	2.19E-09	Opposed	rs12530084	0.967
LY86	Basophil count + eosinophil count	27863252	*Cell*	2016	rs1334577	A	0.02	4.00E-09	G	1.13	2.19E-09	Opposed		0.967
LY86	Pulse pressure	30224653	*Nat Genet*	2018	rs1334576	A	0.11	4.00E-11	G	1.09	2.07E-05	Opposed		0.778
LY86	Leukocyte count	27863252	*Cell*	2016	rs11303054	C	0.03	2.00E-12	C	1.13	7.18E-06	Concordant		0.571
LY86	Urate levels	23263486	*Nat Genet*	2013	rs675209	T	4.39	1.00E-23	C	1.10	1.20E-05	Opposed		0.541
PF4V1	Sum neutrophil eosinophil counts	27863252	*Cell*	2017	rs16850073	T	0.05	2.00E-45	T	1.10	4.23E-04	Concordant	rs6828610	0.513
PF4V1	Granulocyte percentage of myeloid white cells	27863252	*Cell*	2017	rs16850073	T	0.04	5.00E-23	T	1.10	4.23E-04	Concordant		0.513
PF4V1	Leukocyte count	27863252	*Cell*	2017	rs16850073	T	0.05	3.00E-34	T	1.10	4.23E-04	Concordant		0.513
PF4V1	Monocyte percentage of white cells	27863252	*Cell*	2017	rs16850073	T	0.03	5.00E-13	T	1.10	4.23E-04	Concordant		0.513
TNFSF8/15	Biliary liver cirrhosis	23000144	*Am J Hum Genet*	2012	rs4979462	T	1.56	3.00E-14	T	1.11	7.53E-04	Concordant	rs13300483	0.563
TNFSF8/15	Primary biliary cirrhosis	28062665	*Hum Mol Genet*	2017	rs4979462	C	1.60	8.00E-19	T	1.11	7.53E-04	Opposed		0.563
TNFSF8/15	Serum IgA	24676358	*Hum Mol Genet*	2014	rs7853287	A	0.12	3.00E-10	A	1.13	1.89E-05	Concordant		0.682
CARD9	Inflammatory bowel diseases	23128233	*Nature*	2012	rs10781499	A	1.19	4.00E-56	A	1.14	7.21E-11	Concordant	rs4077515	0.987
CARD9	Crohn's disease	26192919	*Nat Genet*	2015	rs10781499	A	1.19	8.00E-43	A	1.14	7.21E-11	Concordant		0.987
CARD9	Ulcerative colitis	26192919	*Nat Genet*	2015	rs10781499	A	1.14	4.00E-26	A	1.14	7.21E-11	Concordant		0.987
CARD9	Ankylosing spondylitis	23749187	*Nat Genet*	2013	rs1128905	C	1.12	2.00E-09	C	1.09	1.34E-06	Concordant		0.754
CARD9	Pediatric chronic inflammatory diseases	26301688	*Nat Med*	2015	rs11145763	C	NA	3.00E-08	C	1.12	4.00E-08	Concordant		0.983
CARD9	Granulocyte percentage of myeloid white cells	27863252	*Cell*	2016	rs3812565	C	0.03	4.00E-13	C	1.12	3.66E-08	Concordant		0.815
CARD9	Vital capacity	28166213	*Nat Genet*	2017	rs10870202	C	0.02	9.00E-10	C	1.09	7.89E-07	Concordant		0.539
REEP3	Schizophrenia	28991256	*Nat Genet*	2017	rs111364339	C	1.10	5.00E-09	T	1.10	6.91E-03	Opposed	rs57917667	0.641
ZMIZ1/PPIF	Crohn's disease	26192919	*Nat Genet*	2015	rs1250546	G	1.12	3.00E-19	A	1.12	1.44E-08	Opposed	rs1108618	0.877
ZMIZ1/PPIF	Granulocyte count	27863252	*Cell*	2016	rs2802372	C	1.16	7.00E-09	A	1.13	4.90E-10	Opposed		0.832
ZMIZ1/PPIF	Inflammatory bowel diseases	23128233	*Nature*	2012	rs1250546	A	1.10	3.00E-18	A	1.12	1.44E-08	Concordant		0.877
ZMIZ1/PPIF	Lymphocyte percentage of leukocytes	27863252	*Cell*	2016	rs1250569	C	0.02	1.00E-11	T	1.13	2.24E-09	Opposed		0.799
ZMIZ1/PPIF	Multiple sclerosis	24076602	*Nat Genet*	2013	ZMIZ1/PPIF	A	1.10	3.00E-15	C	1.10	2.82E-07	Opposed		0.748
ZMIZ1/PPIF	Neutrophil percentage of leukocytes	27863252	*Cell*	2016	rs1250569	C	0.02	2.00E-09	T	1.13	2.24E-09	Opposed		0.799
ZMIZ1/PPIF	Celiac disease	22057235	*Nat Genet*	2011	rs1250552	A	1.12	8.00E-17	A	1.09	1.39E-04	Concordant		0.557
ZMIZ1/PPIF	Pediatric chronic inflammatory diseases	26301688	*Nat Med*	2015	rs1250563	G	NA	1.00E-08	G	1.10	1.57E-05	Concordant		0.584
OVOL1/RELA	Atopic eczema	26482879	*Nat Genet*	2015	rs10791824	G	1.12	2.00E-19	A	1.17	1.70E-12	Opposed	rs10896045	0.593
OVOL1/RELA	Allergy	29083406	*Nat Genet*	2017	rs479844	G	1.04	2.00E-13	A	1.09	3.85E-04	Opposed		0.552
OVOL1/RELA	Systemic lupus erythematosus	27399966	*Nat Genet*	2016	rs494003	A	1.14	6.00E-09	A	1.12	3.75E-04	Concordant		0.530
ETS1	Albumin-globulin ratio	29403010	*Nat Genet*	2018	rs7127911	T	0.03	2.00E-11	T	1.12	2.31E-06	Concordant	rs7121743	0.744
ETS1	Non-albumin protein levels	29403010	*Nat Genet*	2018	rs7127911	T	0.03	3.00E-11	T	1.12	2.31E-06	Concordant		0.744
ITGAM/ITGAX	Autoimmune thyroid disease	22922229	*Hum Mol Genet*	2012	rs57348955	G	1.19	5.00E-08	A	1.09	6.78E-03	Opposed	rs11150612	0.725
IRF8	Biliary liver cirrhosis	21399635	*Nat Genet*	2011	rs11117432	G	1.31	5.00E-11	G	1.12	8.99E-04	Concordant	rs1879210	0.508
IRF8	Primary biliary cirrhosis	22961000	*Nat Genet*	2012	rs11117433	G	1.26	1.00E-09	G	1.09	1.43E-03	Concordant		0.510
IRF8	Multiple sclerosis	19525953	*Nat Genet*	2009	rs17445836	G	1.25	4.00E-09	G	1.12	1.43E-03	Concordant		0.505
IRF8	Eosinophil count	27863252	*Cell*	2016	rs17445836	A	0.03	3.00E-10	G	1.12	1.43E-03	Opposed		0.505
IRF8	Systemic lupus erythematosus	28714469	*Nat Commun*	2017	rs11117433	G	1.18	2.00E-11	G	1.09	1.43E-03	Concordant		0.510
TNFRSF13B	Non-albumin protein levels	29403010	*Nat Genet*	2018	rs4985726	G	0.15	1.00E-193	G	1.14	8.58E-09	Concordant	rs57382045	0.979
TNFRSF13B	Albumin-globulin ratio	29403010	*Nat Genet*	2018	rs57166795	G	0.13	5.00E-166	A	1.16	5.98E-09	Opposed		0.989
TNFRSF13B	Total blood protein levels	29403010	*Nat Genet*	2018	rs4985726	G	0.10	3.00E-107	G	1.14	8.58E-09	Concordant		0.979
TNFRSF13B	Albumin level	29403010	*Nat Genet*	2018	rs34562254	G	0.03	2.00E-11	A	1.16	8.00E-09	Opposed		0.884
TNFRSF13B	IgG levels	29403010	*Nat Genet*	2018	rs74998556	T	0.15	1.00E-26	T	1.11	1.70E-03	Concordant		0.628
TNFRSF13B	Na level	29403010	*Nat Genet*	2018	rs34562254	G	0.03	8.00E-10	A	1.16	8.00E-09	Opposed		0.884
TNFRSF13B	Multiple myeloma	27363682	*Nat Commun*	2016	rs34562254	A	1.30	4.00E-17	A	1.16	8.00E-09	Concordant		0.884
LIF	Lymphocyte count	27863252	*Cell*	2016	rs714027	G	0.03	3.00E-21	G	1.14	3.99E-14	Concordant	rs4823074	0.996
LIF	Type 1 diabetes	25751624	*Nat Genet*	2015	rs4820830	C	1.12	1.00E-12	C	1.07	1.21E-03	Concordant		0.585
LIF	Inflammatory bowel diseases	23128233	*Nature*	2012	rs2412970	A	1.08	3.00E-14	G	1.19	1.56E-14	Opposed		1.000
LIF	Crohn's disease	26192919	*Nat Genet*	2015	rs5763767	A	1.09	6.00E-13	G	1.14	3.00E-14	Opposed		1.000
LIF	Lymphocyte percentage of white cells	27863252	*Cell*	2016	rs5763821	C	0.03	1.00E-13	A	1.14	7.61E-07	Opposed		0.966
LIF	Albumin-globulin ratio	29403010	*Nat Genet*	2018	rs2412974	T	0.04	2.00E-10	C	1.15	1.30E-11	Opposed		0.702
LIF	Non-albumin protein levels	29403010	*Nat Genet*	2018	rs2412975	T	0.03	3.00E-10	T	1.16	1.46E-13	Concordant		1.000
LIF	Neutrophil percentage of white cells	27863252	*Cell*	2016	rs5763821	C	0.02	7.00E-10	A	1.14	7.61E-07	Opposed		0.966
LIF	Tonsillectomy	27941131	*J Med Genet*	2016	rs2412971	G	1.22	1.00E-09	G	1.14	3.11E-14	Concordant		1.000
LIF	Mathematical ability	30038396	*Nat Genet*	2018	rs9614099	A	0.01	1.00E-09	T	1.09	8.18E-05	Opposed		0.561
LIF	Creatine kinase levels	29403010	*Nat Genet*	2018	rs5763790	G	0.03	1.00E-08	C	1.07	7.71E-03	Opposed		0.562
LIF	Optic disc area	25631615	*Genet Epidemiol*	2015	rs2412970	G	0.02	3.00E-08	A	1.19	1.56E-14	Opposed		1.000

Table S11. Pleiotropy analysis of suggestive non-HLA GWAS loci ($P<1x10^{-5}$): lead IgAN SNPs and their LD proxies (r2>0.5) were annotated against the NHGRI GWAS Catalogue to retrieve previously reported GWAS associations with other traits with $P<5x10^{-8}$.

Previously published GWAS associations									Associations with IgAN				Top SNP in the Locus	LD with the top SNP
Locus	DISEASE/TRAIT	PMID	Journal	Year	Index SNP	Risk Allele	OR or BETA	P value	Risk allele	OR	P value	Direction	SNP	R2
FCER1G	Allergy	27182965	*Nat Genet*	2016	rs2070902	T	1.06	1.00E-09	T	1.09	0.001	Concordant	rs4233368	0.507
FCER1G	Crohn's disease	26192919	*Nat Genet*	2015	rs1801274	G	1.08	9.00E-11	A	1.11	4.61E-06	Opposed		0.880
FCER1G	Ulcerative cholitis	21297633	*Nat Genet*	2011	rs1801274	A	1.21	2.00E-20	A	1.11	4.61E-06	Concordant		0.880
FCER1G	Inflammatory bowel diseases	23128233	*Nature*	2012	rs1801274	A	1.12	2.00E-38	A	1.11	4.61E-06	Concordant		0.880
FCER1G	Ankylosing spondylitis	23749187	*Nat Genet*	2013	rs1801274	A	1.12	1.00E-09	A	1.11	4.61E-06	Concordant		0.880
FCER1G	Systemic lupus erithematosus	27399966	*Nat Genet*	2017	rs1801274	G	1.21	6.00E-11	A	1.11	4.61E-06	Opposed		0.880
CXCR2	Ankylosing spondylitis	26974007	*Nat Genet*	2016	rs11676348	T	NA	2.00E-11	C	1.07	6.12E-05	Opposed	rs4674259	0.817
CXCR2	Ulcerative cholitis	21297633	*Nat Genet*	2011	rs11676348	T	1.07	1.00E-10	C	1.07	6.12E-05	Opposed		0.817
INPP5D	Allergy	29083406	*Nat Genet*	2017	rs1057258	C	1.05	1.00E-10	T	1.14	2.01E-06	Opposed	rs14243	0.718
INPP5D	Eosinophil percentage of leukocytes	27863252	*Cell*	2016	rs56235204	C	0.19	3.00E-20	C	1.12	6.84E-07	Concordant		0.785
INPP5D	Eosinophil count	27863252	*Cell*	2016	rs56235204	C	0.03	2.00E-14	C	1.12	6.84E-07	Concordant		0.785
INPP5D	Neutrophil percentage of granulocytes	27863252	*Cell*	2016	rs56235204	C	0.04	2.00E-19	C	1.12	6.84E-07	Concordant		0.785
ZFP36L2	Multiple sclerosis	21833088	*Nature*	2011	rs12466022	C	1.11	6.00E-10	A	1.07	0.0008	Opposed	rs737013	0.547
ZFP36L2	granulocyte percentage of myeloid white cells	27863252	*Cell*	2016	rs28498283	T	0.04	2.00E-18	T	1.07	0.0009	Concordant		0.581
ZFP36L2	monocyte percentage of leukocytes	27863252	*Cell*	2016	rs28498283	T	0.03	6.00E-16	T	1.07	0.0009	Concordant		0.581
RN7SL51P	Crohn's disease	26192919	*Nat Genet*	2015	rs11679753	G	1.13	5.00E-11	A	1.09	2.17E-06	Opposed	rs10865331	0.983
RN7SL51P	Ankylosing spondylitis	23749187	*Nat Genet*	2013	rs6759298	C	1.31	4.00E-41	G	1.09	2.34E-06	Opposed		0.849
TCF7	Multiple sclerosis	24076602	*Nat Genet*	2013	rs756699	A	1.12	9.00E-11	C	1.07	0.0036	Opposed	rs151822	0.539
IL12B	Psoriasis	19169254	*Nat Genet*	2009	rs2082412	G	1.44	2.00E-28	A	1.09	7.39E-05	Opposed	rs3213097	0.982
IL7R	Atopic eczema	26482879	*Nat Genet*	2015	rs10214237	T	1.06	3.00E-14	T	1.09	0.0002	Concordant	rs10213865	0.934
IL7R	Neutrophil percentage of granulocytes	27863252	*Cell*	2016	rs4594881	T	0.03	1.00E-17	G	1.09	0.0004	Opposed		0.810
IL7R	Eosinophil percentage of leukocytes	27863252	*Cell*	2016	rs4594881	T	0.03	3.00E-17	G	1.09	0.0004	Opposed		0.810
IL7R	Primary biliary cirrhosis	22961000	*Nat Genet*	2012	rs6871748	A	1.30	2.00E-13	T	1.09	0.0003	Opposed		0.934
IL7R	Biliary liver cirrhosis	23000144	*Am J Hum Genet*	2012	rs6890853	G	1.47	4.00E-08	G	1.09	4.04E-05	Opposed		0.962
IL7R	Multiple sclerosis	24076602	*Nat Genet*	2013	rs6881706	C	1.12	4.00E-17	G	1.09	5.86E-05	Opposed		1.000
IL7R	Allergy	29083406	*Nat Genet*	2017	rs7717955	C	1.07	9.00E-36	C	1.10	1.47E-05	Concordant		0.995
PTGER4	Crohn's disease	26192919	*Nat Genet*	2015	rs11742570	A	1.28	4.00E-87	T	1.01	0.5421	Opposed	rs4957300	0.537
PTGER4	Inflammatory bowel diseases	23128233	*Nature*	2012	rs11742570	C	1.20	2.00E-82	T	1.01	0.5421	Opposed		0.537
PTGER4	Ulcerative cholitis	21297633	*Nat Genet*	2011	rs6451493	T	1.08	3.00E-09	G	1.01	0.5605	Opposed		0.537
PTGER4	Multiple sclerosis	24076602	*Nat Genet*	2013	rs6880778	G	1.12	8.00E-20	A	1.01	0.512	Opposed		0.537
PTGER4	Allergy	29083406	*Nat Genet*	2017	rs7714574	T	1.03	6.00E-10	T	1.08	0.0008	Concordant		0.522
ANKRD55	Rheumathoid arthritis	20453842	*Nat Genet*	2010	rs6859219	C	1.28	1.00E-11	C	1.15	1.96E-07	Concordant	rs10065637	0.994
ANKRD55	Multiple sclerosis	24076602	*Nat Genet*	2013	rs71624119	G	1.13	3.00E-13	G	1.15	4.25E-07	Concordant		0.842
ANKRD55	Crohn's disease	26192919	*Nat Genet*	2015	rs71624119	G	NA	7.00E-10	G	1.15	4.25E-07	Concordant		0.842
TNFAIP3	Systemic lupus erithematosus	28714469	*Nat Commun*	2017	rs5029939	C	1.48	5.00E-29	G	1.15	0.0004	Opposed	rs58905141	0.670
TNFAIP3	Allergy	29083406	*Nat Genet*	2017	rs5029937	G	1.08	2.00E-08	T	1.17	0.0005	Opposed		0.670
TNFAIP3	Rheumathoid arthritis	24390342	*Nature*	2013	rs7752903	G	1.38	2.00E-29	G	1.14	0.0036	Concordant		0.813
TAGAP	Crohn's disease	26192919	*Nat Genet*	2015	rs212388	G	1.11	2.00E-16	C	1.04	0.0253	Opposed	rs2485360	0.559
TAGAP	Rheumathoid arthritis	24390342	*Nature*	2013	rs2451258	T	1.10	3.00E-11	C	1.08	0.0011	Opposed		0.735
TAGAP	Psoriasis	23143594	*Nat Genet*	2012	rs2451258	C	1.12	3.00E-08	C	1.08	0.0011	Concordant		0.735
TAGAP	Basophil count + neutrophil count	27863252	*Cell*	2016	rs2451279	G	0.03	4.00E-12	A	1.07	0.0049	Opposed		0.671
TAGAP	Leukocyte count	27863252	*Cell*	2016	rs2451279	G	0.03	8.00E-12	A	1.07	0.0049	Opposed		0.671
IKZF1	Granulocyte percentage of myeloid white cells	27863252	*Cell*	2016	rs78697948	G	0.08	1.00E-30	G	1.16	8.95E-05	Concordant	rs79441475	0.827
IKZF1	Monocyte percentage of white cells	27863252	*Cell*	2016	rs78697948	G	0.08	3.00E-30	G	1.16	8.95E-05	Concordant		0.827
IKZF1	Monocyte count	27863252	*Cell*	2016	rs78697948	G	0.06	4.00E-19	G	1.16	8.95E-05	Concordant		0.827
CCAT1	Multiple mieloma	27363682	*Nat Commun*	2016	rs1948915	C	1.13	4.00E-11	C	1.09	1.02E-05	Concordant	rs6989575	0.900

Table S12. Genome-wide genetic correlations between IgAN with and without the HLA region and relevant diseases and traits. All analyses are performed with LDSC software, h2: SNP-based heritability, rg: genetic correlation coefficient, se: standard error, z: z-score, p: p-value.

Disease/Trait	Reference	h2	Correlations with IgAN				Correlations with IgAN without MHC region			
			rg	se	z	p	rg	se	z	p
Allergy	Ferreira et al. Nat Genet 2017	0.03	0.0977	0.0672	1.4545	0.1458	0.1823	0.0652	2.7969	0.0052
Ankylosing spondylitis	Zhou et al. Nat Genet 2018	0.02	0.1493	0.1559	0.9582	0.338	-0.2357	0.1818	-1.2964	0.1948
Crohn disease	De Lange et al. Nat Genet 2017	0.27	-0.171	0.0666	-2.5657	0.0103	-0.2163	0.0722	-2.9974	0.0027
Celiac disease	Zhou et al. Nat Genet 2018	0.05	-0.2835	0.1611	-1.7594	0.0785	-0.0505	0.2704	-0.1869	0.8517
IgA deficiency	Bronson et al. Nat Genet 2016	1.00	0.2702	0.1053	2.5649	0.0103	0.1703	0.202	0.8432	0.3991
Inflammatory bowel diseases	De Lange et al. Nat Genet 2017	0.19	-0.1596	0.0618	-2.5807	0.0099	-0.1832	0.0732	-2.501	0.0124
Membranous nephropathy	Xie et al. Nat Comm 2020	0.53	-0.2574	0.1757	-1.4646	0.143	-0.1075	0.1612	-0.6671	0.5047
Multiple sclerosis	Int. MS Genetics Consortium. Science 2019	0.38	-0.153	0.1369	-1.1171	0.2639	0.0635	0.0774	0.8203	0.412
Primary sclerosing cholangitis	Ji et al. Nat Genet 2017	0.46	-0.3696	0.1288	-2.8704	0.0041	-0.2974	0.1144	-2.6004	0.0093
Rheumatoid arthritis	Okada et al. Nature 2014	0.28	0.3417	0.1813	1.8853	0.0594	0.1596	0.0845	1.8889	0.0589
Systemic Lupus Erythematosus	Bentham et al. Nat Genet 2015	0.39	-0.2242	0.1703	-1.3165	0.188	-0.0109	0.1563	-0.0696	0.9445
Type 1 Diabetes	Zhou et al. Nat Genet 2018	0.014	-0.0384	0.0861	-0.4457	0.6558	-0.0224	0.1303	-0.1721	0.8634
Total IgA levels	Liu et al. (accompanying paper)	0.07	0.1862	0.1144	1.6271	0.1037	0.3138	0.102	3.075	0.0021
Ulcerative Colitis	De Lange et al. Nat Genet 2017	0.16	-0.0834	0.0542	-1.5376	0.1242	-0.0586	0.0787	-0.7439	0.4569
Childhood ear infections	Tian et al. Nat Comm 2017	0.04	0.0484	0.0665	0.7266	0.4675	-0.0044	0.0768	-0.0571	0.9545
Colds last year	Tian et al. Nat Comm 2017	0.016	0.0577	0.1141	0.5055	0.6132	-0.044	0.3077	-0.143	0.8863
Mumps	Tian et al. Nat Comm 2017	0.012	-0.0129	0.1021	-0.1262	0.8996	-0.1247	0.1338	-0.9319	0.3514
Plantar warts	Tian et al. Nat Comm 2017	0.04	0.1229	0.0805	1.5268	0.1268	0.08	0.1612	0.4963	0.6197
Pneumonia	Tian et al. Nat Comm 2017	0.02	0.26	0.0785	3.3133	0.0009	0.2034	0.1008	2.0183	0.0436
Positive TB test	Tian et al. Nat Comm 2017	0.014	0.0859	0.1326	0.648	0.517	0.1716	0.3609	0.4754	0.6345
Rubella	Tian et al. Nat Comm 2017	0.01	0.0146	0.1549	0.0944	0.9248	-0.139	0.1517	-0.9159	0.3597
Scarlet fever	Tian et al. Nat Comm 2017	0.011	-0.0893	0.2421	-0.3688	0.7123	0.244	0.154	1.5837	0.1133
Shingles	Tian et al. Nat Comm 2017	0.014	-0.2477	0.1767	-1.4015	0.1611	-0.0492	0.1532	-0.3213	0.748
Strep. Throat	Tian et al. Nat Comm 2017	0.03	0.0502	0.1022	0.4906	0.6237	0.123	0.116	1.0601	0.2891
Tonsillectomy	Tian et al. Nat Comm 2017	0.04	0.115	0.0895	1.2844	0.199	0.1717	0.0817	2.1016	0.0356
UTI frequency	Tian et al. Nat Comm 2017	0.04	0.253	0.0821	3.082	0.0021	0.2007	0.0963	2.0849	0.0371
Yeast infections	Tian et al. Nat Comm 2017	0.04	0.0713	0.0892	0.7993	0.4241	0.0086	0.0938	0.0921	0.9266
Albuminuria	Haas et al. Am J Hum Genet 2018	0.03	0.0932	0.044	2.1207	0.0339	0.0797	0.0564	1.4145	0.1572
Body Mass Index (BMI)	Locke et al. Nature 2015	0.14	0.0622	0.0477	1.3038	0.1923	0.067	0.0498	1.3444	0.1788
Blood Urea Nitrogen (BUN)	Wuttke et al. Nat Genet 2019	0.02	-0.0169	0.0377	-0.4471	0.6548	-0.0263	0.0519	-0.5065	0.6125
Coronary Artery Disease	Nikpay et al. Nat Genet 2015	0.04	0.0965	0.0331	2.9152	0.0036	0.0803	0.0463	1.7332	0.0831
Creatinine-based eGFR	Pattaro et al. Nat Comm 2016	0.07	0.0585	0.0969	0.6044	0.5456	-0.0073	0.0757	-0.0958	0.9236
Cystatin-C-based eGFR	Pattaro et al. Nat Comm 2016	0.09	0.0707	0.1247	0.5666	0.571	-0.0047	0.1139	-0.0413	0.9671
FEV1/FVC	Shrine et al. Nat Genet 2019	0.11	0.0875	0.0484	1.8072	0.0707	0.0364	0.0383	0.95	0.3421
Height	Wood et al. Nat Genet 2014	0.35	0.023	0.0439	0.5241	0.6002	0.0311	0.0464	0.67	0.5028
Essential Hypertension	Zhou et al. Nat Genet 2018	0.04	0.0811	0.035	2.3144	0.0206	0.0718	0.0436	1.6472	0.0995
LDL cholesterol	Willer et al. Nat Gen 2013	0.04	-0.056	0.0919	-0.6098	0.542	-0.1321	0.0694	-1.9043	0.0569
eGFR creatinine	Wuttke et al. Nat Genet 2019	0.04	0.0157	0.0441	0.3552	0.7224	-0.025	0.0411	-0.6089	0.5426
Serum Cholesterol	Willer et al. Nat Gen 2013	0.05	-0.0196	0.124	-0.1581	0.8744	-0.1222	0.0695	-1.7574	0.0788
Serum Triglycerides	Willer et al. Nat Gen 2013	0.05	0.0631	0.0953	0.6622	0.5078	-0.0023	0.0698	-0.0333	0.9735
Type 2 Diabetes	Xue et al. Nat Comm 1018	0.02	0.0512	0.0637	0.8036	0.4216	0.052	0.0657	0.7916	0.4286

Table S13. Overlapping signals between GWAS for IgAN and GWAS for serum IgA levels. The effects of top independently significant loci for IgAN in GWAS for IgA levels; four most significant loci with concordant effects overlapping between both GWAS studies are highlighted in yellow; five additional loci with concordant effects that are genome-wide significant in IgAN GWAS and nominally significant (P<0.05) in the GWAS for IgA levels are highlighted in blue. The HLA alleles with opposed effects are highlighted in red.

				IgAN GWAS			IgA level GWAS		
Locus	CHR	BP	SNP	Risk Allele	OR	P-value	Beta	P-value	Direction
CFH	1	196686918	rs6677604	G	1.21	1.50E-17	0.013	3.02E-01	-
CFH	1	196603302	rs12029571	A	1.12	2.50E-06	0.015	2.11E-01	-
FCRL3/4	1	157542162	rs849815	A	1.14	3.90E-09	0.011	3.35E-01	-
TNFSF4	1	173146357	rs4916312	A	1.14	5.00E-08	0.037	1.20E-03	Concordant
CD28	2	204584759	rs3769684	T	1.19	5.10E-11	0.027	2.05E-01	-
REL	2	61092678	rs842638	T	1.17	9.60E-10	0.039	2.19E-04	Concordant
PF4V1	4	74725320	rs6828610	G	1.14	3.50E-08	0.011	4.22E-01	-
IRF4	6	249571	rs12201499	C	1.18	3.10E-11	0.034	2.21E-02	Concordant
RREB1	6	7214676	rs12530084	C	1.13	1.30E-09	0.013	2.81E-01	-
HLA	6	32389305	rs9268557	C	1.24	4.50E-47	-0.009	3.70E-01	-
HLA	6	32667829	rs9275355	C	1.26	1.71E-34	-0.047	1.73E-03	Opposite
HLA	6	32599999	rs9272105	A	1.25	1.18E-28	-0.049	5.15E-13	Opposite
HLA	6	32681631	rs9275596	T	1.33	3.16E-36	-0.043	1.33E-04	Opposite
HLA	6	33074288	rs3128927	C	1.22	1.50E-25	-0.012	3.31E-01	-
DEFA1	8	6808722	rs2075836	T	1.21	5.80E-11	0.008	4.58E-01	-
LYN	8	56852496	rs75413466	A	1.40	1.40E-10	0.027	6.34E-01	-
ANXA13	8	124765474	rs34354351	T	1.15	3.50E-08	-0.003	8.48E-01	-
CARD9	9	139266496	rs4077515	T	1.14	2.60E-11	-0.003	7.55E-01	-
TNFSF8/15	9	117643362	rs13300483	T	1.13	1.30E-08	0.079	3.17E-10	Concordant
ZMIZ1/PPIF	10	81043743	rs1108618	A	1.14	1.90E-10	0.002	8.35E-01	-
REEP3	10	65363048	rs57917667	G	1.22	1.10E-08	0.070	2.17E-02	Concordant
OVOL1/RELA	11	65555524	rs10896045	A	1.18	4.70E-13	0.066	2.57E-22	Concordant
ETS1	11	128487069	rs7121743	C	1.13	3.40E-08	0.009	5.22E-01	-
IGH	14	107222014	rs751081288	A	1.17	1.90E-08	0.030	1.67E-01	-
ITGAM/ITGAX	16	31357760	rs11150612	A	1.16	8.40E-14	-0.007	5.30E-01	-
IRF8	16	86017715	rs1879210	T	1.14	9.90E-09	0.007	5.47E-01	-
TNFSF13	17	7462969	rs3803800	A	1.15	1.20E-10	0.065	9.41E-08	Concordant
TNFRSF13B	17	16851450	rs57382045	A	1.16	3.40E-09	0.046	4.74E-03	Concordant
FCAR	19	55397217	rs1865097	A	1.12	7.70E-09	-0.019	1.56E-01	-
LIF/HORMAD2	22	30512478	rs4823074	G	1.16	7.80E-15	0.053	6.75E-17	Concordant

Table S14. Enrichment tests for the GWAS candidate gene set against human ortholog gene sets producing 27 phenotype categories when knocked out in mice.

Knockout mouse phenotype category	No. knockout mouse genes with human ortholog	No. overlap with IgAN genes	P-value
immune system	**3701**	**37**	**1.35E-12**
hematopoietic system	**3667**	**33**	**3.22E-09**
cellular	3782	31	3.07E-07
integument	2046	19	1.58E-05
mortality/aging	5534	35	8.99E-05
neoplasm	996	11	2.00E-04
endocrine/exocrine glands	2445	18	1.80E-03
liver/biliary system	1359	12	2.10E-03
skeleton	2454	17	6.10E-03
embryo	1954	14	1.07E-02
homeostasis/metabolism	5220	28	1.83E-02
digestive/alimentary system	1481	11	2.10E-02
vision/eye	1796	12	3.95E-02
growth/size/body	4508	24	3.96E-02
nervous system	3631	20	4.98E-02
renal/urinary system	1377	9	1.03E-01
respiratory system	1442	9	1.36E-01
behavior/neurological	3944	19	2.07E-01
pigmentation	516	4	2.29E-01
limbs/digits/tail	1158	7	2.46E-01
cardiovascular system	2889	14	3.07E-01
craniofacial	1243	7	3.31E-01
muscle	1537	7	6.82E-01
hearing/vestibular/ear	796	2	8.17E-01
adipose tissue	1156	4	9.23E-01
reproductive system	2263	8	9.39E-01
taste/olfaction	153	0	9.43E-01

Table S15. Genome-wide cell type-specific heritability enrichment for functional annotations based on FUN-LDA scoring system for all ENCODE and Roadmap Epigenomics cell types and tissues. Prop. SNPs: proportion of SNPs enriched. Prop. h2: proportion of heritability explained by the SNPs enriched. Prop. h2 SE: standard error of proportion of heritability. Enrichment: heritability enrichment, calculated as (Prop. SNPs)/(Prop. h2). Enrichment SE: standard error of the enrichment. Enrichment p: p-value of the enrichment. Coefficient: regression coefficient of each cell-type specific FUN-LDA score. Coefficient SE: standard error of the regression coefficient. Coefficient z-score: z score of the regression coefficient.

Epigenome ID	Group	Epigenome Mnemonic	Standardized Epigenome Name	Prop. SNPs	Prop. h2	Prop. h2 SE	Enrichment	Enrichment SE	Enrichment P-value	Coefficient	Coefficient SE	Coefficient Z-score
E030	HSC & B-cell	BLD.CD15.PC	Primary neutrophils from peripheral blood	0.03	0.69	0.12	26.65	4.76	5.96E-10	5.52E-07	2.36E-07	2.34
E041	Blood & T-cell	BLD.CD4.CD25M.IL17M.PL.TPC	Primary T helper cells PMA-I stimulated	0.03	0.54	0.10	20.95	3.92	2.11E-09	5.26E-07	2.99E-07	1.76
E032	HSC & B-cell	BLD.CD19.PPC	Primary B cells from peripheral blood	0.02	0.70	0.14	33.93	6.67	1.99E-08	7.39E-07	3.70E-07	2.00
E031	HSC & B-cell	BLD.CD19.CPC	Primary B cells from cord blood	0.03	0.61	0.12	23.73	4.75	2.36E-08	-1.37E-08	3.60E-07	-0.04
E051	HSC & B-cell	BLD.MOB.CD34.PC.M	Primary hematopoietic stem cells G-CSF-mobilized Male	0.03	0.57	0.11	21.45	4.33	1.14E-07	5.45E-07	3.81E-07	1.43
E115	ENCODE2012	BLD.DND41.CNCR	Dnd41 TCell Leukemia Cell Line	0.02	0.53	0.11	29.81	6.21	2.55E-07	6.87E-07	2.54E-07	2.70
E124	ENCODE2012	BLD.CD14.MONO	Monocytes-CD14+ RO01746 Primary Cells	0.03	0.53	0.11	20.66	4.47	3.10E-07	-1.07E-07	2.63E-07	-0.41
E116	ENCODE2012	BLD.GM12878	GM12878 Lymphoblastoid Cells	0.02	0.56	0.14	29.43	7.23	3.51E-06	2.27E-07	3.34E-07	0.68
E113	Other	SPLN	Spleen	0.02	0.41	0.10	21.84	5.35	4.50E-06	4.49E-07	3.16E-07	1.42
E101	Digestive	GI.RECT.MUC.29	Rectal Mucosa Donor 29	0.02	0.50	0.11	25.04	5.45	6.42E-06	1.28E-06	4.90E-07	2.62
E066	Other	LIV.ADLT	Liver	0.03	0.41	0.10	15.91	3.70	8.61E-06	1.97E-07	1.58E-07	1.25
E042	Blood & T-cell	BLD.CD4.CD25M.IL17P.PL.TPC	Primary T helper 17 cells PMA-I stimulated	0.02	0.44	0.11	22.25	5.38	1.83E-05	3.49E-07	3.86E-07	0.91
E047	Blood & T-cell	BLD.CD8.NPC	Primary T CD8+ naive cells from peripheral blood	0.02	0.42	0.11	22.74	5.89	2.32E-05	5.50E-07	4.82E-07	1.14
E046	HSC & B-cell	BLD.CD56.PC	Primary Natural Killer cells from peripheral blood	0.02	0.49	0.12	27.38	6.61	2.63E-05	2.27E-07	3.90E-07	0.58
E093	Thymus	THYM.FET	Fetal Thymus	0.02	0.44	0.12	22.04	5.80	6.03E-05	-2.85E-08	3.28E-07	-0.09
E037	Blood & T-cell	BLD.CD4.MPC	Primary T helper memory cells from peripheral blood 2	0.02	0.38	0.10	18.42	4.73	9.27E-05	1.55E-07	4.35E-07	0.35
E029	HSC & B-cell	BLD.CD14.PC	Primary monocytes from peripheral blood	0.02	0.49	0.13	22.31	6.14	9.89E-05	-1.53E-07	3.60E-07	-0.43
E033	Blood & T-cell	BLD.CD3.CPC	Primary T cells from cord blood	0.02	0.39	0.11	24.76	6.76	1.10E-04	2.41E-07	4.92E-07	0.49
E045	Blood & T-cell	BLD.CD4.CD25I.CD127.TMEMPC	Primary T cells effector/memory enriched from periph. blood	0.02	0.36	0.11	19.45	5.73	1.60E-04	7.94E-08	4.76E-07	0.17
E043	Blood & T-cell	BLD.CD4.CD25M.TPC	Primary T helper cells from peripheral blood	0.02	0.40	0.11	17.41	4.95	2.02E-04	-4.61E-08	4.18E-07	-0.11
E063	Adipose	FAT.ADIP.NUC	Adipose Nuclei	0.03	0.45	0.12	16.80	4.42	2.11E-04	3.01E-07	2.67E-07	1.13
E110	Digestive	GI.STMC.MUC	Stomach Mucosa	0.02	0.39	0.11	18.54	5.05	2.16E-04	4.31E-07	2.92E-07	1.48
E129	ENCODE2012	BONE.OSTEO	Osteoblast Primary Cells	0.03	0.40	0.10	15.19	3.95	2.21E-04	6.23E-07	2.87E-07	2.17
E040	Blood & T-cell	BLD.CD4.CD25M.CD45RO.MPC	Primary T helper memory cells from peripheral blood 1	0.02	0.36	0.10	16.85	4.69	2.40E-04	-1.42E-07	5.27E-07	-0.27
E119	ENCODE2012	BRST.HMEC	HMEC Mammary Epithelial Primary Cells	0.02	0.37	0.10	19.38	5.07	2.40E-04	4.33E-07	3.98E-07	1.09
E109	Digestive	GI.S.INT	Small Intestine	0.02	0.31	0.09	17.02	4.96	3.20E-04	6.62E-08	3.46E-07	0.19
E034	Blood & T-cell	BLD.CD3.PPC	Primary T cells from peripheral blood	0.02	0.38	0.10	19.75	5.38	3.46E-04	-3.19E-07	4.19E-07	-0.76
E044	Blood & T-cell	BLD.CD4.CD25.CD127M.TREGPC	Primary T regulatory cells from peripheral blood	0.02	0.33	0.10	17.13	4.94	4.35E-04	-3.28E-07	3.66E-07	-0.90
E028	Epithelial	BRST.HMEC.35	Breast variant Human Mammary Epithelial Cells (vHMEC)	0.02	0.35	0.10	18.54	5.09	4.47E-04	2.90E-07	4.05E-07	0.72
E025	Mesench	FAT.ADIP.DR.MSC	Adipose Derived Mesenchymal Stem Cell Cultured Cells	0.03	0.36	0.10	11.14	3.04	6.46E-04	8.05E-08	1.97E-07	0.41
E056	Epithelial	SKIN.PEN.FRSK.FIB.02	Foreskin Fibroblast Primary Cells skin02	0.02	0.38	0.11	15.18	4.27	7.13E-04	3.21E-07	4.84E-07	0.66
E091	Other	PLCNT.FET	Placenta	0.02	0.31	0.09	15.82	4.74	7.44E-04	1.37E-07	1.83E-07	0.75
E059	Epithelial	SKIN.PEN.FRSK.MEL.01	Foreskin Melanocyte Primary Cells skin01	0.01	0.28	0.08	19.06	5.82	8.17E-04	3.11E-07	3.59E-07	0.87
E035	HSC & B-cell	BLD.CD34.PC	Primary hematopoietic stem cells	0.02	0.43	0.13	22.27	6.85	8.59E-04	1.48E-07	4.91E-07	0.30
E106	Digestive	GI.CLN.SIG	Sigmoid Colon	0.02	0.30	0.10	16.40	5.32	8.73E-04	-1.48E-07	4.13E-07	-0.36
E036	HSC & B-cell	BLD.CD34.CC	Primary hematopoietic stem cells short term culture	0.02	0.41	0.13	17.67	5.80	1.03E-03	-3.62E-07	3.61E-07	-1.00
E084	Digestive	GI.L.INT.FET	Fetal Intestine Large	0.02	0.29	0.09	13.13	4.01	1.14E-03	2.10E-07	3.26E-07	0.65
E112	Thymus	THYM	Thymus	0.02	0.32	0.11	21.22	7.23	1.30E-03	-3.14E-07	4.83E-07	-0.65
E061	Epithelial	SKIN.PEN.FRSK.MEL.03	Foreskin Melanocyte Primary Cells skin03	0.02	0.28	0.09	14.32	4.44	1.48E-03	-3.95E-08	2.41E-07	-0.16
E127	ENCODE2012	SKIN.NHEK	NHEK-Epidermal Keratinocyte Primary Cells	0.02	0.31	0.09	14.10	4.20	1.56E-03	-1.26E-07	3.15E-07	-0.40
E057	Epithelial	SKIN.PEN.FRSK.KER.02	Foreskin Keratinocyte Primary Cells skin02	0.02	0.33	0.10	16.92	5.02	1.56E-03	1.70E-07	3.82E-07	0.44
E075	Digestive	GI.CLN.MUC	Colonic Mucosa	0.02	0.31	0.10	16.15	5.17	1.74E-03	-5.20E-08	3.84E-07	-0.14
E107	Muscle	MUS.SKLT.M	Skeletal Muscle Male	0.02	0.31	0.09	12.70	3.86	1.76E-03	1.00E-07	3.20E-07	0.31
E123	ENCODE2012	BLD.K562.CNCR	K562 Leukemia Cells	0.02	0.28	0.09	16.87	5.35	1.85E-03	2.34E-09	2.13E-07	0.01
E090	Muscle	MUS.LEG.FET	Fetal Muscle Leg	0.02	0.33	0.10	14.24	4.50	1.86E-03	5.08E-07	3.56E-07	1.43
E050	HSC & B-cell	BLD.MOB.CD34.PC.F	Primary hematopoietic stem cells G-CSF-mobilized Female	0.02	0.36	0.11	14.74	4.69	1.97E-03	-5.89E-07	3.39E-07	-1.74
E120	ENCODE2012	MUS.HSMM	HSMM Skeletal Muscle Myoblasts Cells	0.02	0.31	0.09	16.45	5.01	1.99E-03	5.71E-07	3.36E-07	1.70
E126	ENCODE2012	SKIN.NHDFAD	NHDF-Ad Adult Dermal Fibroblast Primary Cells	0.02	0.32	0.10	17.81	5.69	2.02E-03	4.58E-07	3.02E-07	1.51
E108	Muscle	MUS.SKLT.F	Skeletal Muscle Female	0.02	0.31	0.10	12.69	3.95	2.03E-03	-1.18E-09	2.76E-07	0.00
E079	Digestive	GI.ESO	Esophagus	0.01	0.27	0.08	19.41	6.01	2.12E-03	3.99E-07	3.91E-07	1.02
E074	Brain	BRN.SUB.NIG	Brain Substantia Nigra	0.03	0.29	0.09	10.79	3.38	2.22E-03	3.41E-07	3.03E-07	1.13
E122	ENCODE2012	VAS.HUVEC	HUVEC Umbilical Vein Endothelial Primary Cells	0.02	0.27	0.09	14.57	4.58	2.32E-03	5.25E-08	1.74E-07	0.30
E062	Blood & T-cell	BLD.PER.MONUC.PC	Primary mononuclear cells from peripheral blood	0.01	0.33	0.12	23.97	8.50	2.51E-03	-1.15E-07	5.19E-07	-0.22
E017	IMR90	LNG.IMR90	IMR90 fetal lung fibroblasts Cell Line	0.02	0.32	0.10	16.62	5.07	2.77E-03	2.59E-07	3.13E-07	0.83
E049	Mesench	STRM.CHON.MRW.DR.MSC	Mesenchymal Stem Cell Derived Chondrocyte Cultured Cells	0.03	0.31	0.10	11.20	3.49	2.94E-03	3.23E-08	2.49E-07	0.13
E098	Other	PANC	Pancreas	0.01	0.23	0.08	18.67	6.56	3.08E-03	5.13E-07	3.61E-07	1.42
E068	Brain	BRN.ANT.CAUD	Brain Anterior Caudate	0.02	0.29	0.09	11.81	3.78	3.10E-03	4.30E-07	2.98E-07	1.44
E038	Blood & T-cell	BLD.CD4.NPC	Primary T helper naive cells from peripheral blood	0.02	0.30	0.10	17.35	5.80	3.17E-03	-2.29E-07	5.52E-07	-0.41
E039	Blood & T-cell	BLD.CD4.CD25M.CD45RA.NPC	Primary T helper naive cells from peripheral blood	0.02	0.28	0.09	13.96	4.59	3.28E-03	-5.34E-07	4.10E-07	-1.30
E078	Sm. Muscle	GI.DUO.SM.MUS	Duodenum Smooth Muscle	0.02	0.32	0.11	14.61	5.08	3.68E-03	-1.88E-08	3.15E-07	-0.06
E054	Neurosph	BRN.GANGEM.DR.NRSPHR	Ganglion Eminence derived primary cultured neurospheres	0.01	0.27	0.10	19.57	6.87	4.06E-03	9.11E-07	4.73E-07	1.93
E114	ENCODE2012	LNG.A549.ETOH002.CNCR	A549 EtOH 0.02pct Lung Carcinoma Cell Line	0.02	0.25	0.08	11.42	3.64	4.11E-03	-5.50E-08	1.56E-07	-0.35
E058	Epithelial	SKIN.PEN.FRSK.KER.03	Foreskin Keratinocyte Primary Cells skin03	0.02	0.26	0.09	12.48	4.08	4.84E-03	-3.30E-07	3.57E-07	-0.92
E085	Digestive	GI.S.INT.FET	Fetal Intestine Small	0.02	0.27	0.10	12.27	4.36	5.08E-03	-1.22E-08	3.70E-07	-0.03
E023	Mesench	FAT.MSC.DR.ADIP	Mesenchymal Stem Cell Derived Adipocyte Cultured Cells	0.03	0.30	0.10	9.90	3.22	5.22E-03	-1.41E-07	2.27E-07	-0.62
E080	Other	ADRL.GLND.FET	Fetal Adrenal Gland	0.02	0.29	0.10	12.86	4.57	5.26E-03	4.44E-08	1.85E-07	0.24
E076	Sm. Muscle	GI.CLN.SM.MUS	Colon Smooth Muscle	0.02	0.27	0.09	11.54	4.03	5.90E-03	2.76E-08	2.62E-07	0.11
E055	Epithelial	SKIN.PEN.FRSK.FIB.01	Foreskin Fibroblast Primary Cells skin01	0.03	0.26	0.09	9.89	3.43	6.37E-03	-4.50E-07	3.74E-07	-1.21
E027	Epithelial	BRST.MYO	Breast Myoepithelial Primary Cells	0.02	0.25	0.09	11.56	4.01	6.42E-03	-2.40E-07	2.01E-07	-1.19
E006	ES-deriv	ESDR.H1.MSC	H1 Derived Mesenchymal Stem Cells	0.02	0.27	0.10	16.36	5.84	6.64E-03	1.30E-07	3.41E-07	0.38
E117	ENCODE2012	CRVX.HELAS3.CNCR	HeLa-S3 Cervical Carcinoma Cell Line	0.02	0.25	0.09	12.23	4.28	8.35E-03	-7.80E-08	1.89E-07	-0.41
E088	Other	LNG.FET	Fetal Lung	0.02	0.25	0.09	13.65	5.04	8.65E-03	3.40E-08	2.51E-07	0.14
E128	ENCODE2012	LNG.NHLF	NHLF Lung Fibroblast Primary Cells	0.02	0.27	0.10	14.90	5.44	9.96E-03	-1.04E-07	4.17E-07	-0.25
E086	Other	KID.FET	Fetal Kidney	0.01	0.24	0.09	17.02	6.68	1.08E-02	2.28E-07	3.55E-07	0.64
E077	Digestive	GI.DUO.MUC	Duodenum Mucosa	0.02	0.26	0.10	11.60	4.57	1.33E-02	-6.39E-07	3.20E-07	-1.99
E013	ES-deriv	ESDR.CD56.MESO	hESC Derived CD56+ Mesoderm Cultured Cells	0.02	0.25	0.09	12.84	4.90	1.36E-02	1.96E-07	2.55E-07	0.77
E001	ESC	ESC.I3	ES-I3 Cells	0.02	0.22	0.09	10.59	4.02	1.51E-02	6.02E-07	2.95E-07	2.04
E103	Sm. Muscle	GI.RECT.SM.MUS	Rectal Smooth Muscle	0.02	0.23	0.09	12.21	4.82	1.59E-02	-2.81E-08	3.65E-07	-0.08
E099	Other	PLCNT.AMN	Placenta Amnion	0.01	0.22	0.09	15.77	6.49	1.65E-02	-3.39E-08	3.18E-07	-0.11
E081	Brain	BRN.FET.M	Fetal Brain Male	0.02	0.24	0.09	12.25	4.67	1.70E-02	1.68E-07	3.05E-07	0.55
E095	Heart	HRT.VENT.L	Left Ventricle	0.02	0.21	0.08	12.48	4.99	1.84E-02	1.20E-07	3.42E-07	0.35
E105	Heart	HRT.VNT.R	Right Ventricle	0.02	0.23	0.09	12.51	5.07	1.86E-02	2.80E-08	3.74E-07	0.07
E083	Heart	HRT.FET	Fetal Heart	0.02	0.20	0.08	8.54	3.53	2.44E-02	-8.68E-08	1.35E-07	-0.65
E092	Digestive	GI.STMC.FET	Fetal Stomach	0.02	0.25	0.10	11.47	4.87	2.57E-02	-5.78E-09	2.64E-07	-0.02
E048	Blood & T-cell	BLD.CD8.MPC	Primary T CD8+ memory cells from peripheral blood	0.02	0.22	0.10	12.39	5.41	2.84E-02	-8.67E-07	4.43E-07	-1.96
E071	Brain	BRN.HIPP.MID	Brain Hippocampus Middle	0.03	0.25	0.10	8.38	3.46	2.85E-02	-3.30E-08	3.27E-07	-0.10
E104	Heart	HRT.ATR.R	Right Atrium	0.01	0.19	0.08	12.84	5.55	2.88E-02	1.22E-07	3.80E-07	0.32
E118	ENCODE2012	LIV.HEPG2.CNCR	HepG2 Hepatocellular Carcinoma Cell Line	0.02	0.20	0.09	10.82	4.70	3.59E-02	-2.47E-07	1.95E-07	-1.27
E111	Sm. Muscle	GI.STMC.MUS	Stomach Smooth Muscle	0.02	0.20	0.09	10.12	4.60	3.77E-02	-2.05E-07	3.10E-07	-0.66
E073	Brain	BRN.DL.PRFRNTL.CRTX	Brain_Dorsolateral_Prefrontal_Cortex	0.02	0.21	0.09	9.21	4.15	4.60E-02	2.88E-08	3.22E-07	0.09
E005	ES-deriv	ESDR.H1.BMP4.TROP	H1 BMP4 Derived Trophoblast Cultured Cells	0.01	0.16	0.08	11.20	5.38	4.96E-02	-1.52E-07	2.88E-07	-0.53
E026	Mesench	STRM.MRW.MSC	Bone Marrow Derived Cultured Mesenchymal Stem Cells	0.02	0.23	0.11	9.48	4.36	0.05	-2.30E-07	3.19E-07	-0.72
E082	Brain	BRN.FET.F	Fetal Brain Female	0.01	0.17	0.08	12.90	6.28	0.05	1.62E-08	3.91E-07	0.04
E012	ES-deriv	ESDR.CD56.ECTO	hESC Derived CD56+ Ectoderm Cultured Cells	0.02	0.15	0.07	9.36	4.73	0.07	4.10E-07	3.15E-07	1.30
E022	iPSC	IPSC.DF.19.11	iPS DF 19.11 Cells	0.01	0.14	0.07	11.07	5.65	0.07	1.02E-07	4.04E-07	0.25
E070	Brain	BRN.GRM.MTRX	Brain Germinal Matrix	0.01	0.16	0.08	12.11	6.26	0.07	-1.24E-07	4.13E-07	-0.30
E100	Muscle	MUS.PSOAS	Psoas Muscle	0.01	0.16	0.08	12.36	6.54	0.08	-1.08E-07	3.48E-07	-0.31
E094	Digestive	GI.STMC.GAST	Gastric	0.01	0.14	0.08	13.84	7.38	0.08	-4.59E-07	4.86E-07	-0.95
E096	Other	LNG	Lung	0.02	0.16	0.09	10.50	5.75	0.09	-7.25E-07	3.86E-07	-1.88
E052	Myosat	MUS.SAT	Muscle Satellite Cultured Cells	0.03	0.21	0.11	8.37	4.45	0.09	-3.42E-07	2.85E-07	-1.20
E067	Brain	BRN.ANG.GYR	Brain Angular Gyrus	0.02	0.18	0.09	7.51	3.97	0.10	-1.14E-07	3.70E-07	-0.31
E121	ENCODE2012	MUS.HSMMT	HSMM cell derived Skeletal Muscle Myotubes Cells	0.02	0.18	0.10	8.75	4.75	0.10	-3.97E-07	2.62E-07	-1.52
E087	Other	PANC.ISLT	Pancreatic Islets	0.01	0.13	0.08	10.83	6.30	0.11	-4.88E-07	3.97E-07	-1.23
E007	ES-deriv	ESDR.H1.NEUR.PROG	H1 Derived Neuronal Progenitor Cultured Cells	0.01	0.12	0.07	12.80	7.69	0.11	2.83E-07	4.85E-07	0.58
E102	Digestive	GI.RECT.MUC.31	Rectal Mucosa Donor 31	0.02	0.17	0.10	8.78	5.07	0.12	-1.05E-06	4.66E-07	-2.25
E097	Other	OVRY	Ovary	0.01	0.13	0.08	11.28	6.87	0.12	-1.38E-07	3.14E-07	-0.44
E053	Neurosph	BRN.CRTX.DR.NRSPHR	Cortex derived primary cultured neurospheres	0.02	0.14	0.09	9.20	5.50	0.13	-4.83E-07	3.67E-07	-1.32
E003	ESC	ESC.H1	H1 Cells	0.02	0.12	0.07	7.37	4.71	0.17	3.69E-07	4.28E-07	0.86
E072	Brain	BRN.INF.TMP	Brain Inferior Temporal Lobe	0.03	0.14	0.09	5.51	3.44	0.18	-3.49E-07	3.84E-07	-0.91
E065	Heart	VAS.AOR	Aorta	0.01	0.09	0.07	8.38	6.18	0.22	-3.86E-07	3.34E-07	-1.16
E069	Brain	BRN.CING.GYR	Brain Cingulate Gyrus	0.03	0.13	0.10	5.06	3.75	0.27	-4.72E-07	3.90E-07	-1.21
E008	ESC	ESC.H9	H9 Cells	0.01	0.09	0.08	6.92	5.61	0.27	1.03E-07	4.37E-07	0.24
E024	ESC	ESC.4STAR	ES-UCSF4 Cells	0.01	0.09	0.07	6.29	5.04	0.29	-1.10E-07	3.65E-07	-0.30
E021	iPSC	IPSC.DF.6.9	iPS DF 6.9 Cells	0.01	0.07	0.06	7.37	6.42	0.31	-1.30E-07	5.39E-07	-0.24
E125	ENCODE2012	BRN.NHA	NH-A Astrocytes Primary Cells	0.02	0.12	0.10	6.00	5.04	0.33	-8.24E-07	3.09E-07	-2.67
E019	iPSC	IPSC.18	iPS-18 Cells	0.02	0.10	0.08	5.13	4.48	0.35	2.19E-07	3.74E-07	0.59
E089	Muscle	MUS.TRNK.FET	Fetal Muscle Trunk	0.02	0.11	0.10	5.11	4.49	0.36	-7.80E-07	3.82E-07	-2.04
E014	ESC	ESC.HUES48	HUES48 Cells	0.02	0.09	0.08	4.77	4.35	0.38	1.62E-07	4.19E-07	0.39
E018	iPSC	IPSC.15b	iPS-15b Cells	0.02	0.07	0.08	4.19	4.42	0.47	-1.27E-07	3.73E-07	-0.34
E002	ESC	ESC.WA7	ES-WA7 Cells	0.01	0.06	0.07	5.29	6.46	0.50	-2.51E-07	4.62E-07	-0.54
E009	ES-deriv	ESDR.H9.NEUR.PROG	H9 Derived Neuronal Progenitor Cultured Cells	0.01	0.07	0.08	4.69	5.46	0.50	-6.17E-08	3.89E-07	-0.16
E011	ES-deriv	ESDR.CD184.ENDO	hESC Derived CD184+ Endoderm Cultured Cells	0.02	0.05	0.08	3.12	4.97	0.67	-2.23E-07	2.89E-07	-0.77
E016	ESC	ESC.HUES64	HUES64 Cells	0.02	0.04	0.07	2.56	4.27	0.71	-2.01E-07	3.97E-07	-0.51
E010	ES-deriv	ESDR.H9.NEUR	H9 Derived Neuron Cultured Cells	0.02	-0.01	0.08	-0.65	4.95	0.74	-6.16E-07	3.46E-07	-1.78
E015	ESC	ESC.HUES6	HUES6 Cells	0.02	0.04	0.08	1.85	4.06	0.83	-4.19E-07	3.46E-07	-1.21
E004	ES-deriv	ESDR.H1.BMP4.MESO	H1 BMP4 Derived Mesendoderm Cultured Cells	0.01	0.02	0.07	1.56	5.11	0.91	-4.33E-07	3.22E-07	-1.35
E020	iPSC	IPSC.20B	iPS-20b Cells	0.02	0.02	0.08	1.23	4.61	0.96	-3.94E-07	3.98E-07	-0.99

Table S16. Top ranked tissues and cell types based on DEPICT enrichment. The analysis was performed for 209 Medical Subject Heading (MeSH) tissue- and cell-type annotations, only results at nominal P<0.05 are displayed and sorted by the level of statistical significance, the results meeting FDR cut-off <5% are flagged (top part, graphically depicted in Figure 3c).

MeSH term	MeSH first level term	MeSH second level term	Nominal P value	False discovery rate < 5%
A15.378.316	Bone Marrow Cells	Hemic and Immune Systems	4.90E-06	Yes
A15.378	Hematopoietic System	Hemic and Immune Systems	4.90E-06	Yes
A11.118.637.415	Granulocytes	Cells	5.88E-06	Yes
A15.382.490.315.583	Neutrophils	Hemic and Immune Systems	6.31E-06	Yes
A15.145	Blood	Hemic and Immune Systems	6.66E-06	Yes
A11.627	Myeloid Cells	Cells	1.11E-05	Yes
A15.145.229	Blood Cells	Hemic and Immune Systems	1.30E-05	Yes
A15.382.680	Phagocytes	Hemic and Immune Systems	1.64E-05	Yes
A11.118.637	Leukocytes	Cells	2.07E-05	Yes
A15.145.300	Fetal Blood	Hemic and Immune Systems	9.39E-05	Yes
A15.382.520.604.700	Spleen	Hemic and Immune Systems	1.51E-04	Yes
A02.835.583.443.800.800	Synovial Fluid	Musculoskeletal System	1.56E-04	Yes
A15.378.316.580	Monocytes	Hemic and Immune Systems	2.24E-04	Yes
A15.382.812	Mononuclear Phagocyte System	Hemic and Immune Systems	2.77E-04	Yes
A15.382	Immune System	Hemic and Immune Systems	3.02E-04	Yes
A11.066	Antigen Presenting Cells	Cells	4.26E-04	Yes
A15.382.812.260	Dendritic Cells	Hemic and Immune Systems	4.26E-04	Yes
A15.382.520	Lymphatic System	Hemic and Immune Systems	4.92E-04	Yes
A10.549	Lymphoid Tissue	Tissues	4.92E-04	Yes
A10.549.400	Lymph Nodes	Tissues	6.11E-04	Yes
A15.382.812.522	Macrophages	Hemic and Immune Systems	6.40E-04	Yes
A02.835.232.043	Bones of Lower Extremity	Musculoskeletal System	1.21E-03	Yes
A02.835.232.043.300.710	Tarsal Bones	Musculoskeletal System	1.35E-03	Yes
A02.835.232.043.300	Foot Bones	Musculoskeletal System	1.35E-03	Yes
A11.872.378.590.635	Granulocyte Macrophage Progenitor Cells	Cells	2.03E-03	Yes
A15.145.229.637.555	Leukocytes Mononuclear	Hemic and Immune Systems	2.66E-03	Yes
A09.371.060	Anterior Eye Segment	Sense Organs	2.66E-03	Yes
A09.371.337.168	Conjunctiva	Sense Organs	2.67E-03	Yes
A09.371.337	Eyelids	Sense Organs	2.67E-03	Yes
A11.627.340.360	Granulocyte Precursor Cells	Cells	4.55E-03	Yes
A11.118.637.555.567.569	T Lymphocytes	Cells	9.17E-03	No
A11.627.624.249	Monocyte Macrophage Precursor Cells	Cells	1.09E-02	No
A11.872.378	Hematopoietic Stem Cells	Cells	1.10E-02	No
A11.627.635	Myeloid Progenitor Cells	Cells	1.48E-02	No
A15.382.520.604.800	Palatine Tonsil	Hemic and Immune Systems	1.52E-02	No
A04.623.603	Oropharynx	Respiratory System	1.52E-02	No
A15.382.216	Bone Marrow	Hemic and Immune Systems	1.96E-02	No
A14.724	Pharynx	Stomatognathic System	2.01E-02	No
A10.165	Connective Tissue	Tissues	2.33E-02	No
A02.835	Skeleton	Musculoskeletal System	2.34E-02	No
A02.835.232	Bone and Bones	Musculoskeletal System	2.36E-02	No
A15.382.490.555.567.537	Natural Killer Cells	Hemic and Immune Systems	2.76E-02	No
A11.329.372.600	Macrophages Alveolar	Cells	2.82E-02	No
A03.556.249.124	Ileum	Digestive System	3.06E-02	No
A03.556.124.684	Intestine Small	Digestive System	3.17E-02	No
A03.556.124.526.767	Rectum	Digestive System	3.25E-02	No
A03.556.249.249.209	Cecum	Digestive System	3.62E-02	No
A03.556.249	Lower Gastrointestinal Tract	Digestive System	3.84E-02	No
A11.872.378.294	Lymphoid Progenitor Cells	Cells	4.15E-02	No
A11.118.637.555.567.562.440	Precursor Cells B Lymphoid	Cells	4.15E-02	No
A03.556.249.249	Intestine Large	Digestive System	4.40E-02	No
A03.556.249.249.356	Colon	Digestive System	4.69E-02	No

Table S17. Top ranked tissues and cell types from GARFIELD enrichment analysis. Enrichment in tissue and cell-type specific ENCODE and Roadmap functional annotations at GWAS P-value threshold $T<1.0x10^{-5}$. Results sorted by significance level and only the top 100 enrichments are depicted; the complete analysis involves 2013 functional annotations across all Roadmap and ENCODE tissues and cell types. Hotspots refer to DNase I–hypersensitive sites. The top scoring cell types across multiple annotations include immune, blood, intestinal mucosa, thymic, and splenic cells.

Cell type	Tissue	Type	Category	OR	Beta	SE	P-value
GM12878	blood	H3K27ac	Histone_Modifications	5.33	1.67	0.14	4.33E-32
CD19_Primary_Cells	blood	hotspots	Hotspots	4.99	1.61	0.15	4.41E-28
GM06990	blood	hotspots	Hotspots	4.71	1.55	0.15	1.53E-25
CD56_Primary_Cells	blood	hotspots	Hotspots	4.66	1.54	0.15	2.38E-24
CD3_Primary_Cells	blood	hotspots	Hotspots	4.39	1.48	0.15	3.96E-23
CD19_Primary_Cells	blood	hotspots	Hotspots	4.30	1.46	0.15	4.83E-23
GM12878	blood	H3K4me2	Histone_Modifications	4.09	1.41	0.14	4.86E-23
CD20+	blood	hotspots	Hotspots	4.19	1.43	0.15	5.86E-23
GM12878	blood	H3K9ac	Histone_Modifications	4.29	1.46	0.15	1.74E-22
GM12878	blood	H3K4me1	Histone_Modifications	3.82	1.34	0.14	3.67E-22
CD14_Primary_Cells	blood	peaks	Peaks	5.22	1.65	0.17	1.51E-21
CD4_Primary_Cells	blood	hotspots	Hotspots	4.06	1.40	0.15	5.74E-21
GM12878	blood	H3K4me3	Histone_Modifications	3.96	1.38	0.15	5.89E-21
CD8_Primary_Cells	blood	hotspots	Hotspots	4.04	1.40	0.15	2.14E-20
CD19_Primary_Cells	blood	hotspots	Hotspots	3.92	1.37	0.15	2.84E-20
CD3_Primary_Cells	blood	hotspots	Hotspots	4.01	1.39	0.15	8.27E-20
CD56_Primary_Cells	blood	hotspots	Hotspots	3.91	1.36	0.15	9.58E-20
GM12878	blood	ENHANCER	Chromatin_States	4.41	1.48	0.17	2.88E-19
CD8_Primary_Cells	blood	hotspots	Hotspots	3.62	1.29	0.15	2.25E-18
CD14+	blood	hotspots	Hotspots	3.55	1.27	0.15	5.77E-18
GM12878	blood	TSS	Chromatin_States	4.15	1.42	0.17	6.52E-18
GM12878	blood	H3K27ac	Histone_Modifications	7.71	2.04	0.24	1.83E-17
CD4_Primary_Cells	blood	hotspots	Hotspots	3.56	1.27	0.15	1.97E-17
GM12878	blood	H3K79me2	Histone_Modifications	3.40	1.22	0.15	4.96E-17
CD14_Primary_Cells	blood	peaks	Peaks	4.33	1.46	0.18	6.58E-17
CD4_Primary_Cells	blood	hotspots	Hotspots	3.40	1.22	0.15	7.89E-17
CD3_Primary_Cells	blood	hotspots	Hotspots	3.50	1.25	0.15	1.86E-16
GM12865	blood	hotspots	Hotspots	3.42	1.23	0.15	2.51E-16
GM12864	blood	hotspots	Hotspots	3.42	1.23	0.15	4.07E-16
GM12878	blood	H2AFZ	Histone_Modifications	3.37	1.22	0.15	4.20E-16
Mobilized_CD4_Primary_Cells	blood	hotspots	Hotspots	3.39	1.22	0.15	4.36E-16
Fetal_Intestine_Large	fetal_intestine,_large	hotspots	Hotspots	3.46	1.24	0.15	4.69E-16
CD14_Primary_Cells	blood	hotspots	Hotspots	3.46	1.24	0.15	6.37E-16
CD4_Primary_Cells	blood	hotspots	Hotspots	3.37	1.21	0.15	9.36E-16
Fetal_Thymus	fetal_thymus	hotspots	Hotspots	3.30	1.20	0.15	1.13E-15
CD14_Primary_Cells	blood	hotspots	Hotspots	3.35	1.21	0.15	1.40E-15
CD8_Primary_Cells	blood	hotspots	Hotspots	3.32	1.20	0.15	1.46E-15
CD20+	blood	peaks	Peaks	4.13	1.42	0.18	2.00E-15
CD3_Primary_Cells	blood	peaks	Peaks	4.18	1.43	0.18	5.79E-15
Mobilized_CD4_Primary_Cells	blood	peaks	Peaks	4.10	1.41	0.18	6.52E-15
Mobilized_CD4_Primary_Cells	blood	hotspots	Hotspots	3.14	1.14	0.15	6.85E-15
CD8_Primary_Cells	blood	hotspots	Hotspots	3.30	1.19	0.15	7.78E-15
GM12865	blood	footprints	Footprints	4.26	1.45	0.19	1.04E-14
CD19_Primary_Cells	blood	hotspots	Hotspots	6.85	1.92	0.25	1.08E-14
CD19_Primary_Cells	blood	peaks	Peaks	4.07	1.40	0.18	1.96E-14
Mobilized_CD34_Primary_Cells	blood	hotspots	Hotspots	3.24	1.18	0.15	1.98E-14
GM12878	blood	tfbs	TFBS	3.39	1.22	0.16	2.66E-14
Mobilized_CD34_Primary_Cells	blood	hotspots	Hotspots	3.17	1.15	0.15	3.80E-14
Mobilized_CD56_Primary_Cells	blood	hotspots	Hotspots	3.09	1.13	0.15	4.78E-14
GM12878	blood	hotspots	Hotspots	3.00	1.10	0.15	6.32E-14
Fetal_Spleen	fetal_spleen	hotspots	Hotspots	3.02	1.11	0.15	1.39E-13
Mobilized_CD34_Primary_Cells	blood	hotspots	Hotspots	3.08	1.13	0.15	1.45E-13
GM12878	blood	H3K4me2	Histone_Modifications	6.00	1.79	0.24	1.58E-13
HeLa-S3	cervix	H3K27me3	Histone_Modifications	5.13	1.63	0.22	1.63E-13
Fetal_Thymus	fetal_thymus	hotspots	Hotspots	2.98	1.09	0.15	1.92E-13
Fetal_Intestine_Small	fetal_intestine,_small	hotspots	Hotspots	2.95	1.08	0.15	4.09E-13
Mobilized_CD4_Primary_Cells	blood	peaks	Peaks	3.67	1.30	0.18	6.56E-13
Mobilized_CD34_Primary_Cells	blood	hotspots	Hotspots	2.98	1.09	0.15	7.04E-13
GM12864	blood	peaks	Peaks	3.55	1.27	0.18	7.17E-13
Mobilized_CD8_Primary_Cells	blood	hotspots	Hotspots	2.93	1.07	0.15	8.93E-13
HeLa-S3	cervix	H3K27me3	Histone_Modifications	2.61	0.96	0.13	1.14E-12
CD34+	blood	hotspots	Hotspots	2.84	1.04	0.15	1.32E-12
Th2	blood	hotspots	Hotspots	2.95	1.08	0.15	1.44E-12
Mobilized_CD34_Primary_Cells	blood	hotspots	Hotspots	2.94	1.08	0.15	1.61E-12
Th1	blood	hotspots	Hotspots	2.81	1.03	0.15	1.68E-12
Mobilized_CD34_Primary_Cells	blood	hotspots	Hotspots	2.95	1.08	0.15	2.29E-12
CD8_Primary_Cells	blood	peaks	Peaks	3.71	1.31	0.19	2.75E-12
Mobilized_CD34_Primary_Cells	blood	hotspots	Hotspots	2.89	1.06	0.15	3.11E-12
GM06990	blood	hotspots	Hotspots	5.80	1.76	0.25	3.97E-12
CD19_Primary_Cells	blood	peaks	Peaks	3.57	1.27	0.18	5.17E-12
CD34+	blood	footprints	Footprints	3.64	1.29	0.19	6.76E-12
GM12878	blood	H3K4me1	Histone_Modifications	4.95	1.60	0.23	9.08E-12
CD56_Primary_Cells	blood	peaks	Peaks	3.61	1.28	0.19	1.47E-11
CD8_Primary_Cells	blood	peaks	Peaks	3.49	1.25	0.19	1.64E-11
GM06990	blood	peaks	Peaks	3.60	1.28	0.19	1.70E-11
Mobilized_CD34_Primary_Cells	blood	hotspots	Hotspots	2.79	1.03	0.15	2.01E-11
Mobilized_CD34_Primary_Cells	blood	hotspots	Hotspots	2.76	1.01	0.15	2.64E-11
Mobilized_CD34_Primary_Cells	blood	hotspots	Hotspots	2.77	1.02	0.15	3.20E-11
CD3_Primary_Cells	blood	hotspots	Hotspots	2.67	0.98	0.15	4.05E-11
Mobilized_CD34_Primary_Cells	blood	hotspots	Hotspots	2.71	1.00	0.15	4.18E-11
Fetal_Thymus	fetal_thymus	hotspots	Hotspots	2.73	1.00	0.15	4.75E-11
CD19_Primary_Cells	blood	peaks	Peaks	3.45	1.24	0.19	5.02E-11
Fetal_Thymus	fetal_thymus	hotspots	Hotspots	2.67	0.98	0.15	5.75E-11
CD3_Primary_Cells	blood	hotspots	Hotspots	5.31	1.67	0.26	6.56E-11
Mobilized_CD34_Primary_Cells	blood	hotspots	Hotspots	2.66	0.98	0.15	6.84E-11
Fetal_Thymus	fetal_thymus	peaks	Peaks	3.26	1.18	0.18	7.09E-11
Mobilized_CD34_Primary_Cells	blood	peaks	Peaks	3.18	1.16	0.18	7.30E-11
Th2	blood	peaks	Peaks	3.48	1.25	0.19	8.26E-11
GM18507	blood	peaks	Peaks	3.28	1.19	0.18	8.84E-11
GM12878	blood	H3K9ac	Histone_Modifications	5.20	1.65	0.25	9.62E-11
CD20+	blood	footprints	Footprints	3.82	1.34	0.21	1.17E-10
CD3_Primary_Cells	blood	peaks	Peaks	3.37	1.22	0.19	1.19E-10
Mobilized_CD56_Primary_Cells	blood	peaks	Peaks	3.25	1.18	0.18	1.45E-10
NB4	blood	footprints	Footprints	3.31	1.20	0.19	1.56E-10
CD34+	blood	peaks	Peaks	3.05	1.11	0.17	1.80E-10
GM12878	blood	H3K4me3	Histone_Modifications	4.90	1.59	0.25	2.20E-10
Fetal_Thymus	fetal_thymus	hotspots	Hotspots	2.63	0.97	0.15	2.29E-10
HUVEC	blood_vessel	H3K27me3	Histone_Modifications	2.45	0.90	0.14	2.83E-10
CD56_Primary_Cells	blood	hotspots	Hotspots	5.15	1.64	0.26	3.09E-10

Table S18. Regulatory Element Locus Intersection (RELI) analysis of IgAN GWAS loci against transcription factor binding sites: (a) limited to genome-wide significant GWAS loci (28 loci), and **(b)** extended to genome-wide significant and suggestive GWAS loci (76 loci). Enrichment statistics and corrected P-values as described in Harley JB et al. (*Nat Gen* 2018)[19].

(a) Significant GWAS loci (total of 28 loci)

Track	Cell	TF	Overlap	Total	Ratio	Mean	STD	Z-score	Enrichment	P-val	Corrected P	Species
ReMap_ChIP	lclgm12878	NFKB1	14	28	0.50	2.13	1.39	8.52	6.57	8.15E-18	1.26E-14	human
TxnFactorChIPV3	H1-hESC	RFX5	3	28	0.11	0.17	0.42	6.76	17.35	7.07E-12	1.09E-08	human
TxnFactorChIPV3	GM12878	ATF2	10	28	0.36	1.86	1.31	6.20	5.39	2.86E-10	4.41E-07	human
TxnFactorChIPV3	GM18505	POLR2A	11	28	0.39	2.31	1.41	6.17	4.76	3.33E-10	5.14E-07	human
TxnFactorChIPV3	GM12878	RUNX3	14	28	0.50	3.50	1.70	6.16	4.00	3.63E-10	5.61E-07	human
ReMap_ChIP	lclgm18951	NFKB1	6	28	0.21	0.78	0.87	5.97	7.66	1.19E-09	1.84E-06	human
TxnFactorChIPV3	GM12878	POLR2A	12	28	0.43	2.75	1.56	5.94	4.36	1.45E-09	2.24E-06	human
ReMap_ChIP	cd4_il12	STAT4	2	28	0.07	0.10	0.32	5.89	19.15	1.94E-09	2.99E-06	human
TxnFactorChIPV3	GM12878	CEBPB	5	28	0.18	0.58	0.77	5.76	8.66	4.15E-09	6.41E-06	human
TxnFactorChIPV3	GM18505+TNFa	RELA	6	28	0.21	0.82	0.90	5.74	7.32	4.87E-09	7.53E-06	human
TxnFactorChIPV3	GM12892	POLR2A	11	28	0.39	2.54	1.48	5.72	4.32	5.28E-09	8.15E-06	human
TxnFactorChIPV3	GM12878+TNFa	RELA	8	28	0.29	1.42	1.15	5.71	5.64	5.51E-09	8.51E-06	human
TxnFactorChIPV3	GM12878	TBL1XR1	7	28	0.25	1.10	1.05	5.63	6.34	9.26E-09	1.43E-05	human
ReMap_ChIP	B-cell	SMARCA4	2	28	0.07	0.12	0.34	5.52	17.10	1.68E-08	2.60E-05	human

(b) Significant and suggestive loci (total of 76 loci)

Track	Cell	TF	Overlap	Total	Ratio	Mean	STD	Z-score	Enrichment	P-val	Corrected P	Species
TxnFactorChIPV3	GM12878+TNFa	RELA	19	76	0.25	3.98	1.86	8.07	4.78	3.58E-16	5.53E-13	human
ReMap_ChIP	lclgm12878	NFKB1	24	76	0.32	5.92	2.28	7.91	4.06	1.24E-15	1.92E-12	human
TxnFactorChIPV3	GM12878	ATF2	21	76	0.28	5.15	2.08	7.62	4.08	1.27E-14	1.96E-11	human
TxnFactorChIPV3	GM12878	FOXM1	20	76	0.26	5.00	2.02	7.43	4.00	5.43E-14	8.38E-11	human
TxnFactorChIPV3	GM12878	CEBPB	11	76	0.14	1.67	1.28	7.28	6.57	1.64E-13	2.53E-10	human
TxnFactorChIPV3	GM12878	TBL1XR1	15	76	0.20	3.06	1.68	7.13	4.91	5.06E-13	7.82E-10	human
TxnFactorChIPV3	GM12878	MTA3	15	76	0.20	3.20	1.68	7.02	4.69	1.13E-12	1.74E-09	human
ReMap_ChIP	lclgm18951	NFKB1	12	76	0.16	2.15	1.41	6.99	5.57	1.41E-12	2.18E-09	human
Cistrome_ChIP	CD14+	IRF1	23	76	0.30	6.47	2.39	6.90	3.55	2.52E-12	3.89E-09	human
TxnFactorChIPV3	GM12878	SPI1	22	76	0.29	6.49	2.31	6.73	3.39	8.68E-12	1.34E-08	human
Misc_ChIP	GM12878	p52	19	76	0.25	4.93	2.11	6.65	3.85	1.43E-11	2.20E-08	human
TxnFactorChIPV3	GM12891	POLR2A	22	76	0.29	6.69	2.31	6.62	3.29	1.81E-11	2.79E-08	human
Misc_ChIP	MutuIII	EBNA2	23	76	0.30	6.81	2.48	6.54	3.38	3.08E-11	4.75E-08	EBV
TxnFactorChIPV3	GM18505+TNFa	RELA	12	76	0.16	2.36	1.50	6.41	5.09	7.30E-11	1.13E-07	human
TxnFactorChIPV3	GM18505	POLR2A	21	76	0.28	6.29	2.30	6.40	3.34	7.89E-11	1.22E-07	human
TxnFactorChIPV3	GM12878	POLR2A	24	76	0.32	7.71	2.56	6.36	3.11	1.03E-10	1.59E-07	human
Cistrome_ChIP	GM12878	NFATC1	21	76	0.28	6.57	2.29	6.30	3.20	1.51E-10	2.33E-07	human
Cistrome_ChIP	GM12878	STAT5A	23	76	0.30	7.41	2.48	6.29	3.10	1.54E-10	2.38E-07	human
TxnFactorChIPV3	GM12878	PAX5	18	76	0.24	5.15	2.05	6.26	3.49	1.90E-10	2.93E-07	human
Pazar_Chip	CD4+	HMGN1	38	76	0.50	17.37	3.32	6.21	2.19	2.66E-10	4.11E-07	human
ReMap_ChIP	lclgm12891	NFKB1	22	76	0.29	7.05	2.41	6.21	3.12	2.67E-10	4.13E-07	human
Misc_ChIP	GM12878	RelB	19	76	0.25	5.48	2.18	6.20	3.47	2.85E-10	4.41E-07	human
ReMap_ChIP	lclgm10861_calcitriol	VDR	15	76	0.20	3.74	1.83	6.16	4.01	3.65E-10	5.64E-07	human
TxnFactorChIPV3	GM12891	SPI1	22	76	0.29	7.09	2.42	6.15	3.10	3.77E-10	5.81E-07	human
Cistrome_ChIP	Monocyte_CD14+	IRF1	13	76	0.17	2.99	1.66	6.04	4.34	7.69E-10	1.19E-06	human
Misc_ChIP	BCells+Sendai_Virus	IRF3	13	76	0.17	2.92	1.68	6.00	4.45	9.83E-10	1.52E-06	human
TxnFactorChIPV3	GM12878	RUNX3	25	76	0.33	9.27	2.64	5.95	2.70	1.32E-09	2.04E-06	human
Cistrome_ChIP	GM12878	PML	22	76	0.29	7.20	2.50	5.93	3.06	1.52E-09	2.34E-06	human
TxnFactorChIPV3	GM12878	NFATC1	13	76	0.17	3.00	1.69	5.92	4.34	1.62E-09	2.51E-06	human
Pazar_Chip	U937+BMP4	SMAD1	17	76	0.22	4.74	2.08	5.89	3.59	1.98E-09	3.06E-06	human
Artem-ChIP	CD4+_T_cells+invitrogen	POLR2A	25	76	0.33	9.21	2.69	5.87	2.71	2.15E-09	3.31E-06	human
Cistrome_ChIP	OCI-Ly10	IRF4	8	76	0.11	1.37	1.13	5.87	5.84	2.18E-09	3.37E-06	human
TxnFactorChIPV3	GM12878	NFIC	19	76	0.25	5.93	2.24	5.84	3.20	2.67E-09	4.12E-06	human
Artem-ChIP	Naive_CD4_Tcell_EI_5h_6	NFATC2	21	76	0.28	6.91	2.43	5.80	3.04	3.24E-09	5.01E-06	human
Misc_ChIP	Kasumi-1	RUNX1	14	76	0.18	3.53	1.81	5.77	3.97	3.87E-09	5.97E-06	human
TxnFactorChIPV3	GM12878	BCL3	13	76	0.17	3.23	1.69	5.76	4.02	4.12E-09	6.37E-06	human
Cistrome_ChIP	GM12891	SPI1	20	76	0.26	6.60	2.35	5.70	3.03	5.95E-09	9.18E-06	human
Cistrome_ChIP	CD14+	STAT1	16	76	0.21	4.70	2.00	5.66	3.40	7.77E-09	1.20E-05	human
TxnFactorChIPV3	GM12878	EBF1	21	76	0.28	7.27	2.43	5.65	2.89	7.80E-09	1.20E-05	human
Pazar_Chip	CD34+prog	SMAD1	12	76	0.16	2.91	1.61	5.63	4.13	8.81E-09	1.36E-05	human
Cistrome_ChIP	GM12878	SP1	20	76	0.26	6.65	2.38	5.61	3.01	9.90E-09	1.53E-05	human
TxnFactorChIPV3	GM12878	EP300	15	76	0.20	4.20	1.94	5.58	3.57	1.23E-08	1.91E-05	human
Cistrome_ChIP	GM12878	PAX5	21	76	0.28	7.25	2.47	5.57	2.90	1.28E-08	1.98E-05	human
ReMap_ChIP	blood_monocyte	SPI1	23	76	0.30	8.63	2.58	5.56	2.66	1.35E-08	2.08E-05	human
TxnFactorChIPV3	GM18951+TNFa	RELA	13	76	0.17	3.32	1.74	5.55	3.91	1.41E-08	2.17E-05	human
Cistrome_ChIP	Monocyte_CD14+	STAT1	16	76	0.21	4.71	2.04	5.52	3.40	1.70E-08	2.62E-05	human
Misc_ChIP	CD34+	RUNX1	19	76	0.25	6.27	2.31	5.51	3.03	1.77E-08	2.73E-05	human
TxnFactorChIPV3	GM12878	IRF4	13	76	0.17	3.26	1.77	5.50	3.98	1.88E-08	2.90E-05	human
Cistrome_ChIP	GM19193	RELA	8	76	0.11	1.49	1.20	5.41	5.37	3.13E-08	4.83E-05	human
TxnFactorChIPV3	GM12878	STAT5A	10	76	0.13	2.17	1.45	5.38	4.60	3.72E-08	5.75E-05	human
Misc_ChIP	BCells+Sendai_Virus	MED1	9	76	0.12	1.86	1.33	5.36	4.83	4.13E-08	6.38E-05	human

Table S19. PPI network confidence scores and module enrichments: (a) pathway enrichment analysis of individual modules, **(b)** confidence scores and network types for each edge in the PPI network.

(a) PPI network module pathway enrichment analysis (only two most significant pathways depicted)

Module	PPI module enrichment p-value	Number of nodes	Number of edges	Functional Enrichment Network	Count in gene set	Adjusted P-value
1	2.82E-05	11	19	GO:0006950: response to stress	11 of 3267	4.34E-06
				GO:0006952: defense response	8 of 1234	2.14E-05
2	1.48E-03	3	2	GO:0050727: regulation of inflammatory response	3 of 338	1.20E-03
				REACTOME: HSA-168249: Innate Immune System	3 of 1012	6.50E-04
3	1.07E-01	6	3	GO:0000398: mRNA splicing, via spliceosome	3 of 284	1.90E-02
				REACTOME: HSA-8953854 Metabolism of RNA	4 of 652	1.60E-03
4	< 1.0E-16	10	45	GO:0070098: chemokine-mediated signaling pathway	10 of 75	5.60E-22
				REACTOME: HSA-380108: Chemokine receptors bind chemokines	10 of 48	8.04E-25
5	4.44E-16	9	17	GO:0006955: immune response	9 of 1560	9.63E-08
				REACTOME: HSA-168256: Immune System	9 of 1925	6.17E-08
6	< 1.0E-16	6	14	GO:0019221: cytokine-mediated signaling pathway	6 of 655	2.12E-07
				REACTOME: HSA-6788467: IL-6-type cytokine receptor ligand interactions	6 of 17	2.07E-17
7	1.83E-06	5	5	GO:0043122: regulation of I-kappaB kinase/NF-kappaB signaling	4 of 167	1.89E-05
				GO:0097190: apoptotic signaling pathway	4 of 295	8.76E-05
8	8.54E-04	2	1	GO:0002227: innate immune response in mucosa	2 of 22	1.60E-04
				GO:0019731: antibacterial humoral response	2 of 47	1.60E-04

(b) Confidence scores and network types for each edge in the PPI network

Protein 1	Protein 2	Confidence Score	Network group	Network
CASP8	PYCARD	1.00	Physical Interactions/Predicted	IREF-INTACT/Wu-Stein-2010
CFH	CFHR1	1.00	Co-expression	Mallon-McKay-2013
CFH	ITGAM	0.11	Physical Interactions	IREF-HPRD
CXCL8	RELA	1.00	Pathway	Wu-Stein-2010
CXCL8	PF4	1.00	Co-expression	Ramaswamy-Golub-2001
CXCR1	CXCL6	1.00	Pathway	Wu-Stein-2010
CXCR1	CXCL3	1.00	Physical Interactions	IREF-HPRD
CXCR1	CXCL2	1.00	Physical Interactions	IREF-HPRD
CXCR1	PPBP	1.00	Physical Interactions	IREF-DIP
CXCR1	CXCL5	1.00	Physical Interactions	IREF-DIP
CXCR2	CXCL8	1.00	Co-expression/Pathway/Physical Interactions	Noble-Diehl-2008/NCI_NATURE/IREF-HPRD
CXCR2	CXCL1	1.00	Co-expression/Pathway/Physical Interactions	Noble-Diehl-2008/Wu-Stein-2010/IREF-HPRD
CXCR2	CXCL3	1.00	Pathway/Physical Interactions/Predicted	Wu-Stein-2010/IREF-HPRD/I2D-INNATEDB-Mouse2Human
CXCR2	CXCR1	1.00	Physical Interactions/Predicted/Shared protein domains	IREF-HPRD/Wu-Stein-2010/INTERPRO
CXCR2	CXCL2	1.00	Co-expression/Pathway/Physical Interactions/Predicted	Noble-Diehl-2008/Wu-Stein-2010/IREF-HPRD/I2D-INNATEDB-Mouse2Human
CXCR2	CXCL5	1.00	Physical Interactions/Co-expression	IREF-DIP/Bild-Nevins-2006
CXCR2	CXCL6	1.00	Co-expression/Pathway/Physical Interactions	Noble-Diehl-2008/Wu-Stein-2010/IREF-HPRD
CXCR2	PPBP	1.00	Pathway/Physical Interactions	Wu-Stein-2010/IREF-HPRD
DEFA3	DEFA1	1.00	Physical Interactions/Shared protein domains	IREF-HPRD/INTERPRO
FASLG	CASP10	1.00	Pathway	NCI_NATURE
FASLG	CASP8	1.00	Co-localization	Schadt-Shoemaker-2004
FUS	CFL1	0.13	Physical Interactions/Co-expression	Wang-Xu-2015/Ramaswamy-Golub-2001
FUS	EIF4A1	0.22	Co-expression	Innocenti-Brown-2011
FUS	SF3A1	1.00	Co-expression	Mallon-McKay-2013
FUS	POLR2A	1.00	Physical Interactions	IREF-HPRD
FUS	RELA	0.35	Physical Interactions	IREF-HPRD
FUS	KAT5	0.18	Physical Interactions	IREF-DIP
IL31A	LIFR	1.00	Physical Interactions	IREF-HPRD
IL6ST	IL31A	1.00	Physical Interactions	IREF-HPRD
IL6ST	LIFR	1.00	Shared protein domains/Physical Interactions	INTERPRO/IREF-HPRD
IL6ST	LIF	1.00	Physical Interactions	IREF-INTACT
IL6ST	OSM	1.00	Physical Interactions	IREF-INTACT
IL6ST	OSMR	1.00	Shared protein domains/Physical Interactions	INTERPRO/IREF-HPRD
IRF8	LY86	1.00	Co-expression	Wang-Maris-2006
IRF8	IRF4	0.39	Co-expression/Shared protein domains	Boldrick-Relman-2002/INTERPRO
LIF	LIFR	1.00	Physical Interactions/Predicted	IREF-HPRD/I2D-BIND-Rat2Human
LYN	FCGR2B	0.39	Co-expression/Physical Interactions/Predicted	Perou-Botstein-2000/IREF-HPRD/Wu-Stein-2010
LYN	FCGR2A	0.37	Physical Interactions/Predicted	IREF-HPRD/Wu-Stein-2010
LYN	CTLA4	1.00	Physical Interactions	IREF-HPRD
LYN	FCAR	0.38	Physical Interactions	IREF-HPRD
LYN	TNFSF12	0.15	Physical Interactions	BIOGRID-SMALL-SCALE-STUDIES
LYN	FASLG	0.25	Physical Interactions	IREF-INTACT
LYN	IL6ST	1.00	Pathway	Hallek-1997
LYN	IL7R	0.11	Co-expression/Physical Interactions	Wu-Garvey-2007/IREF-HPRD
NF2	MAP3K11	0.37	Physical Interactions	IREF-INTACT
NOTCH1	REL	0.36	Physical Interactions	IREF-HPRD
OSM	OSMR	1.00	Pathway/Physical Interactions	Wu-Stein-2010/IREF-HPRD
POLR2A	EHBP1L1	0.11	Physical Interactions	Kristensen-Foster-2012
PYCARD	PYDC1	0.41	Co-expression/Physical Interactions/Shared protein domains	Mallon-McKay-2013/IREF-INTACT/INTERPRO
PYCARD	TP53	0.12	Pathway	NCI_NATURE
REL	IL12B	0.25	Pathway/Predicted	Wu-Stein-2010/I2D-INNATEDB-Mouse2Human
RELA	ASCC2	0.17	Physical Interactions	IREF-SMALL-SCALE-STUDIES
RELA	IL12B	0.33	Pathway/Predicted	Wu-Stein-2010/I2D-INNATEDB-Mouse2Human
RELA	IL7R	0.12	Co-expression	Rosenwald-Staudt-2001
RELA	IRF8	0.25	Physical Interactions	IREF-SMALL-SCALE-STUDIES
RELA	IRF4	0.15	Co-expression/Pathway	Boldrick-Relman-2002/Wu-Stein-2010
RELA	KAT5	0.35	Co-expression	Smirnov-Cheung-2009
RELA	NOTCH1	0.35	Physical Interactions/Predicted	IREF-HPRD/Wu-Stein-2010
RELA	CXCL1	0.21	Pathway/Co-expression	Wu-Stein-2010/Boldrick-Relman-2002
RELA	REL	1.00	Pathway/Physical Interactions/Shared protein domains	Wu-Stein-2010/IREF-HPRD/INTERPRO
RELA	TP53	0.18	Co-expression/Pathway/Shared protein domains	Roth-Zlotnik-2006/Wu-Stein-2010/INTERPRO
TNFSF12	TNFRSF13B	0.26	Pathway	Reactome
TNFSF13	TNFRSF13B	1.00	Physical Interactions/Pathway	IREF-DIP/Wu-Stein-2010
TP53	KAT5	1.00	Physical Interactions/Predicted	IREF-HPRD/Wu-Stein-2010

Table S20. Ligand-receptor pairs encoded by GWAS loci with P<1.0E-05 for at least one member of the pair. The overall enrichment p-value for ligand-receptor pairs in DLRP database: P=0.01. *Blood cis-eQTL effect of the risk allele (eQTL Gen).

LIGAND							RECEPTOR						
GENE	CHR:BP	SNP	RISK ALLELE	OR	GWAS P-value	eQTL effect of risk allele*	GENE	CHR:BP	SNP	RISK ALLELE	OR	GWAS P-value	eQTL effect of risk allele*
CXCL1	4:74725320	rs6828610	G	1.14	3.54E-08	↓	***CXCR1***	2:218991005	rs4674259	G	1.08	3.73E-06	↑
CXCL2	4:74725320	rs6828610	G	1.14	3.54E-08	↓	***CXCR2***	2:218991005	rs4674259	G	1.08	3.73E-06	↑
CXCL3	4:74725320	rs6828610	G	1.14	3.54E-08	-							
CXCL5	4:74725320	rs6828610	G	1.14	3.54E-08	↑							
CXCL6	4:74725320	rs6828610	G	1.14	3.54E-08	-							
CXCL7 (PPBP)	4:74725320	rs6828610	G	1.14	3.54E-08	-							
CXCL8 (IL8)	4:74725320	rs6828610	G	1.14	3.54E-08	↑							
OSM	22:30512478	rs4823074	G	1.16	7.76E-15	↓	***OSMR***	5:38867732	rs395157	T	1.11	1.55E-06	-
							LIFR	5:38867732	rs395157	T	1.11	1.55E-06	-
							IL6ST	5:55438851	rs10065637	C	1.15	1.77E-07	↑
LIF	22:30577771	rs714027	G	1.14	3.99E-14	↑	***LIFR***	5:38867732	rs395157	T	1.11	1.55E-06	-
							IL6ST	5:55438851	rs10065637	C	1.15	1.77E-07	↑
IL6	7:22752731	rs6969599	A	1.09	5.61E-04	-	***IL6ST***	5:55438851	rs10065637	C	1.15	1.77E-07	↑
TNFSF13 (APRIL)	17:7462969	rs3803800	A	1.15	1.21E-10	↑	***TNFRSF13B (TACI)***	17:16851450	rs57382045	A	1.16	3.45E-09	↑
IL7	8:79561083	rs11776243	C	1.09	2.03E-04	↓	***IL7R***	5:35857850	rs10213865	A	1.11	6.57E-06	↑
IL31	12:122652365	rs796259997	GT	1.18	6.26E-04	-	***IL31RA***	5:55438851	rs10065637	C	1.15	1.77E-07	-
TNFSF8	9:117643362	rs13300483	T	1.13	1.27E-08	↓	***TNFRSF8***	1:12096379	rs1208994	A	1.10	3.73E-04	-
TNFSF4	1:173146357	rs4916312	A	1.14	5.00E-08	↓	***TNFRSF4***	1:1193586	rs59549363	A	1.23	7.60E-04	↓
TNFSF3 (LTB)	6:31603591	rs2261033	G	1.17	3.38E-22	-	***TNFRSF3 (LTBR)***	12:6492649	rs11064157	C	1.11	1.51E-04	↓

Table S21. Expression QTLs (eQTL) of top IgAN risk loci and their LD proxies in primary immune cells from the DICE project: the top SNP is reported for each eGene in each cell type, R2 is the measure of linkage disequilibrium between top SNP from GWAS and top SNP for a given eGene, effect sizes are provided for each IgAN risk allele, co-localization probabilities between IgAN GWAS and eQTL summary statistics are also provided: PP3 is the posterior probability that there are two different causal variants. PP4 is the posterior probability that the same causal variant is shared.

											Co-localization	
LOCUS	**CHR**	**BP**	**SNP-risk allele**	**GENE**	**Tissue**	**Effect**	**P-value**	**top SNP**	**R2**	**Effect of risk allele**	**PP3**	**PP4**
REL	2	61091950	rs842636-A	NONOP2	Naïve B cells	0.6695	2.29E-06	rs842638	0.973	↓	0.04	**0.83**
CD28	2	204625370	rs59789950-C	RAPH1	Naïve B cells	0.9634	5.20E-05	rs3769684	0.809	↓	0.04	0.30
CCR6	6	167368885	rs112074021-A	FGFR1OP	Monocytes	1.5011	4.56E-07	rs2282859	0.616	↑	0.03	0.47
IRF4/DUSP22	6	251685	rs12195338-T	IRF4	Non-classical Monocytes	0.8396	1.02E-05	rs12201499	0.888	↓	0.01	**0.65**
IRF4/DUSP22	6	253428	rs6596865-T	DUSP22	Non-classical Monocytes	0.7970	3.51E-05		0.888	↓	0.01	**0.63**
TNFSF8/15	9	117597885	rs34187507-G	TNC	TH1/17 cells	0.4673	5.88E-06	rs13300483	0.886	↓	0.94	0.01
TNFSF8/15	9	117624799	rs35097049-C	TNFSF8	NK cells	0.4491	1.82E-05		0.901	↓	0.71	0.04
ZMIZ1/PPIF	10	81048158	rs942793-G	ZMIZ1	NK cells	0.6207	1.75E-05	rs1108618	0.707	↓	0.02	**0.58**
REEP3	10	65013950	rs76460998-C	NRBF2	Non-classical Monocytes	1.2179	2.23E-05	rs10896045	0.916	↓	0.18	0.37
IGH	14	107166471	rs11624734-T	IGHV3-65	Naïve B cells	0.8644	1.84E-11	rs751081288	0.817	↑	0.32	**0.68**
IGH	14	107141916	rs10139058-C	IGHV1-69	Naïve B cells	0.4402	1.75E-09		0.872	↓	0.39	**0.59**
IGH	14	107166471	rs11624734-G	IGHV4-61	Naïve B cells	0.4134	1.44E-08		0.817	↓	0.06	**0.94**
IGH	14	107157003	rs6576205-C	IGHV3-33-2	TH1/17 cells	0.3894	1.91E-06		0.918	↓	0.22	**0.67**
IGH	14	107166471	rs11624734-G	IGHV3-47	Naïve CD4+ T cells	0.3853	5.23E-06		0.817	↓	0.27	0.43
IGH	14	107169013	rs7140392-T	IGHV3-66	Naïve B cells	0.6112	5.66E-06		0.905	↑	0.41	**0.57**
IGH	14	107169013	rs7140392-C	IGHVII-78-1	Naïve CD8+ T cells	0.3771	1.44E-05		0.905	↓	0.20	**0.62**
IGH	14	107190574	rs10142951-G	IGHV3-38	Naïve B cells	0.5932	1.84E-05		0.945	↑	0.30	0.33
IGH	14	107153577	rs8018138-T	IGHV3-64	Naïve B cells	0.5922	4.02E-05		0.881	↑	0.13	**0.76**
ITGAM/ITGAX	16	31353796	rs12599388-T	ITGAX	Monocytes	0.6361	7.47E-06	rs11150612	0.982	↑	0.35	**0.60**
ITGAM/ITGAX	16	31353796	rs12599388-T	ITGAX	Non-classical Monocytes	0.6148	2.44E-05		0.982	↑	0.04	**0.79**
TNFSF13	17	7448003	rs11078694-T	ATP1B2	Naïve CD8+ T cells	0.7121	3.01E-05	rs3803800	0.500	↑	0.03	0.13
FCAR	19	55396613	rs10402324-G	FCAR	Non-classical Monocytes	0.4094	1.89E-07	rs1865097	1.000	↑	0.98	0.02
FCAR	19	55398101	rs12972637-A	NLRP7	Memory T-reg cells	0.3963	2.09E-06		0.996	↑	0.01	**0.92**
FCAR	19	55396613	rs10402324-G	CTB-61M7.2	Non-classical Monocytes	0.3799	6.45E-06		1.000	↑	0.98	0.02
FCAR	19	55396613	rs10402324-G	NCR1	Naïve CD4+ T cells	0.3756	1.48E-05		1.000	↑	0.01	**0.79**
LIF	22	30486826	rs2412970-G	LIF	NK cells	0.5749	3.45E-05	rs48230748	1.000	↓	0.06	**0.75**
LIF	22	30549071	rs5763821-A	NIPSNAP1	TH1/17 cells	0.3455	5.54E-05		0.966	↑	0.10	0.42

Table S22. Blood eQTLs for the top IgAN risk loci: only significant blood cis-eQTL effects of non-HLA IgAN genome-wide significant SNPs are listed along with co-localization results. PP3: posterior probability that there are two different causal variants. PP4: posterior probability that the same causal variant is shared. Based on the blood eQTL meta-analysis of the eQTLGen Consortium.

									Colocalization	
LOCUS	CHR	BP	SNP-risk allele	eGENE	Z-score	p-value	FDR	Effect of risk allele	PP3	PP4
FCRL3/4	1	157542162	rs849815-G	*FCRL5*	46.5073	3.27E-296	0	↓	0.09	**0.91**
FCRL3/4	1	157542162	rs849815-G	*FCRL3*	49.1059	3.27E-296	0	↓	0.25	**0.75**
FCRL3/4	1	157542162	rs849815-A	*FCRL1*	7.2454	4.31E-13	0	↑	1.00	0.00
FCRL3/4	1	157542162	rs849815-G	*RP11-367J7.2*	5.9941	2.05E-09	1.96E-05	↑	0.99	0.00
TNFSF4	1	173146357	rs4916312-G	*TNFSF4*	16.3284	6.20E-60	0	↓	0.11	**0.89**
CFH	1	196686918	rs6677604-A	*CFH*	9.9646	2.18E-23	0	↓	1.00	0.00
REL	2	61092678	rs842638-C	*PUS10*	19.5107	8.92E-85	0	↓	1.00	0.00
REL	2	61092678	rs842638-C	*RP11-373L24.1*	9.5193	1.75E-21	0	↓	1.00	0.00
REL	2	61092678	rs842638-C	*REL*	9.0551	1.37E-19	0	↓	1.00	0.00
REL	2	61092678	rs842638-C	*USP34*	8.1205	4.65E-16	0	↓	1.00	0.00
REL	2	61092678	rs842638-C	*AC010733.5*	7.6041	2.87E-14	0	↓	0.05	**0.96**
PF4V1	4	74725320	rs6828610-G	*PF4V1*	49.2489	3.27E-296	0	↑	0.04	**0.96**
PF4V1	4	74725320	rs6828610-G	*CXCL5*	8.3989	4.51E-17	0	↑	1.00	0.00
PF4V1	4	74725320	rs6828610-A	*CXCL1*	6.7486	1.49E-11	0	↓	0.02	**0.98**
PF4V1	4	74725320	rs6828610-G	*IL8*	5.3337	9.63E-08	3.39E-04	↑	0.98	0.01
LY86	6	7214676	rs12530084-T	*DSP*	5.6881	1.29E-08	7.06E-05	↓	1.00	0.00
LY86	6	7214676	rs12530084-C	*SSR1*	4.7907	1.66E-06	0.005	↑	1.00	0.00
CCR6	6	167445139	rs2282859-C	*FGFR1OP*	25.0468	1.90E-138	0	↑	0.70	0.26
CCR6	6	167445139	rs2282859-C	*RP1-167A14.2*	9.5649	1.12E-21	0	↑	0.93	0.01
CCR6	6	167445139	rs2282859-C	*RNASET2*	8.601	7.90E-18	0	↑	0.57	0.40
CCR6	6	167445139	rs2282859-C	*AL133458.1*	4.7261	2.29E-06	0.007	↑	0.66	0.30
CCR6	6	167445139	rs2282859-T	*CCR6*	4.3735	1.22E-05	0.034	↓	0.67	0.29
DEFA1	8	6808722	rs2075836-T	*DEFA8P*	14.1255	2.64E-45	0	↑	0.89	0.11
DEFA1	8	6808722	rs2075836-G	*DEFA3*	7.2642	3.76E-13	0	↓	1.00	0.00
ANXA13	8	124765474	rs34354351-G	*FAM91A1*	10.1885	2.23E-24	0	↓	0.80	0.19
TNFSF8/15	9	117643362	rs13300483-C	*TNFSF8*	8.3302	8.07E-17	0	↓	0.89	0.10
CARD9	9	139266496	rs4077515-T	*CARD9*	72.772	3.27E-296	0	↑	0.11	**0.90**
CARD9	9	139266496	rs4077515-C	*INPP5E*	62.5426	3.27E-296	0	↓	0.09	**0.91**
CARD9	9	139266496	rs4077515-C	*SDCCAG3*	44.0373	3.27E-296	0	↓	0.05	**0.95**
CARD9	9	139266496	rs4077515-C	*SEC16A*	23.46	1.04E-121	0	↓	1.00	0.00
CARD9	9	139266496	rs4077515-T	*SNAPC4*	12.5376	4.66E-36	0	↑	1.00	0.00
CARD9	9	139266496	rs4077515-C	*DNLZ*	5.4878	4.07E-08	1.59E-04	↓	1.00	0.00
CARD9	9	139266496	rs4077515-T	*PMPCA*	5.2489	1.53E-07	5.19E-04	↑	0.36	**0.64**
REEP3	10	65363048	rs57917667-A	*NRBF2*	14.5229	8.69E-48	0	↓	1.00	0.00
REEP3	10	65363048	rs57917667-G	*REEP3*	4.9702	6.69E-07	0.002	↑	1.00	0.00
ZMIZ1/PPIF	10	81043743	rs1108618-G	*ZMIZ1*	13.9775	2.14E-44	0	↓	0.08	**0.93**
ZMIZ1/PPIF	10	81043743	rs1108618-G	*PPIF*	10.4062	2.32E-25	0	↓	0.45	**0.55**
RELA	11	65555524	rs10896045-A	*EFEMP2*	21.8385	1.00E-105	0	↑	0.01	**1.00**
RELA	11	65555524	rs10896045-G	*CTSW*	18.8187	5.30E-79	0	↓	1.00	0.00
RELA	11	65555524	rs10896045-A	*SNX32*	13.2675	3.58E-40	0	↑	1.00	0.00
RELA	11	65555524	rs10896045-A	*FIBP*	12.0861	1.25E-33	0	↑	1.00	0.00
RELA	11	65555524	rs10896045-G	*MAP3K11*	11.6803	1.61E-31	0	↓	1.00	0.00
RELA	11	65555524	rs10896045-G	*FAM89B*	10.5176	7.15E-26	0	↓	0.04	0.96
RELA	11	65555524	rs10896045-G	*CFL1*	9.8511	6.77E-23	0	↓	0.86	0.14
RELA	11	65555524	rs10896045-A	*RP11-770G2.2*	8.6002	7.96E-18	0	↑	1.00	0.00
RELA	11	65555524	rs10896045-G	*MUS81*	8.5381	1.36E-17	0	↓	0.81	0.19
RELA	11	65555524	rs10896045-A	*KRT8P26*	7.3516	1.96E-13	0	↑	1.00	0.00
RELA	11	65555524	rs10896045-G	*RNASEH2C*	7.2179	5.28E-13	0	↓	1.00	0.00
RELA	11	65555524	rs10896045-G	*BANF1*	6.4199	1.36E-10	0	↓	1.00	0.00
RELA	11	65555524	rs10896045-A	*LTBP3*	4.635	3.57E-06	0.01	↑	1.00	0.00
ITGAM/ITGAX	16	31357760	rs11150612-A	*ITGAX*	46.6839	3.27E-296	0	↑	0.09	**0.91**
ITGAM/ITGAX	16	31357760	rs11150612-A	*RP11-120K18.3*	20.4771	3.45E-93	0	↑	1.00	0.00
ITGAM/ITGAX	16	31357760	rs11150612-A	*BCKDK*	19.6062	1.37E-85	0	↑	1.00	0.00
ITGAM/ITGAX	16	31357760	rs11150612-A	*ZNF668*	19.0704	4.47E-81	0	↑	1.00	0.00
ITGAM/ITGAX	16	31357760	rs11150612-A	*ITGAD*	18.4896	2.50E-76	0	↑	1.00	0.00
ITGAM/ITGAX	16	31357760	rs11150612-A	*HSD3B7*	12.7532	3.00E-37	0	↑	1.00	0.00
ITGAM/ITGAX	16	31357760	rs11150612-G	*STX4*	12.2608	1.47E-34	0	↓	1.00	0.00
ITGAM/ITGAX	16	31357760	rs11150612-A	*ITGAM*	11.279	1.67E-29	0	↑	1.00	0.00
ITGAM/ITGAX	16	31357760	rs11150612-G	*RP11-196G11.2*	10.8147	2.93E-27	0	↓	1.00	0.00
ITGAM/ITGAX	16	31357760	rs11150612-G	*KAT8*	7.0899	1.34E-12	0	↓	1.00	0.00
ITGAM/ITGAX	16	31357760	rs11150612-A	*VKORC1*	7.075	1.50E-12	0	↑	0.89	0.11
ITGAM/ITGAX	16	31357760	rs11150612-G	*ARMC5*	6.2347	4.52E-10	0	↓	1.00	0.00
ITGAM/ITGAX	16	31357760	rs11150612-A	*C16orf93*	5.7421	9.36E-09	5.79E-05	↑	0.36	**0.64**
ITGAM/ITGAX	16	31357760	rs11150612-G	*SETD1A*	5.0383	4.69E-07	0.002	↓	0.06	**0.94**
ITGAM/ITGAX	16	31357760	rs11150612-A	*PRSS53*	4.9511	7.38E-07	0.002	↑	1.00	0.00
IRF8	16	86017715	rs1879210-C	*RP11-542M13.2*	8.7386	2.36E-18	0	↓	0.99	0.01
IRF8	16	86017715	rs1879210-C	*RP11-542M13.3*	4.7013	2.59E-06	0.007	↓	0.70	0.30
TNFSF13	17	7462969	rs3803800-G	*TNFSF12*	15.0379	4.14E-51	0	↓	1.00	0.00
TNFSF13	17	7462969	rs3803800-A	*TNFSF13*	14.608	2.50E-48	0	↑	0.98	0.03
TNFSF13	17	7462969	rs3803800-A	*ATP1B2*	12.9661	1.91E-38	0	↑	1.00	0.00
TNFSF13	17	7462969	rs3803800-G	*SAT2*	8.5808	9.42E-18	0	↓	1.00	0.00
TNFSF13	17	7462969	rs3803800-A	*CD68*	7.0055	2.46E-12	0	↑	1.00	0.00
TNFSF13	17	7462969	rs3803800-A	*NLGN2*	5.4252	5.79E-08	2.40E-04	↑	0.03	**0.98**
TNFSF13	17	7462969	rs3803800-G	*TP53*	4.3404	1.42E-05	0.04	↓	1.00	0.00
TNFRSF13B	17	16851450	rs57382045-A	*NT5M*	9.7146	2.61E-22	0	↑	1.00	0.00
TNFRSF13B	17	16851450	rs57382045-G	*COPS3*	8.1101	5.05E-16	0	↓	1.00	0.00
FCAR	19	55397217	rs1865097-A	*FCAR*	25.9667	1.18E-148	0	↑	0.99	0.01
FCAR	19	55397217	rs1865097-A	*CTB-61M7.2*	23.6104	3.01E-123	0	↑	0.98	0.02
FCAR	19	55397217	rs1865097-A	*KIR2DL1*	7.3729	1.67E-13	0	↑	1.00	0.00
LIF	22	30512478	rs4823074-G	*MTMR3*	16.8319	1.42E-63	0	↑	1.00	0.00
LIF	22	30512478	rs4823074-G	*NIPSNAP1*	15.9373	3.49E-57	0	↑	1.00	0.00
LIF	22	30512478	rs4823074-A	*UQCR10*	14.2496	4.51E-46	0	↓	1.00	0.00
LIF	22	30512478	rs4823074-G	*SF3A1*	9.9708	2.04E-23	0	↑	1.00	0.00
LIF	22	30512478	rs4823074-G	*ASCC2*	9.4183	4.58E-21	0	↑	1.00	0.00
LIF	22	30512478	rs4823074-G	*SEC14L3*	7.6887	1.49E-14	0	↑	1.00	0.00
LIF	22	30512478	rs4823074-A	*DUSP18*	6.1692	6.87E-10	0	↓	1.00	0.00
LIF	22	30512478	rs4823074-A	*ZMAT5*	4.8488	1.24E-06	0.004	↓	1.00	0.00

Table S23. Significant blood pQTL effects of genome-wide significant IgAN risk loci.

LOCUS	CHR	BP	SNP-risk allele	Target	IgAN top SNP in the Locus	r2	beta	p	IgAN risk allele effect	Cis/Trans	Study
FCRL3/4	1	157670816	rs7528684-G	FCRL3	rs849815	0.24	0.53	1.40E-112	↓	cis	Sun BB et al
FCRL3/4	1	157779182	rs4971155-T	FCRL1		0.21	0.21	6.30E-26	↓	cis	Sun BB et al
FCRL3/4	1	157635373	rs6677006-T	FCRL4		0.17	0.55	5.50E-38	↓	cis	Sun BB et al
CFH	1	196825287	rs7519758-C	LRC19	rs6677604	0.97	0.48	1.40E-307	↑	trans	Sun BB et al
CFH	1	196819479	rs149369377-A	XRCC4		0.97	0.21	3.50E-17	↑	trans	Sun BB et al
CFH	1	196821380	rs67908756-T	Calnexin		0.97	0.19	3.90E-14	↑	trans	Sun BB et al
CFH	1	196814850	rs148235292-A	LIRA5		0.96	0.26	5.90E-18	↓	trans	Sun BB et al
CFH	1	196632004	rs11390840-CA	FYN		0.92	0.48	6.50E-66	↑	trans	Sun BB et al
CFH	1	196584321	rs4657825-A	CFB		0.91	0.22	6.30E-22	↓	trans	Sun BB et al
CFH	1	196886770	rs4915559-T	HPX		0.68	0.68	1.78E-140	↑	trans	Emilsson V et al
CFH	1	196886770	rs4915559-T	CFHR4		0.68	0.66	1.67E-131	↑	cis	Emilsson V et al
CFH	1	196886770	rs4915559-C	NDUFS4		0.68	0.27	5.50E-42	↓	trans	Emilsson V et al
CFH	1	196886770	rs4915559-C	TST		0.68	0.26	1.53E-40	↓	trans	Emilsson V et al
CFH	1	196886770	rs4915559-T	F13B		0.68	0.34	3.55E-36	↑	trans	Emilsson V et al
CFH	1	196886770	rs4915559-T	C1S		0.68	0.27	5.86E-22	↑	trans	Emilsson V et al
CFH	1	196886770	rs4915559-C	CFP		0.68	0.21	7.81E-20	↓	trans	Emilsson V et al
CFH	1	196886770	rs4915559-C	CEACAM7		0.68	0.20	1.46E-19	↓	trans	Emilsson V et al
CFH	1	196886770	rs4915559-C	ANAPC7		0.68	0.17	3.27E-13	↓	trans	Emilsson V et al
CFH	1	196886770	rs4915559-T	CFHR5		0.68	0.20	4.44E-13	↑	cis	Emilsson V et al
CFH	1	196886770	rs4915559-T	PPP2R3A		0.68	0.19	1.15E-11	↑	trans	Emilsson V et al
CFH	1	196886770	rs4915559-T	PDGFRA		0.68	0.17	3.07E-09	↑	trans	Emilsson V et al
CFH	1	196841377	rs57809726-A	CFHR1		0.59	1.30	1.00E-300	↑	cis	Emilsson V et al
CFH	1	196841377	rs57809726-A	PRLR		0.59	0.40	2.26E-28	↑	trans	Emilsson V et al
CFH	1	196841377	rs57809726-A	GALK1		0.59	0.31	2.87E-19	↑	trans	Emilsson V et al
CFH	1	196841377	rs57809726-G	CFH		0.59	0.22	4.71E-16	↓	cis	Emilsson V et al
CFH	1	196815708	rs71524421-C	GSKIP		0.21	0.14	1.56E-10	↓	trans	Emilsson V et al
CFH	1	196815708	rs71524421-G	EFCAB14		0.21	0.16	6.80E-10	↑	trans	Emilsson V et al
CFH	1	196673993	rs1831282-A	BATF3		0.21	0.19	1.80E-21	↑	trans	Sun BB et al
CFH	1	196719716	rs529541-G	ARHGA		0.21	0.31	7.20E-23	↑	trans	Sun BB et al
CFH	1	196667252	rs7539005-A	GL8D1		0.19	0.40	8.30E-206	↑	trans	Sun BB et al
CFH	1	196659237	rs1061170-T	PGRC2		0.19	0.38	1.70E-52	↓	trans	Sun BB et al
CFH	1	196667252	rs7539005-A	TSNA1		0.19	0.26	1.90E-47	↑	trans	Sun BB et al
CFH	1	196668360	rs34813609-GT	APOD		0.19	0.19	4.20E-21	↑	trans	Sun BB et al
CFH	1	196668360	rs34813609-GT	ZNF276		0.19	0.19	7.90E-21	↑	trans	Sun BB et al
CFH	1	196668360	rs34813609-GT	GPD1L		0.19	0.19	9.30E-20	↑	trans	Sun BB et al
CFH	1	196668360	rs34813609-GT	PCDB4		0.19	0.18	5.20E-18	↑	trans	Sun BB et al
CFH	1	196668360	rs34813609-GT	SLAF7		0.19	0.17	2.20E-17	↑	trans	Sun BB et al
CFH	1	196671217	rs28664709-G	SPTA2		0.19	0.17	4.40E-17	↑	trans	Sun BB et al
CFH	1	196668360	rs34813609-GT	KLK14		0.19	0.17	2.30E-16	↑	trans	Sun BB et al
CFH	1	196672454	rs12038333-G	PRP16		0.19	0.17	6.00E-16	↑	trans	Sun BB et al
CFH	1	196668360	rs34813609-GT	sFRP-3		0.19	0.17	1.20E-15	↑	trans	Sun BB et al
CFH	1	196668360	rs34813609-GT	IGFL3		0.19	0.17	2.80E-15	↑	trans	Sun BB et al
CFH	1	196668360	rs34813609-GT	AUGN		0.19	0.17	5.80E-15	↑	trans	Sun BB et al
CFH	1	196668360	rs34813609-GT	MCEM1		0.19	0.16	2.30E-14	↑	trans	Sun BB et al
CFH	1	196668360	rs34813609-GT	C1T9A		0.19	0.16	5.50E-14	↑	trans	Sun BB et al
CFH	1	196672454	rs12038333-G	HXK4		0.19	0.16	5.80E-14	↑	trans	Sun BB et al
CFH	1	196668360	rs34813609-GT	PTP-1B		0.19	0.16	7.20E-14	↑	trans	Sun BB et al
CFH	1	196668360	rs34813609-GT	RGS8		0.19	0.16	8.70E-14	↑	trans	Sun BB et al
CFH	1	196668360	rs34813609-GT	VTN		0.19	0.16	1.00E-13	↑	trans	Sun BB et al
CFH	1	196668360	rs34813609-GT	P3C2A		0.19	0.16	2.40E-13	↑	trans	Sun BB et al
CFH	1	196668360	rs34813609-GT	BIRC5		0.19	0.15	3.70E-13	↑	trans	Sun BB et al
CFH	1	196667252	rs7539005-A	KLK6		0.19	0.15	4.60E-13	↑	trans	Sun BB et al
CFH	1	196668360	rs34813609-GT	SARP-1		0.19	0.15	9.50E-13	↑	trans	Sun BB et al
CFH	1	196672454	rs12038333-G	JAM-B		0.19	0.15	5.80E-12	↑	trans	Sun BB et al
CFH	1	196668360	rs34813609-GT	OSM		0.19	0.15	7.40E-12	↑	trans	Sun BB et al
CFH	1	196668360	rs34813609-GT	RMTL1		0.19	0.15	8.10E-12	↑	trans	Sun BB et al
CFH	1	196670839	rs10754199-A	CD63		0.19	0.15	1.10E-11	↑	trans	Sun BB et al
CFH	1	196657064	rs570618-T	ERVV1		0.18	0.17	5.90E-15	↑	trans	Sun BB et al
CFH	1	196657064	rs570618-T	OPG		0.18	0.15	5.20E-13	↑	trans	Sun BB et al
CFH	1	196657064	rs570618-T	LTBR		0.18	0.15	1.10E-12	↑	trans	Sun BB et al
CFH	1	196671981	rs368465-T	CD22		0.18	0.15	1.40E-12	↑	trans	Sun BB et al
CFH	1	196657064	rs570618-T	CLK2		0.18	0.15	1.50E-12	↑	trans	Sun BB et al
CFH	1	196657064	rs570618-T	FRK		0.18	0.15	1.10E-11	↑	trans	Sun BB et al
CFH	1	196660995	rs528298-T	MLL2		0.18	0.76	3.70E-268	↓	trans	Sun BB et al
CFH	1	196660995	rs528298-T	MA1B1		0.18	0.37	6.30E-50	↓	trans	Sun BB et al
CFH	1	196660995	rs528298-A	DCNL5		0.18	0.15	8.90E-13	↑	trans	Sun BB et al
CFH	1	196660995	rs528298-T	APC7		0.18	0.88	3.5E-401	↓	trans	Sun BB et al
CFH	1	196660995	rs528298-T	APC8		0.18	0.32	3.5E-402	↓	trans	Sun BB et al
CFH	1	196867233	rs6685931-C	DLL3		0.17	0.14	1.75E-10	↑	trans	Emilsson V et al
CFH	1	196867233	rs6685931-T	TNFRSF18		0.17	0.15	2.43E-09	↓	trans	Emilsson V et al
CFH	1	196867233	rs6685931-C	IL10RA		0.17	0.12	5.49E-09	↑	trans	Emilsson V et al
PF4V1	4	74718941	rs941758-C	SNAB	rs6828610	0.40	0.15	5.00E-12	↑	trans	Sun BB et al
PF4V1	4	74718101	rs872914-G	SLC3A2		0.39	0.45	2.23E-250	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	PF4V1		0.39	0.43	1.93E-214	↑	cis	Emilsson V et al
PF4V1	4	74718101	rs872914-G	EMC1		0.39	0.43	8.32E-192	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	TNFAIP8		0.39	0.40	2.55E-160	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	ID2		0.39	0.38	3.39E-124	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	RAB39B		0.39	0.37	1.36E-112	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	EIF4EBP2		0.39	0.32	3.02E-73	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	EVA1B		0.39	0.29	2.05E-57	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	ETNK1		0.39	0.28	8.15E-52	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	KITLG		0.39	0.28	2.12E-49	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	CREBBP		0.39	0.27	1.01E-43	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	SCG2		0.39	0.24	3.33E-34	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	STX1B		0.39	0.24	1.34E-31	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	KPNA4		0.39	0.23	2.59E-31	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	AXIN2		0.39	0.24	3.08E-30	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	NLGN4X		0.39	0.23	2.33E-29	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	ARL1		0.39	0.22	1.15E-27	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	GSTT2B		0.39	0.21	2.84E-23	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	SCGB2A1		0.39	0.21	1.67E-22	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	ARMC5		0.39	0.20	5.84E-22	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	CXCL6		0.39	0.20	9.50E-22	↑	cis	Emilsson V et al
PF4V1	4	74718101	rs872914-G	WFDC13		0.39	0.20	1.03E-21	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	RIC3		0.39	0.19	5.13E-18	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	RAP1GDS1		0.39	0.19	1.04E-17	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	PGK1		0.39	0.18	5.64E-17	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	CXCL5		0.39	0.18	4.04E-16	↑	cis	Emilsson V et al
PF4V1	4	74718101	rs872914-G	VPS29		0.39	0.17	5.39E-15	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	RELB		0.39	0.17	4.09E-14	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	PSG5		0.39	0.17	4.18E-14	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	HERC1		0.39	0.17	4.68E-14	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	DNAJC11		0.39	0.16	8.37E-13	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	WISP3		0.39	0.16	1.44E-12	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	IFNLR1		0.39	0.15	3.48E-11	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	TMCC3		0.39	0.14	3.39E-10	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	DDR1		0.39	0.14	1.13E-09	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	FGFR3		0.39	0.13	1.20E-09	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	PCDH15		0.39	0.14	1.40E-09	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	PSMD9		0.39	0.14	1.41E-09	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	SULT1E1		0.39	0.14	3.62E-09	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	NPPA		0.39	0.14	3.95E-09	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	ZPBP		0.39	0.13	5.93E-09	↑	trans	Emilsson V et al
PF4V1	4	74718101	rs872914-G	TRIL		0.39	0.13	6.96E-09	↑	trans	Emilsson V et al
PF4V1	4	74733558	rs3117603-T	CXCL1		0.23	0.70	1.00E-62	↑	cis	Sun BB et al
DEFA1	8	6878257	rs4284061-T	DEFA1	rs2075836	0.19	0.17	3.30E-12	↓	cis	Emilsson V et al
IGH	14	107211211	rs2073668-G	ATP4B	rs751081288	0.93	0.15	3.20E-12	↓	trans	Sun BB et al
IGH	14	107141916	rs10139058-C	ACP2		0.87	0.21	1.20E-25	↓	trans	Sun BB et al
IGH	14	107167782	rs3814922-G	STIM1		0.86	0.16	2.60E-13	↓	trans	Sun BB et al
IGH	14	107170077	rs11845244-T	DB119		0.71	0.24	2.30E-20	↑	trans	Sun BB et al
IGH	14	107100923	rs12882946-A	EPHB3		0.70	0.21	1.80E-24	↓	trans	Sun BB et al
FCAR	19	55389032	rs73065472-T	KI2LA	rs1865097	0.43	0.73	6.50E-163	↑	trans	Sun BB et al

Table S24. Significant blood trans-eQTL effects of IgAN risk alleles. Based on the blood eQTL meta-analysis of the eQTLGen Consortium.

LOCUS	CHR	BP	SNP-risk allele	eGENE	CHR	BP	Z-score	P-value	FDR	Effect of IgAN risk allele
TNFSF8/15	9	117643362	rs13300483-T	*ALPK2*	18	56222334	8.0631	7.44E-16	0	↑
TNFSF8/15	9	117643362	rs13300483-T	*MSC*	8	72755243	6.4489	1.13E-10	0	↑
TNFSF8/15	9	117643362	rs13300483-T	*HDGFRP3*	15	83830545	5.1624	2.44E-07	0.002354861	↑
TNFSF8/15	9	117643362	rs13300483-T	*GZMK*	5	54325239	5.1005	3.39E-07	0.00313024	↑
TNFSF8/15	9	117643362	rs13300483-C	*SOCS2*	12	93970426	4.6913	2.71E-06	0.019953826	↓
TNFSF8/15	9	117643362	rs13300483-T	*EOMES*	3	27760823	4.6907	2.72E-06	0.020014832	↑
TNFSF8/15	9	117643362	rs13300483-T	*COCH*	14	31353995	4.5529	5.29E-06	0.034565822	↑
TNFSF8/15	9	117643362	rs13300483-T	*VCAM1*	1	101194953	4.532	5.84E-06	0.037549294	↑
CARD9	9	139266496	rs4077515-C	*MX1*	21	42811686	10.1331	3.94E-24	0	↓
CARD9	9	139266496	rs4077515-C	*IFIT1*	10	91158024	9.0114	2.03E-19	0	↓
CARD9	9	139266496	rs4077515-C	*HERC5*	4	89402791	7.8329	4.76E-15	0	↓
CARD9	9	139266496	rs4077515-C	*IFI44L*	1	79097045	7.2547	4.02E-13	0	↓
CARD9	9	139266496	rs4077515-C	*IFI44*	1	79122622	7.1705	7.47E-13	0	↓
CARD9	9	139266496	rs4077515-C	*RSAD2*	2	7022153	6.1956	5.81E-10	2.07E-05	↓
CARD9	9	139266496	rs4077515-C	*OAS3*	12	113393605	5.4093	6.32E-08	0.00081666	↓
CARD9	9	139266496	rs4077515-C	*IFIT2*	10	91065372	5.167	2.38E-07	0.00226768	↓
CARD9	9	139266496	rs4077515-C	*ISG15*	1	949361	5.0655	4.07E-07	0.003626038	↓
CARD9	9	139266496	rs4077515-C	*OAS2*	12	113432864	4.9992	5.75E-07	0.004983771	↓
CARD9	9	139266496	rs4077515-C	*XAF1*	17	6668866	4.827	1.39E-06	0.010901042	↓
CARD9	9	139266496	rs4077515-C	*MX2*	21	42757593	4.6029	4.16E-06	0.028405265	↓
ITGAM/ITGAX	16	31357760	rs11150612-G	*IGHG4*	14	106091545	4.7301	2.24E-06	0.01693569	↓

Table S25. Significant cis-eQTL effects (q<0.05) in tissues and cell types from GTEx.

LOCUS	SNP allele	CHR	BP	eGENE	Tissue	Slope	Slope s.e.	q-val	Top GWAS signal	R2	Effect of IgAN risk allele
CFH	rs7542235-A	1	196823613	CFHR1	Liver	0.51	0.06	1.28E-30	rs6677604	0.97	↑
CFH	rs35253683-G	1	196704039	CFHR3	Lung	0.44	0.06	2.52E-23		0.99	↑
CFH	rs6677460-A	1	196684575	CFHR3	Liver	0.51	0.08	9.60E-21		1.00	↑
CFH	rs2064456-A	1	196704443	CFHR3	Artery_Aorta	0.39	0.08	3.16E-10		0.99	↑
CFH	rs60642321-A	1	196822368	CFHR3	Adrenal_gland	0.44	0.09	4.21E-10		0.97	↑
CFH	rs731557-C	1	196705015	CFHR3	Esophagus_Mucosa	0.37	0.08	1.37E-09		0.99	↑
CFH	rs2064456-A	1	196704443	CFHR3	Heart_Atrial_Appendage	0.37	0.08	3.94E-09		0.99	↑
CFH	rs71631868-T	1	196815711	CFHR3	Testis	0.41	0.09	8.15E-09		0.93	↑
CFH	rs2300429-G	1	196675356	CFHR3	Artery_Coronary	0.46	0.11	7.46E-08		0.99	↑
CFH	rs35253683-G	1	196704039	CFHR3	Stomach	0.41	0.09	1.13E-07		0.99	↑
CFH	rs67908756-T	1	196821380	CFHR1	Testis	0.38	0.09	2.40E-06		0.97	↑
CFH	rs6664877-C	1	196684574	CFHR3	Vagina	0.41	0.13	0.00158222		0.91	↑
CFH	rs35617250-C	1	196679682	CFHR3	Ovary	0.38	0.11	0.00358355		1.00	↑
CFH	rs71631868-T	1	196815711	CFHR1	Brain_Hypothalamus	0.41	0.13	0.00715966		0.93	↑
CFH	rs74696321-A	1	196821120	CFHR4	Testis	0.46	0.11	0.0266843		0.89	↓
CFH	rs6664877-C	1	196684574	CFHR1	Colon_Sigmoid	0.34	0.12	0.0271913		0.91	↑
TNFSF4	rs4090391-T	1	173147090	TNFSF18	Brain_Cerebellar_Hemisphere	0.66	0.12	0.000343688	rs4916312	1.00	↑
TNFSF4	rs7553711-T	1	173131908	RP3-395P12.2	Brain_Cerebellum	0.37	0.11	0.00129703		1.00	↓
TNFSF4	rs7514229-T	1	173154304	TNFSF18	Brain_Cerebellum	0.56	0.11	0.00258856		0.88	↑
REL	rs397724941-T	2	61082633	REL	Testis	0.15	0.04	0.00310488	rs842638	0.99	↑
REL	rs1432297-A	2	61070652	REL	Esophagus_Mucosa	0.11	0.03	0.0283461		0.97	↑
TNFSF8/15	rs4979462-T	9	117567013	TNFSF15	Prostate	0.41	0.14	0.0112187	rs13300483	0.56	↑
CARD9	rs4078099-A	9	139267533	CARD9	Whole_Blood	0.30	0.03	6.33E-22	rs4077515	1.00	↑
CARD9	rs10781499-A	9	139266405	CARD9	Lung	0.16	0.03	5.21E-05		0.99	↑
CARD9	rs35670379-T	9	139270606	SEC16A	Liver	0.18	0.04	0.00596325		0.86	↓
CARD9	rs4498662-C	9	139290251	INPP5E	Lung	0.12	0.03	0.020074		0.84	↓
CARD9	rs11145763-C	9	139263596	SDCCAG3	Muscle_Skeletal	0.10	0.02	0.0275688		0.98	↑
RELA	rs10791824-A	11	65559266	OVOL1	EBV_transformed_Lymphocytes	0.43	0.10	1.25E-07	rs10896045	0.59	↑
RELA	rs12273982-C	11	65535464	AP5B1	Nerve_Tibial	0.20	0.05	0.0278015		0.53	↓
IGH	rs2105987-C	14	107163289	IGHV1-69	Whole_Blood	0.28	0.03	2.03E-26	rs751081288	0.91	↓
IGH	rs8004835-C	14	107142378	IGHV3-66	Lung	0.55	0.04	1.64E-22		0.87	↑
IGH	rs3944157-T	14	107138303	IGHV3-66	Whole_Blood	0.51	0.04	1.55E-21		0.87	↑
IGH	rs756583-T	14	107136019	IGHV3-66	Colon_Transverse	0.38	0.03	3.40E-20		0.87	↑
IGH	rs2097580-C	14	107143461	IGHV3-66	Esophagus_Mucosa	0.41	0.04	1.75E-19		0.87	↑
IGH	rs756583-T	14	107136019	IGHV3-66	Spleen	0.66	0.06	3.08E-15		0.87	↑
IGH	rs756583-T	14	107136019	IGHV3-66	Stomach	0.38	0.04	4.01E-13		0.87	↑
IGH	rs756583-T	14	107136019	IGHV3-66	Adipose_visceral_Omentum	0.44	0.06	8.15E-09		0.87	↑
IGH	rs756583-T	14	107136019	IGHV3-66	Minor_Salivary_Gland	0.71	0.07	9.32E-09		0.87	↑
IGH	rs11624912-G	14	107129907	IGHV3-66	Liver	0.62	0.07	2.52E-08		0.91	↑
IGH	rs8018138-G	14	107153577	IGHV1-69	Esophagus_Mucosa	0.17	0.03	1.11E-07		0.88	↓
IGH	rs55848268-A	14	107207561	IGHV3-66	Thyroid	0.26	0.04	1.97E-07		0.96	↑
IGH	rs8004895-T	14	107193377	IGHV1-69	Colon_Transverse	0.17	0.03	1.56E-05		0.94	↓
IGH	rs11627315-T	14	107210420	IGHV3-73	Whole_Blood	0.17	0.04	0.000634228		0.96	↓
IGH	rs10220646-T	14	107128564	IGHV1-69	Minor_Salivary_Gland	0.29	0.06	0.000738176		0.91	↓
IGH	rs3814917-T	14	107167927	IGHV4-59	Adipose_visceral_Omentum	0.31	0.06	0.000871219		0.85	↑
IGH	rs55848268-G	14	107207561	IGHV1-69	Artery_Aorta	0.25	0.06	0.00090114		0.96	↓
IGH	rs6576200-G	14	107124719	IGHV1-69	Spleen	0.26	0.07	0.00506229		0.90	↓
IGH	rs2006284-G	14	107132201	IGHV1-69	Esophagus_Muscolaris	0.24	0.07	0.0342393		0.90	↓
LIF	rs9614090-T	22	30269907	LIF	Muscle_Skeletal	0.18	0.04	0.000851027	rs48230748	0.90	↓
LIF	rs5752989-G	22	30365780	RP4-539M6.20	Testis	0.27	0.08	0.0107755		0.86	↓

Table S26. Significant kidney compartment-specific eQTL effects of genome-wide significant IgAN risk loci.

LOCUS	CHR	BP	SNP-risk allele	GENE	Effect	s.e.	p-VALUE	Compartment	Effect of IgAN risk allele
CFH	1	196686918	rs6677604-G	*CFHR1*	0.4082	0.1481	6.5067E-06	Glomerulus	↑
CFH	1	196686918	rs6677604-G	*CFHR1*	0.5004	0.1431	3.8659E-11	Tubule	↑
RELA	11	65555524	rs10896045-A	*SNX32*	0.4339	0.133	4.16E-08	Glomerulus	↑
LIF	22	30512478	rs4823074-G	*NIPSNAP1*	0.3662	0.1142	0.00000133	Glomerulus	↑

Table S27. Significant blood mQTL effects of genome-wide significant IgAN risk loci (Metabolomics GWAS Server)

Locus	CHR	BP	SNP-risk allele	Metabolite	Effect	p-VALUE	top GWAS SNP	R2	Effect of risk allele	Study
CFH	1	196823613	rs7542235-A	1-stearoylglycerophosphoinositol:HWESASXX ratio	0.06733	5.22E-09	rs6677604	0.9533	↑	Suhre et al
CFH	1	196823613	rs7542235-A	1-linoleoylglycerophosphocholine:HWESASXX ratio	0.05715	6.74E-08		0.9533	↑	Suhre et al
CFH	1	196823613	rs7542235-A	arachidonate (20:4n6):HWESASXX ratio	0.05476	6.90E-08		0.9533	↑	Suhre et al
CFH	1	196674714	rs2019727-A	1-stearoylglycerophosphoinositol:HWESASXX ratio	0.06348	7.99E-08		0.9108	↓	Suhre et al
CFH	1	196513694	rs10922082-A	HWESASXX:pipecolate ratio	0.049	2.23E-07		0.6755	↓	Suhre et al
CFH	1	196674714	rs2019727-A	arachidonate (20:4n6):HWESASXX ratio	0.05364	2.39E-07		0.9108	↓	Suhre et al
CFH	1	196674714	rs2019727-T	X-11852:X-11858 ratio	0.154	3.50E-07		0.9108	↑	Shin et al
CFH	1	196674714	rs2019727-A	1-eicosadienoylglycerophosphocholine:HWESASXX ratio	0.06188	3.69E-07		0.9108	↓	Suhre et al
CFH	1	196674714	rs2019727-A	1-linoleoylglycerophosphocholine:HWESASXX ratio	0.05506	3.71E-07		0.9108	↓	Suhre et al
CFH	1	196603302	rs12029571-A	X-12450:stachydrine ratio	0.175	4.32E-07		1	↑	Shin et al
CFH	1	196513694	rs10922082-G	asparagine:HWESASXX ratio	0.04621	4.34E-07		0.6755	↑	Suhre et al
CFH	1	196569681	rs16840224-T	HWESASXX:pipecolate ratio	0.047	4.99E-07		0.7059	↓	Suhre et al
CFH	1	196686918	rs6677604-G	gamma-tocopherol:oleoylcarnitine ratio	0.124	5.25E-07		1	↑	Suhre et al
CFH	1	196825287	rs7519758-T	HWESASXX	0.043	5.29E-07		0.9013	↓	Shin et al
CFH	1	196584468	rs12061508-G	X-12450:stachydrine ratio	0.177	5.80E-07		0.9528	↑	Shin et al
CFH	1	196569681	rs16840224-C	asparagine:HWESASXX ratio	0.0448	6.98E-07		0.7059	↑	Suhre et al
CFH	1	196584468	rs12061508-A	X-12855:X-14662 ratio	0.0593	7.65E-07		0.9528	↓	Shin et al
CFH	1	196823613	rs7542235-G	HWESASXX	0.0421	7.76E-07		0.9533	↓	Suhre et al
CFH	1	196686918	rs6677604-A	X-11852:X-11858 ratio	0.1103	8.50E-07		1	↓	Shin et al
CFH	1	196632470	rs6680396-G	X-12855:X-14662 ratio	0.0584	8.66E-07		0.9503	↓	Shin et al
CFH	1	196584321	rs4657825-A	X-12855:X-14662 ratio	0.0575	8.72E-07		0.864	↓	Shin et al
CFH	1	196603302	rs12029571-A	5-alpha-pregnan-3beta,20alpha-disulfate:stachydrine ratio	0.188	9.50E-07		1	↑	Shin et al
CFH	1	196710916	rs16840522-T	HWESASXX	0.0433	1.82E-06		0.981	↑	Shin et al
CFH	1	196674714	rs2019727-T	HWESASXX	0.0398	5.04E-06		0.9108	↑	Suhre et al
CFH	1	196573505	rs10754198-A	HWESASXX	0.038	6.12E-06		0.7116	↑	Shin et al
CFH	1	196513694	rs10922082-A	HWESASXX	0.0332	2.09E-05		0.6755	↓	Suhre et al
CFH	1	196397775	rs1538687-G	HWESASXX	0.0318	5.23E-05		0.5518	↓	Suhre et al
CFH	1	196387741	rs12069983-A	HWESASXX	0.0307	7.02E-05		0.5513	↓	Suhre et al
CFH	1	196584321	rs4657825-A	X-14662	0.0304	9.35E-05		0.864	↓	Shin et al
CFH	1	196584468	rs12061508-A	X-14662	0.0304	9.50E-05		0.9528	↓	Shin et al
CFH	1	196405652	rs7531611-T	HWESASXX	0.0293	0.0001736		0.5489	↓	Suhre et al
CFH	1	196686918	rs6677604-G	gamma-tocopherol	0.058	4.20E-04		1	↑	Suhre et al
CFH	1	196702525	rs2284664-A	stachydrine	0.0876	0.0005332		0.6466	↓	Suhre et al
CFH	1	196642233	rs800292-T	HWESASXX	0.0288	0.000645		0.8085	↓	Suhre et al
CFH	1	196464754	rs12065463-C	stachydrine	0.0975	0.000731		0.6597	↓	Suhre et al
CFH	1	196838060	rs6657442-C	stachydrine	0.0842	0.0007412		0.5731	↓	Suhre et al
CFH	1	196387809	rs12069990-T	HWESASXX	0.0273	0.000746		0.5513	↓	Suhre et al
CD28	2	204584456	rs4675360-A	myristoleate (14:1n5)	0.0369	7.74E-05	rs3769684	0.8431	↑	Shin et al
CD28	2	204601910	rs3181113-G	5-oxoproline	0.02233	0.0001551		0.8056	↑	Suhre et al
CD28	2	204582623	rs4673259-T	5-oxoproline	0.02194	0.0002423		0.8273	↑	Suhre et al
CD28	2	204648661	rs7599230-T	5-oxoproline	0.02156	0.0005041		0.5072	↑	Suhre et al
CD28	2	204601910	rs3181113-G	gamma-glutamylglutamine	0.02539	5.33E-04		0.8056	↑	Suhre et al

Table S28. Drug targets among genes encoded by significant GWAS loci. PNH: paroxysmal nocturnal hemoglobinuria; AMD: age-related macular degeneration; AIHA: autoimmune hemolytic anemia; CAD: cold agglutinin disease; C3G: C3 glomerulopathy; DDD: Dense Deposit Disease, ABOi: ABO incompatible; MAb: monoclonal antibody; COPD: chronic obstructive pulmonary disease; HSC: hemopoietic stem cell; CKD: chronic kidney disease; ADPKD: autosomal dominant polycystic kidney disease; T2D: type 2 diabetes; T1D: type 1 diabetes; FSGS: focal segmental glomerulosclerosis; MN: membranous nephropathy; AAV: ANCA-associated vasculitis, GvHD: graft versus host disease. ^ candidate effector genes prioritized in Figure 5.

Gene	Target	Drug Name	Disease	Study Phase	Mechanism of Action
CFH^	CD21/Factor H	TT-30	PNH	Clinical Trial (Phase I)	links C3d-binding domain of human complement receptor 2 (CD21) with the complement regulatory domain of CFH, inhibiting complement cascade
	C3	APL-2	AMD	Clinical Trial (Phase III)	binds C3 and inhibits its cleavage into C3a and C3b, inhibiting complement cascade
		APL-2	PNH	Clinical Trial (Phase I)	
		APL-2	Glomerulopathies, AIHA, CAD	Clinical Trial (Phase II)	
	C3	POT-4	AMD	Clinical Trial (Phase II)*	binds C3 and inhibits its cleavage into C3a and C3b, inhibiting complement cascade
	C3	AMY-101	C3G, ABOi transplant, PNH, AMD, periodontitis**	Clinical Trial (Phase I)	binds C3 and inhibits its cleavage into C3a and C3b, inhibiting complement cascade
	C5	Eculizumab	aHUS, PNH, C3GN, DDD	Approved	Binds and inactivates C5, inhibiting terminal complement pathway
	C5	Ravilizumab	aHUS, PNH, C3GN, DDD	Approved	Binds and inactivates C5, inhibiting terminal complement pathway
	C5	Cemdisiran	PNH, IgAN	Clinical Trials (Phase I/II)	
	C3/CR3	Imprime PGG immunotherapeutic	Solid tumors, non-Hodgkin's lymphoma	Clinical Trials (Phase II/III)	binds to an alternate site on the neutrophil complement receptor 3 (CR3), priming neutrophils to become cytotoxic when binding to complement on tumor cells via CR3
	Factor B	IONIS-FB-LRx	PNH, IgAN	Clinical Trials (Phase I/II)	Antisense Inhibitor of Complement Factor B
	Factor B	Iptacopan (LNP023)	PNH, C3GN, DD, aHUS, IgAN, MN	Clinical Trials (Phase II/III)	Oral inhibitor of Factor B
	Factor D	Danicopan, ALXN2050	PNH, C3GN, DDD, MPGN	Clinical Trials (Phase I/II/III)	Oral inhibitors of Factor D
TNFSF4^	OX40L	RO4989991 (Oxelumab)	Allergic Asthma, allergis rhinitis	Clinical Trial (Phase II)	anti-OX40L mAb, inhibits OX40/OX40L signaling, inhibiting T cell activation***
	OX40	KHK4083/ISB-830	Atopic dermatitis, Ulcerative colitis. lupus	Clinical Trial (Phase II/I)	anti-OX40 mAb, inhibits OX40/OX40L signaling, inhibiting T cell activation***
	OX40	RG7888 (Vonlerolizumab), MEDI0562	Solid tumors	Clinical Trial (Phase I)	anti-OX40 mAb which acts as an agonist, activating T cell response and anti-tumor immunity
FASLG	CD95 (FAS)	DE-098	Rheumatoid arthritis	Clinical Trial (Phase II)*	induces Fas antigen-mediated apoptosis
CD28^	CD28	Belatacept	Kidney transplant rejection	Approved	Inhibitory activity on T lymphocytes
	CD80/CD86 Receptors	Abatacept	Heart transplant rejection	NDA filed	Inhibition of autoimmune T-Cell activation
			Rheumatoid arthritis	Approved	
	CD28/ICOS	ALPN-101	Inflammatory Bowel Disease	Clinical Trial (Phase I)	Dual inhibitor of the CD28 and ICOS T cell costimulatory pathways.
CTLA4	CTLA4	Ipilimumab	Solid tumors (metastatic melanoma)	Approved	anti-CTLA4 mAb, inhibits CTLA4 inhibitory functions and consequently activates cytotoxic T lymphocyte response against tumoral cells
REL^	C-Rel	IT-603/IT-901	Graft Versus Host Disease, transplant Rejection	Pre-clinical	Not Available
CXCL8 (IL8)	IL-8	ABX-IL8	Melanoma, COPD	Clinical Trial (Phase II)	anti-IL-8 antibody, neutralizes IL-8-dependent human neutrophil activation
		Troxipide	Gastric Ulcers, Gastritis	Approved	inhibit IL-8-induced migration of inflammatory cells, inhibiting neutrophil mediated inflammation and oxidative stress.
	IL-8 receptor B	Clotrimazole	Fungal infections	Approved	Suppression of IL-8 expression, inhibits intestinal inflammation
PF4 (CXCL4)	Heparin	Heparin	Thrombosis	Approved	Activation of Anti-thrombin III and inhibition of cascade coagulation (heparin binds to CXCL-PF4)
	CXCR4	Plerixafor	Non Hodgkin's lymphoma, multiple myeloma before HSC transplantation	Approved	HSC mobilizer, inhibition of CXCR4 chemokine receptors on CD34+ cells, recruiting them in the peripheral blood for collection before HSC transplantation
CCR6^	CCR6	PF-07054894	Inflammatory Bowel Disease	Clinical Trial (Phase I)	CCR6 antagonist, prevents recruitment of CCR6+, IL17-producing cells to the affected tissues
LYN^	LYN	Bafetinib	Chronic lymphocytic leukemia, metastatic hormone refractory prostate cancer, glioma and brain metastasis	Clinical Trial (Phase II/I)	Inhibition of Lyn tyrosine kinase, decreases cellular proliferation and induce apoptosis, osteoclasts inhibitor
	SRC	Dasatinib	Chronic myelogenous leukemia	Approved	Src family tyrosine kinase inhibitor
	SRC	Bosutinib	Philadelphia chromosome-positive chronic myelogenous leukemia	Approved	Inhibition of Src and Abl tyrosine kinases, minimal inhibitory activity against c-KIT or platelet-derived growth factor receptor
TNFSF8 (CD30L)	CD30 (TNFRSF8)	Brentuximab vedotin	Hodgkin's lymphoma	Approved	anti-CD30 mAb, inhibits CD30/CD30L signaling inducing cell cycle arrest and apoptosis of the tumor cells
TNFSF15^ (TL1)	*TNFSF15*	PF-06480605, PR-200	Inflammatory Bowel Disease	Clinical Trial (Phase II/I)	anti-TL1A mAb , it binds to TL1A, neutralizing TL1A-DR3 binding and signaling..
PPIF	Cyclophilin D	Not Available	Not Available	Pre-clinical	NA (note: PPIF encodes cyclophilin D, which is suppressed by Cyclosporine A)
MAP3K11	MAP3K11	URMC-099	Not Available	Pre-clinical	Demonstrates anti-inflammatory and neuroprotective effects in mouse
	SYK	Fostamatinib	Immune Thrombocytopenic Purpura (ITP)	Approved	Syk kinase inhibitor, inhibits signal transduction by Fcγ receptors involved in the antibody-mediated destruction of platelets by immune cells in chronic ITP
RELA^ (p65)	Nrf2 pathway	Tecfidera	Multiple sclerosis	Approved	Up-regulates the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway
	NF-kB	Bardoxolone methyl	IgAN, CKD, Alport syndrome, ADPKD, Pulmonary hypertension, Diabetic kidney disease, T2D	Clinical Trial (Phase III)	Inhibits the activity of nuclear factor kappa-B (NF-kB) activated by tumor necrosis factor (TNF) and other inflammatory agents
		Bardoxolone methyl	T1D-associated CKD, FSGS	Clinical Trial (Phase II)	
		Bardoxolone methyl	Obesity, solid tumors, lymphoid malignancies	Clinical Trial (Phase I)	
	NF-kB	Astaxanthin	Investigated for use/treatment in lymphoma (unspecified), multiple myeloma, and solid tumors.	Pre-clinical	Mediates anti-oxidant and anti-inflammatory actions
	NF-kB	SC-236	cancer therapy, lower back pain, and inflammation	Pre-clinical	Suppresses the nuclear translocation of RelA/p65, inhibiting NF-kB signaling
KAT5	Histone acetyltransferase KAT5	Coenzyme A	Hyperlipoproteinemia	Clinical Trial (Phase II/III)	Acts as a liposoluble antioxidant that can participate in redox reactions
PRSS8	protease, serine, 8	B3C	Not Available	Pre-clinical	Not Available
FUS	Tumor suppressor candidate 2	Fus-1 gene therapy	Non-small cell lung cancer	Clinical Trial (Phase I/II)	Expression of FUS1 protein is absent or reduced in the majority of lung cancers
KAT8	KAT8	Naringenin	Hepatitis C, Cardiovascular diseases	Clinical Trial (Phase I)	Promotes carbohydrate metabolism, increases antioxidant defenses, scavenges reactive oxygen species, modulates immune system activity
TNFSF12	TWEAK (TNFSF12)	BIIB 023	Rheumatoid arthritis, Lupus nephritis	Clinical Trial (Phase II)*	anti-TWEAK mAb, inhibits TWEAK/FN14 pathway, attenuating inflammation
TNFSF13^	TACI	Atacicept	Lymphoma; graft rejection; ITP; RA; Multiple sclerosis	Clinical Trial (Phase II/III)	Blocks binding of BAFF (BLYS) and APRIL to TACI, Inhibits B-cell development & survival, reduces autoimmune response
			IgA Nephropathy	Clinical Trial (Phase II)	
	APRIL	BION1301	IgA Nephropathy	Clinical Trial (Phase II)	Specific anti-APRIL monoclonal antibody
	APRIL	VIS649	IgA Nephropathy	Clinical Trial (Phase II)	Specific anti-APRIL monoclonal antibody
TNFRSF13B^	TACI	Atacicept	Lymphoma; graft rejection; ITP; RA, Multiple sclerosis	Clinical Trial (Phase II/III)	Blocks binding of BAFF (BLYS) and APRIL to TACI
	BAFF	Belimumab	Systemic lupus erythematosus, Lupus nephritis	Approved	Selectively binds to soluble B lymphocyte stimulator (BLyS), also known as BAFF, inhibiting its binding to B cells and their activation
			MN, AAV, COPD/Emphysema	Clinical Trial (Phase II)	
			kidney transplant, GvHD	Clinical Trial (Phase I)	
	BAFF	Blisibimod	Systemic lupus erythematosus, IgA nephropathy	Clinical Trial (Phase II-III)	Fusion protein BAFF binding domains with Fc receptor, inhibits BAFF
FCAR^	CD89 (FCAR)	MDX-214	Cancer	Clinial Trial (Phase I/II)*	anti-CD89 mAb, it inhibits tumor cell growth by mediating antibody-dependent cellular cytototxicity
LIF^	LIFR	Emfilermin (recombinant human LIF)	Infertility	Clinical Trial (Phase I/II)*	Facilitates embryonic development and implantation
NF2	NF2 gene promoter	Not Available	Not Available	Pre-clinical	Not Available

* Clinical Trial has been discontinued; ** Potential target diseases; *** These molecules are not predicted to be effective in IgAN based on eQTL effects

Table S29. Clinical correlations of genetic risk scores and individual risk alleles. Individual risk loci and risk score models were tested for associations with clinical parameters at diagnosis. The association analysis was performed under additive genotype coding using logistic regression for binary outcomes, linear regression for continuous outcomes, and Cox proportional hazards model for survival outcomes. All genetic risk scores were standard normalized to mean 0 and variance of 1 before association testing, thus the depicted effect sizes are expressed per one standard deviation of the score. Significant associations after Bonferroni correction highlighted in bold.

Locus	SNP	Risk Allele	Age at biopsy* (N=5,089)			eGFR at biopsy** (N=4,396)			Proteinuria at biopsy** (N=3,038)			Microhematuria** (N=2,627)			HTN** (N=6,547)			Gross Hematuria** (N=6,547)			Lifetime risk of kidney failure* (N=2,879, 913 events)	
			Beta	SE	P value	Beta	SE	P value	Beta	SE	P value	Beta	SE	P value	Beta	SE	P value	Beta	SE	P value	HR (CI 95%)	P value
FCRL	*rs849815*	A	0.56	2.45	0.82	-0.07	0.12	0.54	0.09	0.14	0.52	0.13	0.89	0.89	-0.17	0.49	0.74	0.71	0.64	0.27	1.28 (0.52-3.11)	0.59
TNFSF4	*rs4916312*	A	-1.81	2.51	0.47	-0.52	0.13	5.0E-05	0.28	0.14	0.047	1.98	1.08	0.07	0.88	0.52	0.09	-0.27	0.57	0.64	1.37 (0.67-2.82)	0.39
CFH	*rs12029571*	A	0.72	2.52	0.77	0.04	0.12	0.74	-0.28	0.15	0.06	-1.19	1.03	0.25	-0.14	0.51	0.78	0.59	0.62	0.34	0.71 (0.28-1.79)	0.47
CFH	*rs6677604*	G	-1.56	2.22	0.48	0.05	0.11	0.63	-0.36	0.13	0.01	1.23	0.89	0.17	0.02	0.46	0.96	0.44	0.52	0.40	1.36 (0.69-2.71)	0.38
REL	*rs842638*	T	1.01	1.99	0.61	-0.02	0.10	0.81	-0.16	0.11	0.16	-0.52	0.81	0.52	-0.15	0.41	0.70	-0.39	0.46	0.40	1.08 (0.58-2.01)	0.81
CD28	*rs3769684*	T	-3.93	1.93	0.04	0.08	0.09	0.37	0.10	0.11	0.37	-0.61	0.73	0.40	0.22	0.39	0.56	-0.31	0.51	0.54	1.08 (0.57-2.02)	0.82
PF4V1/CXCL8	*rs6828610*	G	-0.47	2.48	0.85	-0.03	0.12	0.82	-0.27	0.14	0.06	-0.40	0.97	0.68	0.46	0.51	0.37	-0.95	0.64	0.14	1.27 (0.52-3.10)	0.60
IRF4	*rs12201499*	C	-1.09	2.08	0.60	0.03	0.10	0.77	-0.04	0.12	0.72	0.50	0.79	0.53	0.33	0.43	0.45	1.07	0.53	0.046	1.06 (0.50-2.23)	0.89
LY86	*rs12530084*	C	0.36	2.26	0.87	-0.13	0.11	0.25	0.11	0.13	0.39	0.35	0.89	0.69	0.31	0.46	0.51	0.06	0.57	0.91	1.16 (0.52-2.60)	0.72
HLA	*rs9268557*	C	0.37	1.35	0.79	0.00	0.07	0.97	-0.03	0.08	0.72	-0.14	0.52	0.79	0.00	0.27	0.99	0.39	0.34	0.25	1.06 (0.68-1.66)	0.79
HLA	*rs9272105*	A	-2.17	1.23	0.08	-0.01	0.06	0.88	-0.03	0.07	0.65	-0.76	0.46	0.10	0.43	0.25	0.09	-0.29	0.30	0.33	0.97 (0.63-1.48)	0.88
HLA	*rs9275355*	C	-4.32	1.41	0.002	-0.06	0.07	0.40	-0.01	0.09	0.89	0.37	0.78	0.64	-0.17	0.29	0.57	-0.01	0.30	0.97	1.32 (0.87-2.00)	0.20
HLA	*rs9275596*	T	-2.70	1.29	0.04	0.04	0.06	0.51	-0.05	0.07	0.53	0.25	0.49	0.61	0.12	0.27	0.65	0.08	0.32	0.81	0.98 (0.66-1.44)	0.90
HLA	*rs3128927*	C	-3.85	1.71	0.02	0.08	0.09	0.32	0.05	0.10	0.65	1.79	0.65	0.01	-0.58	0.35	0.10	0.20	0.41	0.62	1.04 (0.59-1.84)	0.90
DEFA	*rs2075836*	T	-3.14	1.67	0.06	-0.02	0.08	0.84	0.06	0.10	0.57	0.62	0.64	0.33	-0.16	0.33	0.64	-0.08	0.41	0.84	1.14 (0.62-2.07)	0.67
LYN	*rs75413466*	A	1.46	1.82	0.42	-0.12	0.09	0.19	0.01	0.12	0.91	0.56	0.87	0.52	0.40	0.37	0.28	0.13	0.43	0.76	1.14 (0.60-2.16)	0.68
ANXA13	*rs34354351*	T	-0.73	2.15	0.73	-0.04	0.10	0.71	-0.11	0.12	0.36	1.78	0.81	0.03	-0.15	0.43	0.73	0.88	0.55	0.11	0.77 (0.35-1.71)	0.52
TNFSF15/TNFSF8	*rs13300483*	T	1.05	2.29	0.65	-0.02	0.11	0.83	-0.14	0.13	0.30	0.62	0.95	0.51	-0.06	0.47	0.90	0.86	0.55	0.12	1.12 (0.50-2.52)	0.78
CARD9	*rs4077515*	T	-3.85	2.26	0.09	0.07	0.11	0.50	-0.01	0.13	0.94	-1.61	0.84	0.055	0.42	0.45	0.35	0.64	0.59	0.28	0.77 (0.33-1.81)	0.56
REEP3	*rs57917667*	G	3.42	2.29	0.13	0.06	0.11	0.59	0.15	0.13	0.26	0.01	0.88	0.995	-0.59	0.45	0.19	0.24	0.61	0.70	0.91 (0.33-2.57)	0.87
ZMIZ1	*rs1108618*	A	-0.28	2.06	0.89	-0.22	0.10	0.03	-0.04	0.12	0.76	1.17	0.82	0.15	0.21	0.41	0.61	-0.02	0.50	0.96	1.39 (0.66-2.94)	0.38
RELA	*rs10896045*	A	0.30	1.61	0.85	-0.16	0.08	0.045	0.16	0.09	0.08	0.30	0.65	0.64	0.16	0.33	0.62	0.00	0.39	0.99	1.20 (0.69-2.08)	0.52
ETS1	*rs7121743*	C	-2.98	2.42	0.22	-0.19	0.12	0.11	0.03	0.14	0.83	0.50	0.97	0.61	0.79	0.49	0.11	0.85	0.61	0.16	1.47 (0.65-3.32)	0.36
IGH	*rs751081288*	A	1.07	1.76	0.54	-0.04	0.09	0.67	0.12	0.10	0.21	1.31	0.67	0.049	-0.43	0.36	0.23	0.09	0.41	0.83	0.88 (0.48-1.62)	0.69
ITGAM	*rs11150612*	A	0.61	1.84	0.74	-0.08	0.09	0.36	-0.03	0.11	0.76	0.84	0.73	0.25	0.38	0.38	0.31	0.49	0.45	0.28	1.11 (0.63-1.94)	0.72
IRF8	*rs1879210*	T	2.98	2.32	0.20	-0.07	0.12	0.52	0.17	0.13	0.20	-0.24	0.95	0.80	-0.37	0.48	0.43	0.52	0.55	0.35	1.02 (0.49-2.15)	0.95
TNFSF13	*rs3803800*	A	-1.34	2.05	0.51	-0.09	0.10	0.37	0.00	0.12	0.99	1.22	0.82	0.14	0.55	0.42	0.19	-0.53	0.50	0.29	1.22 (0.58-2.57)	0.61
TNFRSF13B	*rs57382045*	A	-4.12	2.03	0.04	-0.19	0.10	0.06	0.00	0.12	0.97	1.41	0.84	0.09	0.20	0.41	0.62	0.49	0.51	0.34	1.53 (0.71-3.30)	0.28
FCAR	*rs1865097*	A	-1.75	2.35	0.46	0.24	0.12	0.04	0.32	0.14	0.02	1.20	0.95	0.21	-0.04	0.48	0.93	-0.80	0.57	0.16	0.79 (0.34-1.82)	0.58
HORMAD2/LIF	*rs4823074*	G	-2.91	1.81	0.11	0.00	0.09	0.96	0.07	0.10	0.47	-0.06	0.71	0.93	0.16	0.37	0.66	0.00	0.44	0.995	1.44 (0.80-2.62)	0.23
15-SNP Genetic Risk Score			**-0.03**	**0.01**	**9.7E-05**	0.00	0.00	0.80	0.00	0.00	0.15	0.00	0.00	0.45	0.00	0.00	0.26	0.00	0.00	0.06	1.00 (0.99-1.00)	0.37
30-SNP Genetic Risk Score			**-0.81**	**0.19**	**2.6E-05**	-0.02	0.01	3.8E-02	0.00	0.01	0.95	0.21	0.07	6.0E-03	0.05	0.04	0.24	0.07	0.05	0.17	**1.12 (1.05-1.20)**	**6.4E-04**
77-SNP Genetic Risk Score			**-0.82**	**0.19**	**2.3E-05**	-0.02	0.01	4.9E-02	0.00	0.01	0.78	0.18	0.08	2.0E-02	0.06	0.04	0.10	0.09	0.05	0.053	**1.15 (1.08-1.22)**	**2.5E-05**
Genome-wide Polygenic Score			**-0.81**	**0.20**	**5.5E-05**	-0.02	0.01	0.12	0.00	0.01	0.77	0.09	0.08	0.26	-0.03	0.04	0.49	0.08	0.05	0.07	**1.17 (1.09-1.24)**	**3.3E-06**

* Adjusted for Sex, Site, and Race/Ethnicity; ** Adjusted for Age, Sex, Site, and Race/Ethnicity

Table S30. Meta-PheWAS of the genome-wide polygenic risk score (GPS) for IgAN with and without HLA. Only the top associations meeting the Bonferroni-corrected significance level in either analysis are listed; the phenotypes significant in both analyses are highlighted in grey. Before association testing, GPS with and without HLA were standard normalized (mean 0 and variance of 1) thus the depicted effect sizes are expressed per one standard deviation of a GPS. OR: odds ratio; SE: standard error; P: *P*-value.

Phenotype	Description	Group	GPS with HLA			GPS without HLA			No. of cases	No. of controls
			OR	SE	P	OR	SE	P		
557.1	Celiac disease	digestive	0.601	0.020	4.16E-148	0.892	0.020	1.89E-08	2770	388104
714	Rheumatoid arthritis and other inflammatory polyarthropathies	musculoskeletal	1.147	0.010	1.10E-39	1.061	0.011	9.50E-08	10652	465415
714.1	Rheumatoid arthritis	musculoskeletal	1.155	0.011	2.82E-39	1.067	0.012	2.94E-08	9365	465415
335	Multiple sclerosis	neurological	0.814	0.022	2.81E-21	0.959	0.023	6.77E-02	2309	463423
593	Hematuria	genitourinary	1.064	0.007	7.26E-21	1.038	0.007	9.32E-08	27491	442554
244.4	Hypothyroidism NOS	endocrine/metabolic	1.053	0.006	2.61E-16	1.034	0.007	6.48E-07	31035	463751
244	Hypothyroidism	endocrine/metabolic	1.050	0.006	1.99E-15	1.032	0.007	1.10E-06	32836	463751
477	Epistaxis or throat hemorrhage	respiratory	1.092	0.015	2.55E-09	1.070	0.016	1.30E-05	5277	446984
695.4	Lupus (localized and systemic)	dermatologic	0.879	0.025	2.13E-07	1.001	0.027	9.57E-01	2000	474880
250.1	Type 1 diabetes	endocrine/metabolic	1.061	0.012	1.48E-06	1.041	0.013	2.26E-03	7915	450116
495	Asthma	respiratory	1.024	0.005	1.50E-06	1.026	0.005	5.99E-07	51118	436029
695.42	Systemic lupus erythematosus	dermatologic	0.883	0.026	2.10E-06	1.005	0.029	8.64E-01	1788	474880
717	Polymyalgia Rheumatica	musculoskeletal	1.095	0.020	4.02E-06	1.028	0.021	1.84E-01	2822	510063
250	Diabetes mellitus	endocrine/metabolic	1.025	0.005	4.41E-06	1.024	0.006	2.45E-05	48837	450116
695.41	Cutaneous lupus erythematosus	dermatologic	0.814	0.045	5.43E-06	0.923	0.050	1.08E-01	584	474880
401.1	Essential hypertension	circulatory system	1.016	0.003	8.37E-06	1.009	0.004	1.20E-02	149236	354167
401	Hypertension	circulatory system	1.015	0.003	9.96E-06	1.009	0.004	1.42E-02	150452	354167
697	Sarcoidosis	dermatologic	0.887	0.028	2.10E-05	0.946	0.030	6.54E-02	1501	477327

SUPPLEMENTAL NOTES

Discovery Cohorts

Italian, French, British, US, and Beijing-I Cohorts:

The composition, genome-wide genotyping, and genotype quality control (QC) of these cohorts have been published previously[1]. As part of this study, the genotype data was re-imputed using the latest ancestry-matched reference panels of 1000 Genome Project (Phase 3). The numbers of common and high-quality imputed markers (R^2>0.8, MAF>0.01) used in downstream analyses were as follows: 6,898,974 (French cohort), 7,058,018 (Italian cohort), 7,241,153 (US cohort), 4,344,488 (UK cohort) and 5,979,671 (Beijing-I cohort).

Turkish Cohort:

This cohort consists of 525 individuals (133 biopsy-diagnosed cases and 392 healthy controls) recruited at the Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. All cases had a histology-proven diagnosis of IgAN. The genotyping was performed using the Illumina Multi-ethnic Global Ancestry Array (MEGA) at the University of Michigan genotyping facility. Genotype calls were performed in Illumina Genome Studio software. All SNPs were called on the forward strand. Standard quality filters included per-sample genotype call-rates >95%, per-SNP genotype call rates >95% and MAF >0.01. Controls were also filtered by HWE test p-value $1x10^{-4}$. The duplicated and cryptic relatedness was assessed using the software KING software (http://people.virginia.edu/~wc9c/KING/). We excluded individuals based on a pairwise kinship coefficient >0.354 (third-degree relatives). Sex of each individual was imputed based on the analysis of sex chromosome markers and individuals with mismatched gender were excluded. Autosomal heterozygosity was calculated using KING and individuals who deviated ±3 SD from the sample's heterozygosity rate mean were excluded. Ancestry was evaluated using Principal Component Analysis (PCA)[5], we selected a subset of 126,864 high quality and independent (r2 <0.05) markers. PCA produced four significant PCs and adequate matching between cases and controls within the cohort. After QC, the final dataset was comprised of 439 individuals (115 cases and 324 controls) and 715,590 makers genotyped with an overall genotyping rate of 99.9%. We carried out imputation analysis as described below. A total of 7,543,852 high-quality common markers were imputed and used in downstream analysis.

European Cohort I:

All individuals were self-reported White/Caucasians of European ancestry. The following institutions contributed to this cohort (only centers contributing >10 cases to this cohort are listed): Columbia University, New York, USA; University Hospitals in Leuven, Belgium; University of Aachen, Germany; Jean Monnet University, Saint Etienne, France; Poznan, Warsaw, Wroclaw, Gdansk, and Bialystok Universities of Medical Sciences in Poland; Charles University, Prague, Czech Republic; Karolinska and Danderyd University Hospitals, Stockholm, Sweden; Zagreb Medical School, Zagreb, Croatia; University of Utah, Salt Lake City, USA; The Aristotle University of Thessaloniki, Greece; University of Turin, Italy; Regina Margherita Children's Hospital in Turin, Italy; Universities of Messina, Italy; University of Pavia, Italy, University of Modena and Reggio Emilia, Italy; Gaslini Institute, Genoa, Italy; Nephrology and Dialysis A.R.N.A.S. Civico and Benfratellio, Palermo, Italy; VU University Medical Center, Amsterdam, the Netherlands; and the Hospital Universitario Puerta del Hierro Majadahonda, Spain. All cases were ascertained based on a biopsy-proven diagnosis of IgAN. In total, 1,072 cases and 1,536 ancestry and geography-matched controls were genotyped using the Illumina Multi-ethnic Global Ancestry Array (MEGA) at the University of Michigan genotyping facility. The analysis of intensity clusters and genotype calls were performed using the Illumina Genome Studio software and all SNPs were called on the forward strand. The same standard QC as in the above cohorts were performed. For PCA, we selected a subset of 122,697 high-quality independent markers, resulting in seven significant PCs. The PCA identified and excluded six ancestry outliers, resulting in a total of 920 cases and 1,536 controls. After imputation a total of 7,867,380 high-quality markers were used in association analysis.

European Cohort II:

This cohort consisted of 976 individuals (503 biopsy-diagnosed cases and 473 controls) recruited among self-reported White/Caucasian individuals of European ancestry. The healthy controls were recruited from the same geographic regions as the cases. This cohort was built based on cases and controls recruited by the following institutions (only the centers that contributed >10 cases to the cohort are listed): Columbia University, New York, USA; University of Alabama at Birmingham, USA; University of Toronto, Canada; Karolinska and Danderyd University Hospitals, Stockholm, Sweden; Charles University, Czech Republic; University of Brescia, Italy; University of Milan, Italy; University of Verona, Italy; Poznan, Warsaw, and Gdansk Universities of Medical Sciences, Poland; Bern University,

Switzerland; University of Istanbul, Turkey. The genotyping was performed at the University of Michigan genotyping facility using the Illumina Multi-ethnic Global Ancestry Array (MEGA). Genotype calls were performed in Illumina Genome Studio software. All SNPs were called on the forward strand. The same standard genotype QC was performed as above. For PCA, we selected a subset of 126,479 high-quality independent makers. The PCA of the final dataset resulted in five significant PCs and demonstrated minimal population stratification and a successful matching between cases and controls within the cohort. In total 781,848 SNPs passed all the QC filters in the remainder 754 individuals (397 cases and 357 controls) with an overall genotyping rate of 99.9%. After imputation using European samples from 1000 Genome Project as a reference, a total of 7,718,643 high-quality markers were used in downstream analyses.

Argentinian Cohort:

This cohort was recruited at the University of Buenos Aires, Buenos Aires, Argentina, and consisted of 198 individuals (101 biopsy-diagnosed cases and 97 healthy controls) all self-reported Argentinian Whites. The genotyping was performed at the University of Michigan genotyping facility, using the Illumina Multi-ethnic Global Ancestry Array (MEGA). The same genotype processing steps and standard QC analyses were performed as above. The PCA based on 125,264 independent markers demonstrated excellent genetic matching between cases and controls, resulting in four significant PCs of ancestry. After QC, the final dataset consisted of 194 individuals (100 cases and 94 controls) and 750,842 makers genotyped with an overall genotyping rate of 99.9%. Imputation was carried out as described below. A total of 7,739,980 high-quality imputed markers were used in downstream analysis.

Japanese Cohort:

This cohort consisted of 807 individuals (427 biopsy-diagnosed cases and 380 controls) recruited among self-reported Japanese. The participants were recruited by the Division of Nephrology, Juntendo University Faculty of Medicine in Tokyo, Japan as well as by the Division of Nephrology in Niigata University Graduate School of Medical and Dental Science, Niigata, Japan. The DNA was genotyped using the Illumina Multi-ethnic Global Ancestry Array (MEGA). The same genotype processing steps and standard QC analyses were performed as above. The PCA using an independent set of high-quality markers resulted in two significant PCs and demonstrated minimal population stratification and a successful matching between cases and controls within the cohort. In total 590,245 SNPs passed all the QC filters in the remainder 776 individuals (414 cases and 362 controls) with an overall genotyping rate of 99.9%. After imputation a total of 6,027,358 high-quality markers were included in downstream analysis.

Shanghai Cohort:

This cohort consisted of 1,413 individuals (690 biopsy-diagnosed cases and 723 controls) all self-reported as Han Chinese from the Shanghai area recruited from the clinics of the Department of Nephrology of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. The genotyping was performed using the Illumina Multi-ethnic Global Ancestry Array (MEGA). The same genotype processing steps and standard QC analyses were performed as above. The PCA using high quality independent markers demonstrated excellent genetic mismatch between cases and controls, resulting in three significant PCs of ancestry. After QC, the final dataset consisted of 1,345 individuals (656 cases and 689 controls) and 593,475 markers genotyped with an overall genotyping rate of 99.9%. Imputation was carried out as described below. A total of 6,056,327 high-quality imputed markers were used in downstream analysis.

Korean Cohort:

The cases and controls were recruited from Seoul National University Hospital, Seoul, South Korea. and consisted of 1,463 individuals (750 biopsy-diagnosed cases and 713 healthy controls) all self-identified as Korean. The genotyping was performed using the Illumina Multi-ethnic Global Ancestry Array (MEGA). Genotype calls were performed in Illumina Genome Studio software. All SNPs were called on the forward strand. Same standard QC as in the above cohorts was performed. No individual was excluded based on PCA, heterozygosity, or gender mismatch. The final PCA demonstrated excellent genetic matching between cases and controls, resulting in only one significant PC of ancestry. After QC, the final dataset consisted of 1,443 individuals (735 cases and 708 controls) and 598,716 makers genotyped with an overall genotyping rate of 99.9%. Imputation was carried out as described below. A total of 5,942,775 high-quality imputed markers were used in downstream analysis.

Beijing Cohort II:

This cohort was recruited by the Renal Division in the Department of Medicine of Peking University First Hospital, Beijing, China. The cohort consisted of 4,623 individuals (500 biopsy-proven diagnosed cases and 4,123 controls), all self-reported as of Han Chinese ancestry. The genotyping was performed using the Illumina Infinium OmniZhongHua-8 v1.3 array. Genotype calls were performed in Illumina Genome Studio software. All SNPs were called on the forward strand. Same standard QC as in the above cohorts was performed. PCA on a subset of 46,958 high quality independent makers resulted in two significant PCs and demonstrated minimal population stratification and a successful matching between cases and controls within the cohort. In total 727,733 SNPs passed all the QC filters in the remainder 4,151 individuals (479 cases and 3,672 controls) with an overall genotyping rate of 99.9%. After imputation using 1000 Genomes Phase 3 v5 as reference panel, a total of 7,797,150 high-quality markers were used in downstream analysis.

Beijing Cohort III:

This cohort was recruited by the Renal Division in the Department of Medicine of Peking University First Hospital, Beijing, China. The cohort consisted of 3,152 individuals (1,230 biopsy-proven diagnosed cases and 1,922 controls), all self-reported as Han Chinese. The genotyping was performed using the Illumina Infinium Global Screening Array-24 v1.0 (GSA) BeadChip. Genotype calls were performed in Illumina Genome Studio software. All SNPs were called on the forward strand. Same standard QC as in the above cohorts was performed. For PCA, we selected a subset of 59,525 high quality independent makers. The PCA of the final dataset resulted in two significant PCs and demonstrated minimal population stratification and a successful matching between cases and controls within the cohort. In total 362,250 SNPs passed all the QC filters in the remainder 2,352 individuals (1,112 cases and 1,240 controls) with an overall genotyping rate of 99.9%. After imputation using 1000 Genomes Phase 3 v5 as reference panel, a total of 6,019,668 high quality markers were used in downstream analysis.

Immunochip Cohorts:

The Immunochip Consortium was formed to design a custom Illumina Infinium array that leveraged the genetic overlap of susceptibility loci identified across a range of autoimmune diseases. Briefly, the chip contains 196,524 SNPs designed to perform both replication of suggestive findings from autoimmune and inflammatory disease GWAS and fine-mapping of the established loci for autoimmune diseases[6,7]. Using this chip, we generated high-quality genotypes for 2,201 cases with a kidney biopsy diagnosis of IgAN referred for genetic studies across our network of collaborating European nephrology centers, including in Germany, France, Italy, Poland, Croatia, Hungary, Czech Republic, Turkey, and the UK. For controls, we used a total of 11,038 previously genotyped European population controls previously genotyped by the Immunochip consortium[6]. To avoid any potential genotype artifacts, genotype calls were performed jointly for all cases and controls from primary idat files in a single Illumina Genome Studio project. All SNPs were called on the forward strand. The genotype QC filters included per-sample genotype call-rates >95%, per-SNP genotype call-rates >98%, and MAF >0.01. We have also performed cryptic relatedness analysis based on genotype data and excluded any duplicate case and control within the Immunochip cohort and across all other European cohorts used in this study. Based on iterative PCA and clustering analyses, we subdivided our case-control cohorts into three separate cohorts broadly mapping to North Europe (NE), South Europe (SE) and Central-West Europe (CWE). The controls were matched genetically to the cases, and ancestry outliers were eliminated. The final PCA using 20,620, 20,863 and 20,505 high-quality independent markers for NE, SE and CWE cohorts, respectively, demonstrated excellent genetic matching between cases and controls, resulting in three significant PCs for the NE cohort, five significant PCs for the SE cohort and seven significant PCs for the CWE cohort. After final QC and removal of outliers, the three analysis datasets consisted of the following: the NE cohort with 7,624 individuals (527 cases and 7,097 controls) and 128,307 genotyped markers with overall genotyping rate of 99.9%; the SE cohort with 3,219 individuals (514 cases and 2,705 controls) and 127,837 genotyped markers with overall genotyping rate of 99.9%; and the CWE cohort of 2,202 individuals (966 cases and 1,236 controls) and 128,470 genotyped markers with overall genotyping rate of 99.8%.

GCKD Testing Cohort

This cohort was used for independent testing the performance of genome-wide polygenic score (GPS) optimized based on the discovery GWAS. The GCKD Study has previously been described in detail[3,4]. For GPS testing, we constructed a GCKD kidney-biopsy sub-cohort composed on 314 chronic kidney disease (CKD) patients with a biopsy-diagnosed IgAN cases and 663 patients with a biopsy-diagnosis of non-IgAN CKD to serve as controls. All participants were genotyped using the Illumina Omni2.5Exome array and imputed using the HRC version r1.1 reference panel. The best-performing GPS based on the discovery study explained 7.3% of variance in IgAN risk (P=3.1x10^{-12}) with AUROC of 0.65 (95% CI: 0.61-0.68).

Supplemental References

1. Kiryluk, K. *et al.* Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. *Nat Genet* **46**, 1187-96 (2014).
2. Vilhjalmsson, B.J. *et al.* Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. *Am J Hum Genet* **97**, 576-92 (2015).
3. Titze, S. *et al.* Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German Chronic Kidney Disease (GCKD) cohort. *Nephrol Dial Transplant* **30**, 441-51 (2015).
4. Wunnenburger, S. *et al.* Associations between genetic risk variants for kidney diseases and kidney disease etiology. *Sci Rep* **7**, 13944 (2017).
5. Price, A.L. *et al.* Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet* **38**, 904-9 (2006).
6. Trynka, G. *et al.* Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. *Nat Genet* **43**, 1193-201 (2011).
7. Cortes, A. & Brown, M.A. Promise and pitfalls of the Immunochip. *Arthritis Res Ther* **13**, 101 (2011).
8. Stanaway, I.B. *et al.* The eMERGE genotype set of 83,717 subjects imputed to ~40 million variants genome wide and association with the herpes zoster medical record phenotype. *Genet Epidemiol* **43**, 63-81 (2019).